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Vascular smooth muscle proliferation follows upon endothelial injury, 
and is thought to be an early component in the pathogenesis of 
atherosclerosis, and a possible noxious consequence of vascular surgery.
We have shown that heparin suppresses vascular smooth muscle 
proliferation iri vivo and in vitro. The inhibitory effect is specific for 
heparin, and not other anions, and is not related to the antithrombin III 
binding activity of heparin. It is dependent on the size of the molecule, 
(hexasaccharidees or smaller being ineffective), and O-sulfation, but not 
N-sulfation.
We have further shown that endothelial cells in vitro produce a 
similar inhibitory activity, which is probably due to heparin, and that 
this activity requires a endoglycosidase for its release from the 
endothelial cell surface.
These results implicate heparin in the growth regulation of vascular 
smooth muscle, both in physiological and pathological circumstances.
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1OVERVIEW
GROWTH REGULATION BY HEPARIN OF VASCULAR SMOOTH MUSCLE
Vascular smooth muscle (myointimal) proliferation is a common and 
important sequela of endothelial injury. Indeed, one of the modem theories 
of the pathogenesis of atherosclerosis involves myointimal proliferation as 
an crucial initial step in the formation of the lesion. Furthermore, it 
appears that myointimal proliferation not infrequently follows vascular 
surgery, and may contribute to surgical failures by compromising lumenal 
patency.
We present here a series of papers which demonstrate that heparin 
prevents vascular smooth muscle cell proliferation, in vivo and in vitro. 
These observations have important pharmacological and therapeutic 
implications and raise interesting questions as to the role of heparins and 
heparans in the (patho)biology of the vessel wall, and the role of these 
macromolecules in the regulation of cell growth in physiological and 
pathological conditions.
Paper I. Presents an experimental iri vivo model for producing myointimal 
proliferation in the carotid artery of the rat, following endothelial injury 
caused by dessication. This "air-drying" injury has the advantages of 
damaging only the endothelium, and not the underlying smooth muscle, and of 
being reproducible, and quantitative. It shows the relationship between 
endothelial injury, platelet deposition and degranulation, and the subsequent 
myointimal proliferation. It forms the basis for our subsequent in vivo 
studies, and has been successfully utilized in a number of other 
laboratories.
Paper II. Because Paper 1^ showed a relationship between platelet deposition 
and degranulation following endothelial injury, and because platelets are 
thought to release potent mitogen(s) for vascular smooth muscle, we tested to 
see if we could prevent vascular smooth muscle proliferation following 
endothelial injury in vivo by using antiplatelet drugs. Despite the fact 
that platelet-rich plasma from aspirin-, reserpine-, and fluobiprofen- 
treated rats showed markedly decreased platelet aggregation in response to 
collagen, and normal or slightly decreased aggregation in response to ADP or 
thrombin, as compared to platelets from control animals, none of these drugs 
when infused in vivo affected the degree of myointinal thickening, the 
morphology of the lesions, nor the extent of platelet deposition on the 
injured arterial wall.
Similarly, we were able to show (Papers III and IV) that in rats made 
hyperlipemic and hypercholesterolemic, there was no effect on the degree of 
myointimal proliferation. Superimposed on the basic proliferative lesion
2found in normolipemic animals, was the presence of foam cells in the intima.
In long-term hypercholesterolemic animals the foam cell lesions persisted but 
the regression of the myointimal proliferation was the same as in 
normolipemic controls.
Because the clotting sequence is no doubt activated in arterial injury, 
and because thrombin had been shown to be a mitogen, at least for some cell 
types, we thought it would be of interest to see if activation of the 
clotting sequence, and the generation of thrombin, was in any way related to 
the smooth muscle cell proliferation. In Paper we tested the effect of 
heparin, which destroys thrombin by activation of antithrombin III, on the 
degree of myointimal proliferation. We found that myointimal proliferation 
was almost completely suppressed. There was no effect of the heparin on the 
number of circulating platelets, on the number of platelets deposited at the 
site of the lesion, their degranulation and structure, or on the rate of 
endothelial regeneration.
The next question asked was whether the antiproliferative activity of 
heparin was truly related to its anticoagulant activity. Commercial heparin 
is a mixture containing fractions that bind and activate antithrombin, and are 
therefore anticoagulant in activity, as well as fractions that are non- 
antithrombin binding, and are thus non-anticoagulant. Therefore, in Paper 
VI, the experiments were repeated with anticoagulant and non-anticoagulant 
heparin, separated by affinity chromatography with antithrombin as the 
adsorbant. It was clear that nonanticoagulant heparin was just as effective 
in preventing myointimal proliferation as was anticoagulant heparin.
Although our original hypothesis was wrong, the fact that a non­
anticoagulant heparin was a potent antiproliferative agent, was clearly of 
interest. In order to explore the subtleties of the system further, we turned 
to in vitro systems. The test cells, bovine aortic endothelial and smooth 
muscle cells, and rat aortic smooth muscle cells were first grown in vitro, 
and then growth arrested. They were then released from growth arrest with 
either serum or platelet-extract - the latter containing platelet-derived 
growth factors (mitogens) - , and the effects of adding exogenous heparin, or 
other related compounds, were assayed in terms of increase in cell number 
over defined time periods.
In Paper VII we showed that heparin markedly inhibited the growth of 
vascular smooth muscle, and that anticoagulant heparin and non-anticoagulant 
heparin were both effective. Other anionic macromolecules (sulfated 
glycosaminoglycans), such as chondroitin sulfate, dermatan sulfate etc., were 
ineffective. We also showed that heparin interacts with the cell surface, 
that interaction with platelet growth factors in the culture media is not 
responsible for the heparin inhibitory effect, and that the mechanism of 
action is not mediated through an interaction with thrombin. Thus we 
concluded that heparin has some direct regulatory effect on smooth muscle 
cell growth.
In Paper VIII we extended these studies. We showed that heparin is 
inhibitory for vascular smooth cells, but not for endothelial cells. (In 
unpublished studies we have tested a large number of cell types: vascular
3smooth muscle cells are at least 100 fold more sensitive to heparin than are 
other cell types). Anticoagulant and non-anticoagulant heparin were equally 
effective as inhibitors of vascular smooth muscle cell proliferation in 
vitro. Once again, the inhibitory effect was specific for heparin: highly
purified heparin sulfates, dermatan sulfate, chondroitin ABC sulfates, and 
hyaluronic acid, at comparable doses were barely effective.
In order to establish what size of heparin molecule would have 
inhibitory effects, fragments of heparin were made by limit digest with 
nitrous acid and separated by chromatography. The detailed results are given 
in a forthcoming publication, but are summarized in Paper X. It was found 
that an inhibitory effect required an hexasaccharide or larger. Maximum 
inhibition was found in the dodecamer to 20- saccharide size range.
Chemical modification of the heparin molecule showed that 0-sulfation 
was necessary for antiproliferative activity: however, N-sulfation was not.
For instance, 0-sulfated, N-desulfated, N-acetylated heparin was potent 
(Paper X).
The importance of the active heparin fragments and the active 
chemically-modified heparins is that they have lost anticoagulant activity, 
but have retained high antiproliferative activity; thus these compounds may 
have clinical usage in preventing myointimal proliferation, eg. after 
vascular surgery, without the dangers of causing bleeding.
35Jn Paper X it is also reported that Scatchard analysis of S -labelled 
and H -labelled heparin - binding to vascular smooth muscle cells shows high 
affinity binding with a Kd^ of 2 x 10 M, with 2 x 10 sites per cell. 
Furthermore, in work to be published we show that the molecule is 
internalized by a receptor-mediated process. As given in preliminary form in 
Paper X, DNA synthesis is inhibited in a marked and immediate fashion, down 
to 20 percent of normal within three hours. RNA and protein synthesis are 
only affected late. Flow microfluorimetry shows decreased entry of cells 
into SI, and eventually the cells end up arrested in Gl. The mechanism(s) 
whereby heparin growth arrests vascular smooth muscle cells is currently 
under investigation in our laboratory.
The pharmacologic effects of heparin detailed above are of some 
interest, and of potential clinical importance. However, it was of moment to 
see whether a similar growth regulating system might be operative in situ in 
the vascular wall, utilizing endogenous heparin.
From our _in vivo studies (Papers _I and II) we had the impression that 
the vascular smooth muscle (myointimal) proliferation observed following 
endothelial injury ceased when re-endothelialization of the injured area 
occurred. Was it possible that endothelial cells had some sort of growth 
regulatory influence on the growth of vascular smooth muscle cells? We 
therefore examined the possible effect of endothelial cell secretions on 
vascular smooth muscle cell growth, in vitro.
In Paper VIII we show that conditioned media from confluent primary 
cultures of endothelial cells inhibited the growth of vascular smooth cells, 
released from growth arrest with serum.
4Was this effect specific for the endothelial cell as producer cell, and 
the vascular smooth muscle cell as the target cell? In both cases the answer 
is in the affirmative (Paper VIII): only conditioned medium from endothelial
cells was inhibitory, and only vascular smooth muscle cells were inhibiited.
What is the chemical nature of the inhibitory activity? The biochemical 
properties of the medium conditioned by endothelial cells, in relation to the 
antiproliferative activity, were established. (Paper IX). The activity was 
heat stable, protease insensitive, and was also insensitive to hyaluronidase 
and chondroitin sulfate ABC lyase. However, a highly purified flavobacterial 
heparinase, which had no protease activity, and which did not degrade 
chondroitin sulfates, dermatan sulfate or hyaluronic acid, almost completely 
abolished the inhibitory activity in the endothelial cell conditioned medium. 
This strongly suggested that the inhibitory activity was due to heparin. A 
glycosaminoglycan fraction of the medium was also inhibitory, and the 
activity was heparinase- sensitive. It was, therefore, concluded that 
endothelial cells produce heparin, or a heparin-like molecule, which was 
capable of inhibiting the proliferation of vascular smooth muscle.
In Paper IX we show the role of a new type of endoglycosidase 
(heparitinase) in the release of the heparin from the surface of endothelial 
cells. In our previous experiments it had become evident to us that the 
release of inhibitory activity (heparin) from endothelial cells always 
required the presence of a small amount of serum. This suggested the 
possibility that a component of serum derived from platelets was involved. 
This idea was made more cogent by the fact that platelet- free- plasma did 
not release the activity. One candidate for a platelet component was a new 
type of endogylycosidase (heparitinase) present in the lysosomes of 
platelets. This had been recently characterized by our colleague, Dr. Robert 
D. Rosenberg, and his collaborators. (Oosta, G.M., Favreau, L.V., Beeler, 
D.L. and Rosenberg, R.D. Purification and properties of human platelet 
heparitinase. J. Biol. Chem. 257;11249-11255, 1982). The enzyme is present 
in other cells and tissues, as well as platelets.
As shown in Paper IX, treatment of endothelial cells with this 
heparitinase in buffer or platelet- free- plasama effectively released the 
inhibitory activity. This enzyme differs from the bacterial enzyme in that 
it cleaves only glucuronosyl-glucosamine linkages, whereas the bacterial 
enzyme cleaves randomly at the relatively common glucosamine-iduronate bonds 
within sulfated regions. As a consequence the platelet-derived enzyme 
differs from the bacterial enzyme in that it yields, from heparin, on the 
average, dodecasaccharides, which are, as we have shown, inhibitory, whereas 
the bacterial enzyme yields disaccharides, which are inactive. Thus, the 
activity released by the platelet-derived heparitinase, was completely 
abolished by subsequent treatment with the bacterial enzyme. We take these 
results to indicate that platelet-derived heparitinase activity may be 
necessary, in vivo, for the release of the activity from endothelial cells, 
and they explain the serum requirement for release of activity found in 
vitro.
5In Paper we summarize our observations to date.
Coda
The above observations raise interesting questions as to the possible 
role of heparin or heparin-like compounds in growth regulation in the 
vascular wall. We have shown that exogenous heparin suppresses the growth of 
vascular smooth muscle cells iri vivo and in vitro, and the endothelial cells 
produce a similar inhibitory activity in vitro, presumably heparin.
In the normal, uninjured artery, endothelial cells might serve as a 
source of heparin-like substances. Experiments are now on-going to establish 
whether smooth muscle cells might play a similar role. Sulfated glycosamino- 
glycans are found in the arterial wall in both the intima and the media, and 
are strategically positioned to prevent proliferation. It is possible that 
smooth muscle and, or, endothelial cells produce the endoglycosidase, as the 
enzyme has been found in the lysosomes of several cell types (L.V. Favreau 
and R.D. Rosenberg, personal communcation). We would surmise that the enzyme 
is secreted into the extracellular milieu, where it could function to release 
antiproliferative heparin-like components from endothelial or other cells.
Upon endothelial injury, platelets would adhere and secrete their 
products, including platelet factor IV and mitogens. The presence of 
mitogens alone would not be sufficient to stimulate smooth muscle 
proliferate: the endogenous antiproliferative heparin must be overcome.
This hypothesis is based on our observations that in vitro, even in the 
presence of large amounts of serum, or platelet extract, heparin in low doses 
suppresses a proliferative response (see Papers VII and VIII). Suppression 
by exogenous heparin also occurs under _in vivo conditions (see Papers V and 
VI). There are several possible reasons as to why, after endothelial injury, 
in the absence of exogenous heparin, proliferation does occur. These are, 
inter alia:-
(a) damage or loss of the endothelium removes a major source of 
heparin-like molecules;
(b) endoglycosidase from platelets adhering to the injured area might 
cleave heparin-like substances into inhibitory fragments, but these 
could be washed away since the injury has removed the physical 
barrier to hydraulic flux provided by the endothelium;
(c) the local concentration of mitogens may be so high that smooth 
muscle cells can proliferate despite the presence of the complex 
carbohydrates; and
(d) platelet factor 4 could inactive heparin-like molecules.
Once the suppressing action of heparin is negated, the smooth muscle cells 
can migrate into the intima and proliferate. However, as soon as the damaged 
area is re-endothelialized, smooth muscle cell growth ceases (Paper I). This 
could be due to the presence of heparin-like substances released by the 
endothelial cells behind the regenerating front. The observations of Wight 
et al. (Wight, T.N., Curwen, K.D., and Hinick, C.R. (1982) Am. J. Pathol, in 
press) that substantial amounts of heparan sulfates accumulate behind the 
regenerating endothelial front support this suggestion.
6The cellular and molecular mechanisms of growth regulation in blood 
vessels are undoubtedly more complicated than the simple model presented 
above. However, alterations in the biosynthesis of heparin-like molecules by 
endothelial cells or other cells, changes in the production or release of 
endoglycosidases by platelets, smooth muscle cells, or endothelial cells, and 
alterations in the response of smooth muscle cells to these complex 
carbohydrates could, in part, be responsible for the initiation of the 
atherosclerotic process.
Lastly, one would like to know the precise biochemical mechanism whereby 
heparin produces these antiproliferative effects on vascular smooth muscle. 
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Endothelial Regeneration in the Rat Carotid 
Artery and the Significance of Endothelial 
Denudation in the Pathogenesis 
of Myointimal Thickening
Jay A. F ishman, G raeme B. R yan, M.B., B.S., Ph.D., and M orris J. K arnovsky, M.B., B.Ch. 
Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115
A new model was developed to study endothelial regeneration and the effects of endothelial denuda­
tion in large arteries. Complete endothelial loss was produced in a sharply defined, unbranched seg­
ment of the rat common carotid artery by brief drying with a gentle steam of air along the lumen of the 
vessel. Platelets became attached to the denuded surface, but no polymorphonuclear or mononuclear 
leukocytic adherence or infiltration was observed. Regeneration occurred by the ingrowth, from each 
end of the denuded segment, of sheets of rapidly dividing endothelial cells. Endothelial replacement 
was complete by 7 to 10 days after drying. It was also noted that, by 14 days after drying, a striking 
myointimal thickening developed in the central region of the denuded segment. This central region was 
the last area to be covered with new endothelium; while still denuded, the region showed edema and 
signs of cellular proliferation in the innermost medial layer. The myointimal thickening consisted of 
smooth muscle-like cells in a fibroelastic stroma in the deeper zones, and a layer of rounded, relatively 
undifferentiated cells in the superficial zones. Progressive regression and condensation of the thicken­
ing was observed between 14 days and 3 months.
In this model, the clear demarcation and completeness of endothelial denudation in the arterial seg­
ment allow study of the over-all process of endothelial replacement, avoiding the confusion imposed 
by islands of residual endothelium or contributions from branch vessels. The results suggest that the 
new endothelium in this situation is derived from each end of the segment. In addition, because the 
method of inducing denudation does not cause significant damage to the underlying media (as shown 
by the absence of inflammatory cell attachment or infiltration), the model offers a unique opportunity 
to study the relationship between endothelial loss and changes in the vessel wall. The correlation be­
tween the duration of endothelial denudation and the extent of myointimal thickening suggests that 
sustained insudation of certain, as yet undefined, factors from the lumen may provoke cellular prolif­
eration in the arterial wall. Further investigation of this model should provide information relevant 
to the pathogenesis of the fibromuscular thickenings of human atherosclerosis.
Additional key words: Atherosclerosis, Smooth muscle cells, Medial edema, Platelets, Scanning elec­
tron microscopy, Transmission electron microscopy, Autoradiography.
The origin of the cells responsible for endothelial 
regeneration following arterial injury is disputed. Al­
though early studies of experimentally induced endo­
thelial lesions indicated that replacement occurs by slow 
ingrowth of endothelial cells from the periphery of the 
denuded area (5, 6, 32, 33), later work suggested that 
blood leukocytes were the source of the new cells (1, 9. 
27, 42). More recently, studies of regeneration following 
injury with a balloon-tip catheter have led to the 
proposal that redifferentiation of underlying smooth 
muscle results in the formation of new endothelium (40). 
Data obtained with this model also suggested that 
myointimal proliferation occurs in response to loss of the 
endothelial layer (35, 41), although it is difficult to 
exclude the possibility that this proliferation was due to 
medial damage caused by distention with the balloon.
The relationship of such myointimal proliferation to that 
seen in atheromatous lesions has been reviewed by Ross 
and Glomset (35).
In the present study, we have developed a new model 
to examine endothelial regeneration in large arteries. 
The advantages of this model are: (1) endothelial 
denudation is complete in a defined segment of the 
vessel; (2) the segment has no side branches from which 
endothelium could be derived: and (3) injury to the 
media at the time of denudation is minimal, as shown by 
an absence of inflammatory cells in the area. Our 
findings indicate that regeneration can be attributed to 
rapid endothelial ingrowth from the ends of the injured 
segment of vessel; in addition, we have obtained clearer 
evidence that massive intimal thickening can result from 
endothelial denudation.
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MATERIALS AND METHODS
One hundred six male Sprague-Dawley rats (Charles 
River Breeding Laboratories. North Wilmington, Massa­
chusetts), weighing 250 to 050 gm., were used in this 
study. Animals were anesthetized with ether and the 
right common carotid artery was exposed for a distance 
of 2.5 to 3.0 cm. in the neck. Two ligatures of 1 0  nylon 
were tightly tied around the artery, separated by a 
distance of approximately 1.5 cm.; no branches were 
present along this segment of the vessel. A 30-gauge 
needle attached to a syringe filled with phosphate-buff­
ered saline was inserted into either the upper or lower 
end of the isolated segment. After filling the artery with 
saline, the needle was passed along the lumen, avoiding 
contact with the vessel wall until the far end of the 
isolated segment was reached. At this point the needle 
was allowed to penetrate the vessel wall briefly and w’as 
withdrawn back along the lumen to a point just inside 
the initial point of entry (Fig. 1). All blood was rinsed 
from inside the isolated segment with saline, following 
which the syringe was replaced by a regulated source of 
compressed air. A gentle stream of air (25 ml. per 
minute) was passed along the lumen of the vessel for 3 
minutes to produce drying injury of the endothelium 
(Fig. L); this procedure was adapted from the technique 
used by Ryan. Grobety, and Majno (36) to study injury 
of peritoneal mesothelium. The segment was then re­
filled with saline prior to removal of the needle from the 
vessel. The ligatures were cut with iris scissors and 
removed. Bleeding stopped after 2 to 3 minutes of gentle 
pressure at the needle holes with a swab dampened with 
saline. The skin was closed with 7.5-mm. metal clips and 
washed with 70 per cent alcohol and Mercurochrome. 
Animals were sacrificed at various times after surgery, 
ranging from 1 hour to 3 months. Only five animals 
subsequently developed thrombosis in the dried seg­
ment: these were discarded.
en F ace S ilver S taining
The technique of Poole. Sanders, and Florey (32) for 
staining of intercellular junctions was used to examine 
regrowth of endothelium at various times after injury. 
Animals were anesthetized with ether and received 
intravenous injections of heparin (Liquaemin; Organon, 
Inc., West Orange, New Jersey). 100 U.S.P. units per 100 
gm. of body weight. The abdomen was opened and a 
retrograde cannula was inserted into the abdominal 
aorta. After cutting both jugular veins, the animal was 
subjected to perfusion successively of 100 ml. of a 5 per 
cent solution of glucose followed by 0.25 per cent silver 
nitrate (13 ml.), 5 per cent glucose (30 ml.), 3 per cent 
cobaltous bromide and 1 per cent ammonium bromide 
(80 ml.). 5 per cent glucose (30 ml.), and 4 per cent 
formalin (50 ml.). Perfusion was continued with formalin 
at a pressure of 130 cm. water for 30 minutes. Both 
carotid arteries were dissected free for a length of 
approximately 4.5 cm., at least 0.5 cm. beyond the tie 
points at each end of the dried segment . Each vessel was 
opened along its length and pinned on dental wax with 
entomologic pins. Preparations were cleared in glycerol 
or 1.4-dioxane (both reagent grade: Fisher Scientific 
Company. Fair Lawn. New Jersey).
S canning  and T ransm ission  E lectron  M icroscopy
Animats were anesthetized with ether and received 
intravenous injections of 100 U.S.P. units of heparin per 
100 gm. body weight. A retrograde cannula was inserted 
into the abdominal aorta, and both jugular veins were 
opened to allow flow. Blood was washed from the animal 
by brief perfusion with Hanks’ balanced salt solution 
(Microbiological Associates, Inc., Bethesda, Marvland), 
pH 7.3. at room temperature. Perfusion was continued 
with a mixture of 1 per cent paraformaldehyde (Mathe- 
son, Coleman and Bell, East Rutherford, New Jersey) 
and 1.25 per cent glutaraldehyde (Polysciences. Inc.. 
Warrington, Pennsylvania) in 0.1 m cacodylate buffer 
(pH 7.3) (Karnovsky’s fixative (21), diluted 1:3) at a 
pressure of 130 cm. water for 15 minutes. The left and 
right common carotid arteries were removed intact and 
fixed overnight in 1:1 diluted Karnovsky’s fixative (2 per 
cent paraformaldehyde and 2.5 per cent glutaralde­
hyde). Each vessel was washed with 0.1 M cacodylate 
buffer (pH 7.4) by flushing the lumen with a 26-gauge 
needle on a syringe and four changes of buffer solution 
before postfixation in 2 per cent osmium tetroxide in 0.1 
m cacodylate buffer for 2 hours at 4° C. After washing in 
buffer, as above, and dehydration in acetone, each vessel 
was sliced lengthwise in half. One half was left intact 
and processed for scanning electron microscopy. After 
drying in a Samdri PVT-3 C 02 critical point drying 
apparatus (Biodynamics Research Corporation, Rock­
ville, Maryland), the preparation was attached to a 
metal stud with double sided tape, shadowed with 
palladium-gold (40:60) in a Ladd vacuum evaporator 
(Ladd Research Industries, Burlington, Vermont), and 
examined with an ETEC scanning electron microscope 
(ETEC Corporation. Hayward, California). The remain­
ing half of each vessel was processed for light and 
electron microscopy. The complete length was cut into 
sequential pieces and embedded in Epon 812. Thick 
sections (2 fim.) for light microscopy were cut with glass 
knives on a Porter-Blum MT-2 ultramicrotome (Ivan 
Sorvall, Inc., Norwalk, Connecticut) and stained with 
0.1 per cent toluidine blue and 0.1 per cent sodium 
borate. Light photomicroscopy was performed using a 
Zeiss photomicroscope (Carl Zeiss, Inc., New York, New 
York) with Kodak Panatomic-X film. Thin sections were 
cut with a diamond knife on an LKB LUtrotome III (LKB 
Instruments, Inc., Bromma, Sweden), mounted on 200- 
mesh grids, stained with uranyl acetate and lead citrate, 
and examined at 60 kv. with a Philips 200 electron 
microscope (Philips Electronic Instruments, Mount Ver­
non, New York).
A utoradiographic Studies
At times ranging from 3 hours to 2 months after drying 
of the carotid artery, nine rats received intravenous 
injections of tritiated thymidine (0.75 nCi. per gm. body 
weight (specific activity. 2 Ci. per mmole): New England 
Nuclear Corporation, Boston. Massachusetts). One hour 
later, the animals were killed and the carotid arteries 
were removed, opened lengthwise, and pinned on dental 
wax before fixation with 1:1 diluted Karnovsky’s fixa­
tive. Each preparation was then attached to a slide, 
endothelium uppermost, with Kaiser s glycerol jelly. En
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face autoradiography was performed on these vessels In- 
dipping each slide into 70 per cent Ilford L-4 emulsion 
(Ilford Ltd., Essex, England) and drying vertically for 00 
minutes. After incubation for 27 days, the preparations 
were treated for 6 minutes in Kodak D-19 developer (15.5 
per cent), rinsed briefly in distilled water, and fixed for 8 
minutes in 30 per cent sodium thiosulfate.
Another group of three rats was sacrificed 1 hour after 
a dose of tritiated thymidine at 5, 7, or 10 days after 
drying. The animals were heparinized and fixed by 
perfusion with paraformaldehvde-glutaraldehyde as 
above. Pieces of the carotid arteries were embedded in 
Epon 812, sectioned for light and electron microscopy, 
and left unstained. Thick sections on precleaned glass 
slides were dipped into 50 per cent Ilford L-4 emulsion 
and dried for 1 hour on a cold metal plate (34). Thin 
sections on 200-mesh grids were coated with 50 per cent 
Ilford L-4 emulsion by the loop technique of Hay and 
Revel (15). After 21 days, light microscopic autoradio­
graphs were developed as above and then air-dried and 
stained for 30 seconds with 0.1 per cent toluidine blue. 
Also after 21 days, electron microscopic autoradiographs 
were developed for 3 minutes in D-19 developer, rinsed in 
distilled water, and fixed for 1 minute in sodium 
thiosulfate; the sections were then treated for 10 minutes 
in 0.1 N sodium hydroxide before staining with uranyl 
acetate and lead citrate.
RESULTS
en F ace O bservations of E ndothelial  R egeneration
Silver Staining. One hour after drying of the carotid 
artery, the interendothelial silver lines were thickened 
and irregular. At 3 hours, disruption was more advanced 
and some areas showed endothelial loss. By 12 hours, the 
dried segment was totally denuded of endothelium 
except for a small patch of cells sometimes found 
between the needle insertion hole and the proximal 
ligature site. Presumably, this patch of cells was pro­
tected from the stream of air by a small drop of saline 
between the needle and the ligature (Fig. 1). Between 2 
and 4 days after drying, a sheet of elongated endothelial 
cells could be seen spreading upward from the proximal 
ligature site toward an identical sheet spreading down­
ward from the distal ligature site (Fig. 2). At no stage 
could cellular outlines be discerned on the bare interven­
ing area. The edges of these advancing sheets of endothe­
lium became confluent near the central region of the 
dried segment between 7 and 10 days after the injury. By 
1 month, the appearance of the silver lines within the 
segment was indistinguishable from normal.
Scanning Electron Microscopy. The time course and 
pattern of endothelial loss and regrowth found with 
silver staining were confirmed by scanning electron 
microscopy. By 12 hours, the dried area was covered with 
a carpet of platelets; no endothelial cells were present. 
Commencing at 2 days after drying, the platelet carpet 
was progressively replaced from each end by a sheet of 
endothelium (Figs. 3 and 4). These sheets were in 
continuity with normal endothelium beyond the ligature 
sites and, although each spreading edge showed an 
irregular outline, the cells maintained contact with one
AIR
F ig. 1. Depiction of carotid drying model for endothelial denuda­
tion. Ligatures are placed 1.5 cm. apart on the common carotid artery. 
A gentle stream of air is then passed along the lumen of this segment 
for 3 minutes: the air is introduced by means of a needle (at the left of 
the diagram) and exits via a small hole at the distal end of the 
segment (at the right). The ligatures are then removed to restore blood 
flow. The area (marked with x) between the needle and the proximal 
ligature site sometimes showed residual surviving endothelium, but 
the rest of the vessel became completely denuded.
Fig. 2. En face silver-stained preparation of the advancing edge of 
a new endothelial sheet 4 days after denudation. Endothelial cells (E) 
are delineated by silver lines; the bare area (at the right) shows faint 
transverse streaks. x200.
F ig. 3. Low power scanning electron micrograph of the distal end of 
a carotid artery segment 4 days after endothelial denudation. A sheet 
of endothelium (£) has grown across the ligature site (L) and is 
spreading over the denuded area ID). The advancing endothelial edge 
is indicated by an arrow. x90.
another. Isolated cells were not seen on the denuded 
area. The cells composing the endothelial sheets were 
elongated along the vessel length, showed nuclear 
humps, and displayed multiple microvilli (particularly
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bver the trailing ends of the cells) (Fig. 5). In addition, at 
the margins between cells, irregular holes were often 
found (Fig. 5): these resembled the intercellular “pores" 
sometimes detected in normal endothelium (Fig. 6). 
(These pores, the significance of which is unknown, are 
not to be confused with the much smaller true capillary 
pores described by physiologists (22).) Polymorphonu­
clear leukocytes were found at. or adjacent to, the sites 
directly injured by the ligatures (Fig. 7), but were not 
seen on the dried area at any stage. After confluence of 
the endothelial edges between 7 and 10 days, the cells
slowly flattened and became normal in appearance by 1 
month.
E ndothelial  R egen era tion  and I ntimal T hickening  in
S ection ed  M aterial
Histology. Light microscopy of thick Epon sections 
(Fig. 8) confirmed the loss of endothelium in the dried 
segment, the presence of a thin layer of platelets on the 
denuded surface, and the progressive ingrowth of new 
endothelium from each end. This new endothelium 
usually consisted of a single layer of flattened cells (Fig.
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8C) but sometimes showed double layering close to the 
spreading edge. At the ligature sites, there was rupture 
of the elastic laminae, leaving an ulcer-like crater with a 
base covered at first with a thin layer of fibrin and 
infiltrated with polymorphonuclear leukocytes and mac­
rophages, but soon (within 2 to 3 days) covered by 
endothelium. Apart from the immediate vicinity of the 
ligature sites, polymorphonuclear leukocytes were never 
seen along the dried segment, either attached to the 
surface or infiltrating the media. By 24 hours after
drying, the denuded segment developed edema of the 
innermost medial zone (Fig. SB). This edema disap­
peared only when the surface was reendothelialized and 
was present for at least 7 days in the central region of the 
dried segment: mitoses were prominent in this residual 
edematous zone of the media at the end of the 1st week. 
Normally, the endothelium sits almost directly upon the 
internal elastic lamina (Fig. 8A). However, by 14 days 
after drying, massive intimal thickening (to approxi­
mately 3 times the thickness of the media) was present.
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F ig. 6. Scanning electron micrograph of normal rat carotid artery 
endothelium. The intercellular borders between individual endothelial 
cells are characterized by a row of small, irregular projections and 
sometimes show small “pores" (arrows). Note microvilli (V). xl.100.
mainly in the central region of the denuded segment 
(Figs. 8D and 9). This thickening consisted of large 
numbers of cells in a fibroelastic stroma. At later stages, 
there was a progressive decrease in the number of cells in 
the thickened zone, along with condensation of the 
stroma (Fig. 8E and F). By 3 months, the intima was 
approximately one-third the thickness of the media (Fig. 
8G). No such intimal thickening developed in sham- 
operated animals in which ligatures were applied to the 
carotid artery for 10 minutes but no drying was per­
formed.
Transmission Electron Microscopy. Examination of 
thin sections of the denuded area showed that platelets 
were attached to a thin layer of loosely fibrillar material 
on the surface of the internal elastic lamina (Figs. 10 and 
11). The platelets displayed various degrees of degranu­
lation. No fibrin was detected. The internal elastic 
lamina appeared normal. At the spreading edge of the 
endothelial sheet, the cytoplasm was flattened against 
the surface (Fig. 10) and often extended as a thin veil 
beyond the cell body (Fig. 11); no platelets were trapped 
beneath the endothelium. Near the spreading edge, two 
layers of endothelial cells were sometimes seen. Between 
adjacent cells, junctional complexes like those in normal 
carotid endothelium were found (Fig. 10). The new 
endothelial cells contained many ribosomes, some rough 
endoplasmic reticulum, scattered microtubules, and 
abundant microfilaments, but no lysosomal granules. 
The microfilaments were commonly arranged in dense 
bundles along the underside of the cell (Fig. 11). 
Pinocytotic vesicles were present at the cell margins, and 
microvilli were found at the trailing ends of the cells 
(Fig. 10).
At the end of the 1st week, many of the cells in the 
edematous innermost zone of the media were packed 
with ribosomes and contained relatively few microfila­
ments (see Fig. 18): conventional smooth muscle cells 
with well developed bundles of microfilaments and 
dense bodies were in a minority in this region. At 14 
days, the massively thickened intima (see Fig. 9) was 
packed with cells separated by a fibroelastic stroma 
(Figs. 12 and 13); collagen fibers and elastin were 
particularly dense in the deeper zones, i.e., near the 
internal elastic lamina (Fig. 12). The deep cells were 
elongated and showed predominantly smooth muscle-like 
features, with prominent muscles bundles (Fig. 12). In 
contrast, cells closer to the luminal surface were more 
rounded and contained large amounts of rough endoplas­
mic reticulum and relatively few microfilaments (Fig. 
13). By 3 months, the intima consisted of a very dense 
fibroelastic stroma containing mature smooth muscle 
cells.
A utoradiographic  S tud ies
The pattern of tritiated thymidine labeling in en face 
preparations at various stages after drying of the carotid 
artery is shown in Figure 14. Control preparations from 
normal rats sacrificed 1 hour after the administration of 
tritiated thymidine showed labeling in only 0.2 to 0.3 per 
cent of endothelial cells. No increase occurred in the 
labeling of the endothelium at the ends of the dried 
segment until 2 days after drying. At this stage, there 
was extensive labeling in the proximal remnant endo­
thelial cells (between the needle insertion hole and the 
proximal ligature site) and in a small area above the
F ig. 7. Scanning electron micrograph of the surface immediately 
above the distal ligature site. 2 days after injury, showing multiple 
round polymorphonuclear leukocytes adhering to endothelium. Such 
cells were seen only in the vicinity of the ligature sites and not in the 
central regions of the denuded segment. • 800.
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F ig. 8. Composite histologic figure illustrating the changes occur­
ring in the wall of the carotid artery after endothelial denudation. To 
aid comparison of intimal thickness at each stage, the elastic laminae 
of the media are aligned. The vessel lumen is at the right of each 
picture. A, Normal vessel showing flat endothelium. B, Central area of 
the segment, 4 days after denudation, showing loss of endothelium and 
prominent edema of the innermost zone of the media. C, Newly 
covered area, 7 days after denudation, showing plump endothelial cells
F ig. 9. Histologic section of myointimal thickening at 14 days after 
endothelial denudation. Note the elastic fibers between cells of the 
deeper areas and the somewhat rounded appearance of the cells 
composing the more superficial zone next to the vessel lumen (top). 
Electron micrographs of thin sections from this block of tissue are 
shown in Figure 12 (deep zone) and Figure 13 (superficial zone). x 4 10.
distal tie (Fig. 15). By 7 days, a high proportion 
(approximately 25 per cent) of cells in the central region 
was labeled (Fig. 16), with little or no labeling apparent 
at the ends of the segment. At 14 days, labeling had 
returned to normal levels.
The presence of endothelial labeling, in cells at or near 
the advancing edge, was confirmed in sectioned material 
(Fig. 17). At the end of the 1st week after drying, labeling 
was also present in cells of the innermost zone of the 
media, almost exclusively in the edematous central part 
of the dried segment. These labeled medial cells were 
packed with ribosomes and rough endoplasmic reticu­
lum but contained relatively few microfilaments (Fig. 
18).
DISCUSSION
The earliest experiments on arterial endothelial injury 
suggested that repair was dependent upon endothelial 
ingrowth from the periphery of the induced lesion (32,
and resolution of the medial edema. D, Central area of the segment. 14 
days after denudation, showing the massive extent of myointimal 
thickening. E. Central area, at 17 days, showing a slight decrease in the 
thickness of the myointimal layer. F and G. Central area, at 1 and 3 
months, respectively, showing progressive condensation of thickened 
zone. x320.
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Fig. 11. Electron micrograph of a thin endothelial cell veil (E) at 
the growing edge 4 days after denudation. Note internal elastic lamina
33), but the severity of the lesion and the slowness of 
regeneration (up to 7 months) led others to question the 
pertinence of the model used. Florey et al. (5, 6) found 
that Dacron grafts in the abdominal aorta of baboons 
w'ere more rapidly covered (in less than 10 weeks), 
apparently from endothelial ingrowth from the ends of 
the graft and from small vascular channels that devel­
oped openings, at scattered points along the lumen. On 
the other hand, studies by other workers suggested that 
such new endothelium was derived from blood-borne 
cells (1, 9, 27. 42). Ghani and Tibbs (9) supported this 
view on the basis of light microscopy of Terylene grafts 
inserted into dog aortas. DeBakey’s group (27, 42) 
originally came to the same conclusion in studies of the 
endothelialization of Dacron hubs suspended in the 
aortic lumen of pigs. However, these workers revised this 
opinion when they found that the new endothelium 
which lined impermeable Silastic vascular prostheses 
appeared to derive from endothelium at the ends of the 
implant (10). Using a model in which a halloon catheter 
was inserted, inflated, and withdrawn from the iliac ar­
tery of rabbits, Baumgartner and Spaot (1) reported the 
adhesion of platelets, granulocytes, and mononuclear 
cells to the denuded surface and suggested that mono­
cytes may form the new endothelium. However. Spaet. 
Stemerman. and Lejneiks (40) more recently proposed 
that smooth muscle cells redilferentiate into endothe­
lium in this system. The conflicting results obtained by 
(different groups studying this problem may relate to 
[inherent difficulties of the models used. Thus, the
(EL), platelets (P), and basally located intracellular bundles of 
microfilaments (arrow), x 10,500.
balloon-tip catheter model does not allow denudation of 
a clearly delineated segment of vessel, and the denuda­
tion obtained is often incomplete (35. 41). Furthermore, 
as indicated by the studies by Stemerman and Ross (41). 
it appears that significant medial damage is inflicted by 
the inflated catheter tip, resulting in local adhesion and 
infiltration of leukocytes in the injured area. It is 
difficult to isolate the effects of this nonspecific damage 
on endothelial regeneration or subsequent intimal thick­
ening. In addition, the use of arterial segments with 
branch vessels may complicate studies of regrowth 
patterns because endothelium can grow into the dam­
aged area from the mouths of these branches.
These considerations prompted us to develop a new- 
model for the study of endothelial regeneration. A 
sharply defined length of rat common carotid artery with 
no side branches was subjected to brief drying with a 
gentle stream of air along the lumen. Such preparations, 
approximately 1.5 cm. in length, could then be examined 
in toto for histology and transmission and scanning 
electron microscopy, as well as allowing cn face pre para - 
t ions of the entire area for silver staining and autoradiog­
raphy. We found that, soon after drying, the endothe­
lium disappeared completely from the area and was 
replaced by a carpet of platelets. There was no adhesion 
or infiltration of inflammatory cells. By 48 hours after 
drying, the remaining endothelium at the ends of the 
denuded surface showed signs of proliferation. This 
resulted in the development of an advancing sheet of 
endothelium which grew over the denuded area from
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Fir;. 12. Electron micrograph of the deep zone of myointimal thick- ment bundles with dense bodies (armies 1. and intercellular elastic 
ening shown in Figure 9. Note internal elastic lamina (EL) in the lou er tissue (ED. ■ 7,200. 
right corner, elongated smooth muscle-like cells containing microfila-
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F ig. 13. Electron micrograph of the superficial zone of mvointimal far fewer microfilaments than do cells in the deeper zone (seen in Fig. 
thickening shown in Figure 9. The luminal surface is just beyond the 12). In addition, there are smaller amounts of intercellular elastic 
upper left corner. The cells in this region are more rounded and contain tissue (ED. <7,200.
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C A P C YI O  A R T E R Y
F ig. 14. En face autoradiographic labeling with tritiated thymidine 
of surface cells at various stages after endothelial denudation. As 
indicated, the abscissa represents the segment of carotid artery along 
which autoradiographic counts were performed; note the position of 
the ligature (“tie") sites. At each time, the bars indicate the number of 
labeled nuclei counted in successive  ^430 microscopic fields along the 
length of the vessel. Note heavy labeling at each end of the denuded 
segment at 2 and 4 days and in the central region at 7 days.
F ig. 15. En face autoradiographic labeling of endothelial cells 
immediately above distal ligature site (L), 2 days after endothelial 
denudation. At this stage, no labeling is seen in the denuded area (D) 
to the left of the ligature site. \200.
either end of the segment, displacing platelets from the 
surface. By 7 to 10 days after drying, tne two growing 
edges of actively dividing endothelium had met in the 
center of the denuded surface and had stopped division 
by 2 weeks. By 1 month, the endothelial layer appeared 
to be normal. These findings strongly suggest that the 
new endothelium in such lesions is derived from endo­
thelial cells at the periphery of the denuded region, 
although an origin from blood mononuclear cells has not 
yet been formally excluded. Kinetic studies to clarify 
this point are in progress.
In these experiments, we also observed the develop­
ment of striking thickening of the intimal layer between 
the endothelium and the internal elastic lamina. The 
greatest thickening occurred in the central region of the
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segment, that is, in the last area to be recovered by the 
ingrowth of endothelium. The thickening was maximal 
at 14 days after denudation, achieving a width approxi­
mately 3 times that of the normal vessel wall. After 14
* 0  
m
f a
F ig. 16. En face autoradiographic labeling of cells in the central 
region of the previously denuded segment, 7 days after drying. x850.
Fig. 17. Electron microscopic autoradiograph of an advancing edge 
7 davs after injury, showing silver grains over the endothelial nucleus, 
x 6,250.
Fig. 18. Electron microscopic autoradiograph of labeled cell in the 
innermost zone of the media 7 days after endothelial denudation. The 
cytoplasm of this cell contains many ribosomes but few microlila- 
ments. x 16.300.
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days, the thickness of the intima decreased gradually 
until, at 3 months after denudation, it was approxi­
mately one-third the width of the media. At 14 days, the 
deeper part of this new layer was largely composed of 
smooth muscle-like cells separated by collagen and 
elastic fibers. The luminal part was made up of rela­
tively undifferentiated cells densely filled with ribo­
somes and very few microfilaments. The number of these 
undifferentiated cells decreased rapidly and were rarely 
seen at 1 month after injury. By 3 months, the new layer 
was highly condensed and was composed of smooth 
muscle cells, collagen, and elastic tissue.
The origin of this new myointimal layer is not clear. It 
occurred to the greatest degree in the area longest 
exposed to plasma protein insudation (as shown by 
medial edema) and to platelet adherence. At the end of 
the 1st week after denudation, the inner edematous zone 
of the media showed many relatively undifferentiated 
cells that became labeled with tritiated thymidine: 
mitoses also were common in this area. The origin of 
these undifferentiated cells, and of the new cells in the 
thickened intima at 14 days, has not yet been estab­
lished; in other studies, similar cells have been presumed 
to derive from medial smooth muscle (35). It is possible 
that stimulatory plasma or platelet factors leak into the 
arterial wall, where they trigger cells to proliferate and 
migrate into the intima via fenestrations in the elastic 
laminae. Such proliferation may be analogous to that of 
fibroblasts in granulation tissue, the stimulatory mecha­
nism for which has also not been identified.
Smooth muscle cells are the predominant cellular 
component in the focal fibromuscular intimal lesions in 
human atherosclerosis (8, 14, 25) and in similar plaques 
induced experimentally in animals (7, 29-31, 38, 41, 
44 46), including the present model. It has been pro­
posed, as recently reviewed by Ross and Glomset (35). 
that such lesions develop as a result of focal proliferation 
of smooth muscle cells, followed by intracellular and 
extracellular lipid deposition. Other workers have sug­
gested that the primary and crucial event in atherogene- 
sis is lipid deposition with or without subsequent intimal 
thickening (39, 43). It has been noted, however, that 
these two processes can occur independently in most 
species (4). Duncan (3) suggested that increased pene­
tration of the plasma proteins into the vessel wall could 
result from focal alteration in the permeability proper­
ties of the endothelial lining, presumably due to some 
form of injury. Recent studies indicate that, in regions of 
increased hemodynamic shearing stress, there is in­
creased histamine synthesis in the endothelial layer and 
an increase in vascular permeability (16) which would 
allow penetration of plasma factors into the vessel wall. 
It has also been demonstrated that sites of endothelial 
damage have been associated with a local accumulation 
of tracer molecules (such as Evans blue or radioactively 
labeled albumin (2. 7, 20. 28. 38)) or subsequent intimal 
thickening (7. 12, 26, 31, 35. 41, 46), or both (11, 46). In 
addition, experiments by Ross and Glomset (35) demon­
strated the in vitro stimulation of smooth muscle prolif­
eration by low molecular weight plasma lipoproteins. 
More recent work by Harker et al. (13) has shown that a
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platelet-derived factor caused similar proliferation in 
smooth muscle cultures. In related experiments on 
induced homocvstinuria in baboons, focal loss of endo­
thelium, coupled with the appearance of atheromatous 
lesions, was observed (13). Similarly, in man, homocys- 
tinuria is associated with mvoproliferative intimal le­
sions with intracellular and extracellular lipid deposition 
(19, 23, 24). The primary event in this disease is believed 
to be focal loss of endothelium, without apparent medial 
damage (19, 23, 24). In situations of endothelial damage 
induced by hypertension (2, 17, 18) or by “shear forces" 
(4, 16) at bifurcations, “intimal pads” characterized by 
fibromuscular proliferation are frequently seen with or 
without subsequent lipid deposition (4). Flaherty et al. 
(4) have noted that the type of lesion varied not only 
with age and species but also from vessel to vessel; 
incidentally, these workers pointed out that the common 
carotid artery shows relatively little deposition.
In our model, endothelial denudation resulted in 
myointimal thickening without lipid deposition in a 
localized segment of the common carotid artery in the 
rat, an animal not predisposed to arteriosclerosis. This 
localized hyperplasia occurred most strikingly in regions 
that were exposed to medial edema and surface platelet 
adhesion for the longest period of time. It is important to 
note that the thickening occurred in response to endo­
thelial denudation rather than to direct physical damage 
to the media, that relatively undifferentiated cells were 
the only medial cells showing signs of active prolifera­
tion, and that regression of the new myointimal layer 
was observed over a period of 3 months. We are currently 
using the model to determine the origin and fate of the 
cells in the thickened zones and the factors involved in 
the persistence of such lesions.
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Absence of Enhanced Intimal Thickening in the 
Response of the Carotid Arterial 
Wall to Endothelial Injury in 
Hypercholesterolemic Rats
Alexander W. C lowes, M.D., G raeme B. R yan, M.B., B.S., Ph.D., J an L. B reslow , M.D.,
and M orris J .  K arnovsky, M .B ., B .C h .
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Young male Sprague-Dawley rats fed a high cholesterol, thyroid-suppressive diet were subjected to 
drying injury of carotid artery endothelium; animals were sacrificed at various times up to 3 months 
after injury, and the vessels were examined by light, scanning, and transmission electron microscopy. 
The diet induced marked elevation of serum cholesterol mainly present in lipoproteins of density < 1.063. 
The morphology and degree of intimal thickening in the injured carotids of such animals were com­
pared with the changes found in control groups of normolipemic rats. In the control groups, endothelium 
was completely regenerated between 7 and 14 days; intimal thickening was present at 14 days and at 
later stages and contained smooth muscle cells without lipid. In the cholesterol-fed animals, endothelial 
regeneration and intimal thickening occurred as in the controls with the following additional features: 
in the zone of intimal thickening in the injured segment, lipid was present in smooth muscle cells and, at 
later stages, in the extracellular matrix; undifferentiated mononuclear cells were also noted in the thick­
ened intima and, at 3 months, were found adhering to normal and regenerated endothelium. However, 
no differences were found between control and hypercholesterolemic rats with respect to the degree of 
intimal thickening within the injured segment; enhancement of the smooth muscle proliferative response 
was not evident in the hypercholesterolemic rats. Our findings suggest that this form of hypercholes­
terolemia and its associated hyperlipoproteinemia may not be directly responsible for rat smooth muscle 
proliferation following endothelial denudation. They also indicate that hyperlipemia does not necessarily 
cause persistence of myointimal hyperplasia in arteries.
Additional key words: Arteriosclerosis, Lipoproteins, Smooth muscle cell.
Smooth muscle hyperplasia appears to be the princi­
pal event leading to intimal thickening following arterial 
injury (4, 12, 15, 22, 29, 32, 34, 35, 39, 45). However, the 
growth factors responsible for stimulating smooth mus­
cle cell proliferation have not been clearly identified. 
Various lipoproteins and platelet factors have been 
reported to have mitogenic activity for smooth muscle 
cells in vitro, but not unequivocally in vivo (11, 31, 36, 
37). Several in vivo studies have examined the response 
to endothelial injury in arteries of animals fed a high 
cholesterol diet. Such diets induce high serum levels of 
cholesterol mainly present in lipoproteins of D <  1.063 
(26, 27, 40, 42). Using a balloon catheter technique, Nam 
et al. (32) noted enhanced aortic intimal thickening in 
hypercholesterolemic swine. On the other hand, Hardin, 
Minick, and Murphy (19) found that hypercholes­
terolemia did not increase the number of proliferative 
intimal lesions in rabbit arteries injured by repeated 
injections of horse serum.
In the present study, we have examined the effect of a
high cholesterol diet upon the the smooth muscle prolif­
erative response in the air-dried rat carotid artery (12). 
In this model, the endothelium is dried by infusing a 
stream of air along a segment of rat common carotid 
artery; this results in rapid loss of endothelium in the 
dried zone. A carpet of platelets quickly covers the 
denuded area, but no leukocytes are present. Endo­
thelial ingrowth occurs from normal endothelium at the 
ends of the injured zone, and endothelial replacement is 
complete between 7 and 10 days after drying. The most 
striking change in such arteries is noted at 2 weeks after 
injury: marked myointimal thickening develops in the 
central region of the injured segment, i.e., in the area 
which was denuded of endothelium for the longest period 
of time. The advantages of this technique for studying 
the role of endothelial loss in intimal thickening are as 
follows: endothelial loss is complete and occurs over a 
clearly defined area; the injured segment has no side 
branches from which endothelium can be derived so that 
endothelium is regenerated only from sources of normal
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endothelium at the ends of the injured segment; the 
initial injury is limited to the endothelium, with no 
direct effects detectable upon cells in the media; the 
lesion is not complicated by infiltration with leukocytes 
or the development of thrombosis; and the resultant 
myointimal thickening is highly reproducible. We were 
particularly interested in using this technique to deter­
mine whether the altered blood lipid levels in hyper- 
cholesterolemic rats would be associated with exacerba­
tion or unusual persistence of intimal smooth muscle 
proliferation. Because normolipemic rats show a peak 
proliferative response at 2 weeks, followed by a progres­
sive decrease in intimal thickness over the ensuing weeks 
(12), we concentrated upon the changes found in the 
hyperlipemic animals during the first 3 months after 
injury. This avoided confusion with the potential long 
term complications of a high cholesterol diet, such as 
thrombosis and intramural necrosis, hemorrhage, and 
calcification (32).
MATERIALS AND METHODS 
Animals and D iet
Seventy-four male Sprague-Dawley rats (Charles 
River Breeding Laboratories, Inc., North Wilmington, 
Massachusetts) weighing 250 to 350 gm. (3 to 4 months 
old) were used (Table 1). Rats became hypercholes- 
terolemic on a diet (9, 10, 33) containing 4 per cent 
cholesterol, 1 per cent cholic acid, and 0.5 per cent 
2-thiouracil (Sigma Chemical Company, St. Louis, Mis­
souri) mixed with standard stock diet (Purina rat chow, 
Ralston Purina Company, St. Louis, Missouri) and 
pelleted at the New England Regional Primate Center, 
Southboro, Massachusetts. Normal control animals were 
fed the standard stock diet. Hypothyroid control animals 
were fed a diet containing 1 per cent cholic acid and 0.5 
per cent 2-thiouracil mixed with standard stock diet. 
Normal control animals gained weight at the rate of 25 
gm. per week whereas hypothyroid control and choles­
terol-fed animals maintained their weight at a constant 
level throughout the course of the experiment; the 
growth curves were similar to those previously published 
(10) .
L ipid and L ipo pro tein  A nalysis
Blood samples were obtained 1 week after commenc­
ing the high cholesterol diet and at the time of sacrifice; 
the blood was anticoagulated with ethylenediaminetet- 
raacetic acid (EDTA) (1 mg. per ml.) and plasma was 
obtained by centrifugation of the samples at 900 x g for 
30 minutes. Total plasma cholesterol and triglyceride 
levels (expressed in milligrams per 100 milliliters ± 
standard error) were measured using the Technicon Auto
T able 1. E xperimental P rotocol
Diet” 2 da. 7 da. 14 da. 1 mo. 2 mo. 3 mo.
High cholesterol 3* 3 8 12 6 6
Normal control 2 2 7 9 4 4
Hypothyroid control 4 4
“ Diet was started 10 to 14 days before carotid injury.
* Number of rats examined at time points after carotid injury.
Analyzer II (Technicon Instruments Corporation, Tarry- 
town, New York). For lipoprotein studies, plasma was 
spun in a Beckman preparative ultracentrifuge (Beck­
man Instruments, Inc., Fullerton, California) at varying 
densities. Density adjustments were made with solid 
KBr according to standard techniques (24). Plasma from 
control rats was spun sequentially at D 1.006, D 1.040, D
1.063, and D 1.21. The supernatants were refloated 
through salt solutions of their own density, isolated, and 
dialyzed extensively against buffer A (0.15 m  NaCl and 
0.3 mM EDTA, pH 7.4). Lipoproteins of D <1.006, D 
1.006 to D  1.040, and D 1.063 to D 1.21 were isolated and 
characterized. The turbid hyperlipemic plasma obtained 
from rats fed the cholesterol rich diet was spun at D
1.063. Under these conditions, the turbid material 
floated and the isolated supernatant was refloated 
through a salt solution, D  1.063, reisolated, and dialyzed 
extensively against buffer A.
Aliquots of whole plasma and isolated lipoproteins 
from normal and hyperlipemic animals were subjected 
to agarose electrophoresis at pH 8.6 using the Millipore 
Panagel electrophoresis system (Millipore Biomedica, 
Acton, Massachusetts). The lipoproteins were stained 
with Sudan black.
E xper im en ta l  P rocedure
Air injury of the right carotid artery was performed as 
described by Fishman, Ryan, and Karnovsky (12) 10 to 
14 days after commencing the diets. Animals were 
sacrificed at each of the following times after injury 
(Table 1): 2 days, 7 days, 14 days, 1 month, 2 months, 
and 3 months. Perfusion fixation was performed (12), 
and both common carotid arteries were removed and 
fixed for an additional 4 hours in 2 per cent paraformal­
dehyde and 2.5 per cent glutaraldehyde in 0.1 M cacodyl- 
ate buffer, pH 7.4. The arteries were then processed for 
light microscopy, scanning electron microscopy, and 
transmission electron microscopy (12). Carotids used for 
oil red O preparations were cut on a model CTD 
International Harris cryostat (International Equipment 
Company, Needham, Massachusetts). Carotids proc­
essed for light microscopy and transmission electron 
microscopy were dehydrated through alcohol after post­
fixation in 2 per cent osmium tetroxide for 2 hours at 
room temperature; they were then embedded in paraffin 
or Epon 812 for longitudinal or seriated cross-sectioning 
along their entire length. Paraffin sections (6 *tm.) were 
stained with hematoxylin and eosin; Epon sections (2 
M m .) were stained with toluidine blue. Maximal plaque 
thickness (distance from luminal surface to internal 
elastic lamina) and adjacent media thickness (distance 
from internal elastic lamina to the most external elastic 
lamina) were measured with an ocular graticule. Plaque 
size was expressed as a ratio of plaque to media thickness 
± the standard error.
RESULTS
L ipid  and L ipo pr o tein  A nalysis
Rats on the high cholesterol diet developed marked 
hypercholesterolemia. At 1 week, the mean plasma 
cholesterol level in such rats was 910 ± 79 mg. per 100
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ml. (normal control 53 ± 6 mg. per 100 ml., p <  0.001; 
hypothyroid control 109 =t 8 mg. per 100 ml., p < 0.001); 
at sacrifice, the value was 1047 ± 132 mg. per 100 ml. 
The mean plasma triglyceride level at sacrifice in the 
hypercholesterolemic rats was 79 ± 12 mg. per 100 ml., a 
value slightly higher than that found in the normal 
controls (56 ± 10 mg. per 100 ml., 0.1 < p <  0.2) and 
unchanged from hypothyroid control values (83 ± 9 mg. 
per 100 ml.). Lipoprotein electrophoresis showed that 
normocholesterolemic rat plasma from normal and hypo­
thyroid controls had a-bands and a faint /3-band; hyper­
cholesterolemic rat plasma had a normal a-region with a 
prominent /3-band (Fig. 1).
The lipoproteins of D <1.006, D 1.006 to 1.040, and D 
1.063 to 1.21 isolated from the normal control animals 
had on lipoprotein electrophoresis pre-/3-, d-, and a- 
mobility and had cholesterol to triglyceride ratios of 
0.06, 0.47, and 30, respectively. In view of the prominent 
/3-band on lipoprotein electrophoresis hypercholes­
terolemic plasma was spun at density 1.063. The result­
ant D < 1.063 fraction migrated as a single /3-band and 
had a cholesterol to triglyceride ratio of approximately 
60.
L ig h t  M icroscopy
Control Animals. The changes found in the air-dried 
right carotid arteries of the control normolipemic group 
of rats were identical with those found by Fishman, 
Ryan, and Karnovsky (12). At 2 days after endothelial 
injury, a layer of platelets covered the denuded zone. 
There was no evidence of cell death in the media, and no 
polymorphonuclear leukocytes were present in the in­
jured carotids except where the ligatures had been 
applied. Marked interstitial edema was present in the 
innermost layer of the media beneath the platelet 
covering and persisted wherever endothelium was ab­
sent. The regenerating endothelial layer grew from 
normal endothelium at the ends of the injured zone and 
advanced progressively towards the center of the de­
nuded segment. By 7 days, only a small central area of 
denudation remained; by 14 days, new endothelium
F ig. 1. Lipoprotein electrophoresis of plasma from normal control 
(left) and cholesterol-fed rats (right). Note the prominent /1-band in 
the plasma of cholesterol-fed animals. The bars mark the origin.
covered the entire zone of injury and appeared normal. 
Intimal thickening in the midportion of the injured 
segment developed under the newly regenerated endo­
thelium between 7 and 14 days. Portions of carotid 
sectioned longitudinally often showed thickening on one 
side of the artery and minimal or no thickening on the 
other when both sides of the artery happened to be in­
cluded in the same section; this asymmetric thicken­
ing was confirmed in seriated cross-sections. Injured 
carotids examined at later stages had variable intimal 
thickening composed of cells and progressively increas­
ing amounts of extracellular material which stained with 
toluidine blue; mitoses were seen in the media and 
intima up to 2 weeks after carotid injury but not 
afterwards. No differences were seen between normal 
and hypothyroid control animals at 2 weeks and 1 
month. Over the 3-month period, the uninjured left 
carotid remained unchanged, and in neither right nor 
left carotids were leukocytes or lipid seen.
Hypercholesterolemic Animals. At 2 days and 7 days, 
injured carotids from hypercholesterolemic rats resem­
bled the controls in respect to the presence of platelets 
and medial edema in the denuded area. In addition, the 
rate of endothelial regeneration appeared unchanged. 
However, unlike the controls, hypercholesterolemic ani­
mals had lipid in the media, as shown by staining with 
oil red O. By 2 weeks, the endothelial layer was 
reestablished and covered a thickened intima. The 
intima in hypercholesterolemic animals differed from 
controls only by the presence of intracellular vacuoles 
which stained with osmium and oil red O; mitotic figures 
were observed in cells of the media and intima at 7 days 
and 2 weeks after injury but not at later times (Fig. 2A 
and B). Evaluation of rats at 2 weeks, 1 month, 2 
months, and 3 months demonstrated considerable varia­
bility in the degree of intimal thickening. The mean 
maximal plaque size (expressed as a ratio of maximal 
intimal thickness to adjacent medial thickness) was 1.9 
at 2 weeks (the equivalent ratio in the normal control 
animals being 1.4 and hypothyroid controls 1.7); 1.3 at 1 
month (normal control 1.1 and hypothyroid control 1.4); 
1.0 at 2 months (normal control 1.9); and 1.0 at 3 months 
(normal control 1.7) (Fig. 3). The maximal plaque size 
progressively diminished in the cholesterol-fed animals. 
The extent of longitudinal and circumferential spread of 
the zone of intimal thickening in such rats, although va­
riable, did not differ significantly from the controls. 
Plaques examined 1 month and 2 months after injury 
demonstrated increasing amounts of intracellular lipid 
(Fig. 2C and D). At 3 months, extracellular crystallint 
structures also became evident at the base of tht 
thickened intima and in the underlying media (Fig. 2 f  
and F). These accumulations of extracellular lipid were 
not present in the media proximal or distal to the zone ol 
intimal thickening. Of particular note was the appear 
ance of mononuclear cells adherent to the endothelium 
of the plaque and in the left carotid artery at 3 months 
Such cells sometimes appeared to invade the intim£ 
(Fig. 4). Except for the adherent mononuclear cells at Z 
months, the left carotids of hypercholesterolemic rati 
were normal in appearance; no lipid could be demon­
strated in the media by oil red O stain, althoug)
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Fig. 2. Composite figure showing histologic changes occurring in 
e carotid artery of hypercholesterolemic rats after endothelial 
nudation. The vessel lumen is at the top of each photograph. A, 
■ntral area of segment, 14 days after denudation, showing marked 
■imal thickening with lipid-containing cells. B, Higher power view of
A showing mitosis. C and D, Central area, at 1 month, showing foam 
cells in intima and media. E  and F, Central area, at 3 months, showing 
mononuclear cells adhering to the surface, foam cells, and crystalline 
structures in the intima and media. Note progressive decrease in the 
thickness of the intima. A, C, and E, x600; B, D, and F, x 1,500.
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Fig. 3. Bar graph depicting the maximal plaque thickness of 
injured rat carotids from hypothyroid controls, normal controls, and 
hypercholesterolemic animals. The differences are not significant. The 
error bars are the standard errors of the mean.
occasional small vacuoles were observed in the vessel 
wall in Epon-embedded material.
S canning  E lectron  M icroscopy
Control Animals. The scanning electron microscopy 
observations made in control animals at all six stages 
confirmed the observations made by light microscopy 
and the scanning electron microscopy results of the 
previous study (12). The endothelial growing edge seen 
at 2 days and 7 days advanced steadily and was in 
continuity with normal endothelium at the ends of the 
injured segment. The denuded segment was covered 
with a dense carpet of normal platelets but no leuko­
cytes. By 2 weeks the endothelium was completely 
regenerated and, thereafter, resembled the normal unin­
jured endothelium of the left carotid artery.
Hypercholesterolemic Animals. Changes seen in the 
carotids from hypercholesterolemic animals were the 
same as those in the normolipemic animals, with two 
additional features. First, small spherical smooth struc­
tures, 0.5 to 1.5 nm. in diameter, were observed adhering 
to the endothelium of injured and uninjured carotid endo­
thelium after 2 weeks; the nature of these structures is 
uncertain although they may be lipid particles (Fig. 5A) 
(46). Second, at 3 months but not before, leukocytes 
were found attached to the endothelium of both carotids; 
occasionally such adherent cells were seen with their 
processes extending between adjacent endothelial cells 
(Fig. 5B).
T ransm ission  E lectron  M icroscopy
Control Animals. Transmission electron microscopy 
confirmed the light microscopic findings at each stage. 
At 2 days and 7 days after injury, a layer of flattened, 
degranulated platelets was present on the intimal sur­
face. Interstitial edema, but no evidence of cell death, 
was present in the underlying media. As described 
previously (12), the advancing endothelial edge con­
sisted of cells containing a prominent band of microfila­
ments near the abluminal surface, abundant rough
endoplasmic reticulum, and relatively fewer pinocytotic 
vesicles than usually found in endothelium. The prolifer­
ating endothelium appeared to grow under and displace 
platelets as it moved. At 2 weeks, as shown also by 
scanning electron microscopy, the endothelium formed a 
complete layer over the thickened intima and resembled 
the left carotid endothelium. At 2 weeks, the thickened 
intimal zone contained a mixture of undifferentiated 
mononuclear cells, and cells with many of the character­
istics of smooth muscle cells, i.e., a limiting basement 
membrane, micropinocytotic vesicles, and bundles of 
cytoplasmic myofilaments. At later stages, all of the 
intimal cells appeared to be mature smooth muscle cells; 
no undifferentiated mononuclear cells were observed 
after 2 weeks. The stroma showed progressively increas­
ing amounts of collagen and elastin. Fibrin was never 
seen on the surface or in the intima.
Hypercholesterolemic Animals. Injured hypercholes­
terolemic rat carotids developed the same ultrastruc- 
tural changes as normal rats except for findings previ­
ously noted by light microscopy: accumulations of intra­
cellular lipid vacuoles and extracellular lipid crystals, 
and adherent and invading mononuclear cells. At 2 days 
and 7 days, the platelets and endothelial cells appeared 
normal whereas many of the medial smooth muscle cells 
contained lipid vacuoles. At 2 weeks, smooth muscle 
cells and undifferentiated mononuclear cells (Fig. 6), 
sometimes containing lipid vacuoles (Fig. 7), were ob­
served in the thickened intima and in the media; 
occasionally, intracellular lipid vacuoles were seen in 
endothelium. At 3 months, undifferentiated mononu­
clear cells were seen attached to the endothelium of both 
carotids (Figs. 8 and 9) and appeared to be migrating 
into the intima between adjacent endothelial cells (Fig. 
10). These undifferentiated cells contained lysosome-like 
granules and occasional phagocytic vacuoles; presum­
ably, they were monocytes. In the right carotid, similar 
cells, sometimes containing lipid, were present in the 
zone of intimal thickening, intermingled with mature 
smooth muscle cells (Fig. 8). Also at 3 months, the
Fig. 4. Histologic section of uninjured left carotid from a rat 
sacrificed after 3 months on high cholesterol diet. Note mononuclear 
cells adherent to the endothelium. The lumen is at the top of the 
picture, x 1,300.
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F ig . 5. Scanning electron micrographs of the lum inal surface of 
carotids from cholesterol-fed rats at 3 m onths after injury. A, M ononu­
clear cells adherent to endothelium  in the central segm ent o f the  
injured right carotid. T he sm aller, sm ooth particles m ay be lip id
rem nants. B, M ononuclear cell with cell processes extending in to  in- 
tim a betw een adjacent endothelial cells o f uninjured left carotid. A , 
x  4,000; B, x 12,500.
crystalline extracellular material noted by light micros­
copy at the base of the plaque and in the media appeared 
as large empty spaces in transmission electron micros­
copy. As noted in controls, elastin and collagen formed 
much of the extracellular material; here again, fibrin 
was not seen.
DISCUSSION
A consistent finding in studies of arterial injury in 
animals and man has been the development of intimal 
thickening due to smooth muscle proliferation at sites of 
endothelial damage (4, 12,15, 22, 39, 45). However, there 
has been little clarification of the process by which 
smooth muscle cells in the media are induced to prolifer­
ate. To study this problem, several groups have resorted 
to cell and organ culture of smooth muscle cells and 
intima-media strips in an attempt to identify growth- 
promoting factors. Myasnikov and Block (31) and Flo- 
rentin et al. (13) have reported that hyperlipemic serum 
stimulated cellular outgrowth from intima-media strips. 
Fisher-Dzoga, Chen, and Wissler (11) found that lipo­
proteins with D 1.019 to 1.063 from hyperlipemic mon­
keys accelerated cellular outgrowth from medial ex­
plants whereas the same fraction from normolipemic 
animals did not affect the growth rate. On the other 
hand, Ross and Glomset (36) have identified both low 
density and high density lipoproteins from normolipemic 
animals as growth factors in primate smooth muscle cell 
cultures. Further work by this group has shown that 
platelets and insulin may be important contributors to 
the pool of necessary growth factors (37, 47). Other 
investigators have identified platelet products (25) and 
thrombin (6) as growth factors for fibroblasts.
Although a number of potential growth factors have 
been identified in vitro there is little evidence that any of 
them specifically provokes smooth muscle proliferation 
in vivo. In the present study we have examined the 
effect of a high cholesterol diet upon myointimal pro­
liferation in the air-dried rat carotid artery model. Hyper- 
cholesterolemic and control rats both developed 
centrally located zones of intimal thickening in the air- 
injured segment. The hypercholesterolemic animals 
showed progressive accumulation of intracellular and 
extracellular lipid in the plaques, and, at later stages, 
the presence of mononuclear cells adherent to the 
endothelial layer and invading the intima. However, we 
found that, over the course of 3 months, the high 
cholesterol diet did not significantly affect the arterial 
smooth muscle proliferative response; that is, no differ­
ences were noted in the number of medial and intimal 
mitoses or in the maximal plaque size in hypercholes­
terolemic versus normocholesterolemic rats. Thus, in 
this model, cholesterol feeding and the attendant hyper­
cholesterolemia and hyperlipoproteinemia did not en­
hance or prolong smooth muscle proliferation.
A number of investigators have examined the effects of 
high cholesterol diets on the arterial response to endo­
thelial injury in vivo. In general, however, these studies 
have not focussed attention upon the problem of smooth 
muscle proliferation. Nam et al. (32) found that the 
combination of aortic endothelial injury using the bal­
loon catheter technique and cholesterol feeding in swine 
produced thicker zones of intimal proliferation by 3 
months than endothelial injury alone. After 3 months 
this effect was even more pronounced. In addition, these 
animals showed extensive lipid-filled lesions with necro-
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Fig. 6. Transmission electron micrograph of intimal thickening in intracellular lipid in vacuoles (V). x 8,000. 
central segment of right carotid of a hypercholesterolemic rat 2 weeks F ig. 7. Transmission electron micrograph of undifferentiated 
after injury. Note the undifferentiated mononuclear cell (M) lacking mononuclear cell (M) found in the myointimal thickening of a
the basement membrane and dense zones of myofilaments characteris- hypercholesterolemic rat 2 weeks after injury. Note the intracellular
tic of mature smooth muscle cells (SM). Unlike controls, smooth accumulation of lipid, x 10,000. 
muscle cells in cholesterol-fed animals show large accumulations of
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Fig. 8. Transmission electron micrograph of intimal thickening in myointimal thickening of right carotids of control animals at 2 weeks,
[ht carotid of a cholesterol-fed rat at 3 months. Note particularly the but not at 3 months, after injury. Note smooth muscle cells (SM)
pence of mononuclear cells (M) in the intima and on the luminal massively engorged with lipid vacuoles. x9,100. 
rface adherent to the endothelium (E). These cells are found in the
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F ig. 9. T ransm ission electron m icrograph show ing m ononuclear  
cells (M ) adherent to endoth elium  (E) and invad ing the in tim a of an 
uninjured left carotid from a hypercholesterolem ic anim al at 3 m onths.
L um en (L) is at top and internal e lastic  lam ina (IEL) at bottom of 
photograph. x9 ,100 .
sis, hemorrhage, calcification, and superimposed throm­
bosis. These long term results may not be due to a direct 
growth-promoting effect of cholesterol and lipoproteins 
on the smooth muscle cell; rather, they may represent a 
secondary effect due to lipid-induced endothelial injury, 
perhaps of an inflammatory type, with subsequent 
exposure of smooth muscle to other growth-promoting 
factors. In contrast, Hardin, Minick, and Murphy (19) 
studied a model of endothelial injury produced by 
repeated injections of horse serum into rabbits fed a 
normal or high cholesterol diet and found the same 
number of proliferative lesions in each group. Interest­
ingly, Wissler et al. (49) found that coronary prolifera­
tive lesions were less common in hypertensive rats on a 
cholesterol-rich diet than in hypertensive rats on a low 
cholesterol diet. In other studies on the effect of a high 
cholesterol diet on arteries subjected to endothelial 
injury (7, 14, 35, 38, 48), the accumulation of intracellu­
lar and extracellular lipid in the thickened intima has 
been reported, but no data were provided concerning the 
rate or the extent of the smooth muscle proliferative 
response.
In our studies, the development of intimal thickening 
appeared to be related to the length of time that the 
media was exposed. We have found that if the carotid 
segment subjected to injury is too short (1 cm. or less) 
intimal thickening does not occur; in such cases, endo­
thelial replacement is complete within 5 to 7 days after 
injury (A. W. Clowes, G. B. Ryan, J. L. Breslow, and M.
J. Karnovsky, unpublished results). This suggests that 
in this model, mitogenic factors take several days to 
activate myointimal proliferation. Although hyper­
cholesterolemia did not appear to stimulate growth, 
other factors that could leak into the vessel wall during 
the period of endothelial loss and stimulate growth are 
thrombin and platelet degradation products (6, 25, 37). 
Thrombin has growth-promoting activity for fibroblasts 
in culture (6). However, if clotting factors were responsi­
ble for stimulating smooth muscle proliferation in the 
injured carotid artery, we might expect to find signifi­
cant accumulations of fibrin on the denuded surface. 
This was not seen. On the other hand, platelets were 
observed to accumulate on the injured carotid surface, 
and in view of recent in vitro work (37), they may be 
responsible for instigating the smooth muscle hyperplas­
tic response. In support of this hypothesis, certain drugs 
which inhibit platelet aggregation also appear to prevent 
intimal thickening after endothelial injury (23).
In agreement with others (12, 17, 34, 45), we have 
found that smooth muscle cells predominate in the 
thickened intima. Additional undifferentiated mononu­
clear cells lacking smooth muscle cell characteristics 
were present in the plaques of normal and hypercholes­
terolemic animals at 2 weeks; such cells may be undif­
ferentiated smooth muscle cells (12, 17, 18). However, 
mononuclear cells were also seen in the intima at later 
stages in hypercholesterolemic animals, but not controls. 
Because such cells resembled the monocytes (3, 28, 46)
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F ig. 10. T ransm ission electron m icrograph show ing m ononuclear  
cell (M) inserted betw een  two adjacent endothelia l cells  (E) o f an 
uninjured left carotid o f  a hypocholesterolem ic rat at 3 m onths. T h e
arrows mark the lim its  o f the endoth elia l cells. N o te  sm ooth m uscle  
cell (SM)  w ith  cell process exten d ing  in to  internal e lastic  lam in a  
(IEL). T h e blood vessel lum en (L) is a t th e  top. x 11,300.
attached to the endothelial surface in these animals, 
they may be bone marrow-derived mononuclear phago­
cytes. In support of this, Spraragen et al. (41) have 
shown that exogenous radioactively labeled macro­
phages, when injected intravenously into hyperlipemic 
rabbits, not only adhere to the endothelium but also 
invade the intima.
The accumulation of intracellular lipid and, at later 
stages, extracellular lipid crystals in the air-dried ca­
rotid artery distinguished the injured carotids of hyper- 
cholesterolemic rats from those of control animals. The 
origin of this lipid is unclear, although it is probably due 
to continued insudation from the blood (21, 44). Signifi­
cant endogenous cell synthesis of cholesterol is unlikely 
in view of work by Breslow et al. (5) showing that the D  
<1.063 lipoproteins from hypercholesterolemic rat 
plasma is a potent suppressor of cholesterol biosynthe­
sis in rat hepatocytes and fibroblasts in culture (refer­
ence 5 and A. W. Clowes, G. B. Ryan, J. L. Breslow, and 
M. J. Kamvsky, unpublished results). Cell death may 
make a contribution to the extracellular lipid deposits; 
that smooth muscle cells become foam cells and then 
lyse as cholesterol crystals form liberating lipid into the 
extracellular tissues is an hypothesis that has had some 
support (8, 16, 20, 43). The extracellular crystals seen at 
3 months resemble the crystals of cholesterol and
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cholesterol ester in subcutaneous implants studied by 
Abdulla, Adams, and Morgan (1). They reported that in 
rats, subcutaneous implants of cholesterol, free fatty 
acids, and saturated and mono-unsaturated cholesterol 
esters were slowly resorbed and induced a macrophage 
response, followed by fibroblastic activity and collagen 
deposition. In our study the presence of adherent mono­
cytes and intimal macrophages at 3 months may signify 
the onset of a similar sclerogenic response to lipid crys­
tals in the arterial wall; continued influx of the mono­
cytes into the intima through endothelial gaps may also 
be the result of a low grade, chronic endothelial injury in 
part caused by the hypercholesterolemic plasma (2, 30). 
Such a response might lead to renewed smooth muscle 
cell stimulation and intimal thickening in animals exa­
mined after 3 months; long term experiments are now in 
progress to examine this hypothesis.
In conclusion, although cholesterol feeding has been 
implicated in the formation of proliferative lesions in 
rats (9, 10, 49) we found, on the contrary, that hyper­
cholesterolemia did not exacerbate or prolong the intimal 
hyperplastic response in rats subjected to carotid artery 
endothelial injury. This implies that the association of 
hypercholesterolemia with arterial intimal thickening 
may result from a secondary tissue response to the inti­
mal deposition of lipids rather than a direct mitogenic 
effect of lipoproteins of D <  1.063 or cholesterol on 
smooth muscle cells.
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Regression of Myointimal Thickening 
following Carotid Endothelial Injury and 
Development of Aortic Foam Cell Lesions in 
Long Term Hypercholesterolemic Rats
Alexander W. Clowes, M.D., Jan L. Breslow, M.D., and 
Morris J. Karnovsky, M.B., B.Ch .
Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115
In an earlier report (Clowes AW, Ryan GB, Breslow JL, Karnovsky MJ: Lab Invest 35:6, 1976) we 
demonstrated that cholesterol feeding of rats led to hypercholesterolemia but no increase in smooth 
muscle cell (SMC) proliferation in right carotid arteries subjected to a standard endothelial injury when 
compared with normolipemic control animals. We have now examined these plaques at 6 months and 1 
year after injury. In control animals, the carotid initimal thickening regressed to a relatively small, 
acellular, fibrous scar; there was no evidence of renewed endothelial injury and secondary SMC prolifera­
tion. Regression of the intimal thickening in the injured carotids of cholesterol-fed animals proceeded 
exactly as in control animals except for the accumulation of lipid. Unlike control animals, cholesterol-fed 
rats developed aortic intimal lesions containing extracellular lipid crystals and lipid-laden macrophages 
derived from mononuclear phagocytes in the blood. In addition to the lack of continued intimal SMC 
proliferation in the injured carotid, in the face of severe hypercholesterolemia the intima of the aorta did 
not contain mature SMC, or SMC-derived collagen and elastin. There was also no evidence of increased 
permeability to Evans blue, injected intravascularly. These findings suggest that hypercholesterolemia in 
the rat does not produce chronic endothelial injury, development of proliferative fibrous plaques, or 
enhancement of established SMC lesions.
Additional key words: Smooth muscle cell, Arteriosclerosis.
In a previous report (4) we addressed ourselves to the 
proposition that cholesterol feeding of rats might lead to 
enhanced intimal thickening in carotid arteries sub­
jected to endothelial injury; the associated hypercholes­
terolemia and hyperlipoproteinemia might be expected 
to stimulate increased smooth muscle cell proliferation 
because in vitro studies had shown low density lipopro­
teins to be mitogens for smooth muscle cells (7, 22). 
Increased thickening of the intima was not observed in 
the injured carotids of hypercholesterolemic animals, 
and, therefore, we concluded that in this model hyper­
cholesterolemia and the associated hyperlipoprotein­
emia induced by cholesterol feeding were not important 
growth factors for rat smooth muscle cells. However, 
because monocytic cells were observed invading the in­
tima of injured and uninjured arteries in hypercholes­
terolemic animals, we surmised that cholesterol feeding 
might induce chronic arterial endothelial injury leading 
to recrudescence of intimal cellular proliferation at a 
later stage. In support of this hypothesis Nam et al. (19) 
have shown that 3 months or more after injury the 
aortas of cholesterol-fed swine show complex lesions
containing not only massive intimal thickening and 
lipid accumulations but also hemorrhage, thrombosis, 
necrosis, and calcification.
In the current study, the original injury was produced 
by infusing a stream of air along the lumen of an 
isolated 1.5-cm. segment of right common carotid ar­
tery. As was shown previously (4, 8), after blood flow 
was restored the desiccated endothelium was washed 
away and was replaced by a carpet of platelets. Endo­
thelial regeneration proceeded from normal sources of 
endothelium at the ends of the injured segment and was 
complete between 7 and 14 days. In the central zone of 
the injured artery, marked intimal thickening due to 
smooth muscle cell proliferation developed by 14 days 
but subsequently regressed in animals sacrificed be­
tween 14 days and 3 months. Substantial accumulations 
of cholesterol were present inside and later outside the 
cells of the thickened intima in cholesterol-fed animals 
but not in control animals.
In this long term study we have examined the right 
carotid arteries of hypercholesterolemic rats 6 months 
and 1 year after endothelial injury. To assess the devel­
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opment of arteriosclerotic lesions, the changes in the 
intima of the uninjured left carotid artery and the tho­
racic aorta have been compared in ultrastructural stud­
ies with the changes in the intima of the injured right 
carotid artery. Permeability changes have been as­
sessed using the dye Evans blue as a tracer for albumin 
(20). Our data demonstrate that during long term expo­
sure to hypercholesterolemia, injury-induced prolifera­
tive lesions in the carotid artery regress, whereas aortic 
foam cell lesions, devoid of a proliferative component, 
develop.
MATERIALS AND METHODS 
A n i m a l s  a n d  D i e t
Thirty-nine male Sprague-Dawley rats (Charles 
River Breeding Laboratories, Inc., North Wilmington, 
Massachusetts) weighing between 300 and 350 gm. were 
used. Experimental animals became hypercholesterol- 
emic on a diet containing 4 per cent cholesterol, 1 per 
cent cholic acid, and 0.5 per cent 2-thiouracil (Sigma 
Chemical Company, St. Louis, Missouri) mixed with 
standard stock diet (Purina rat chow, Ralston Purina 
Company, St. Louis, Missouri) and pelleted at the New 
England Primate Center, Southborough, Massachu­
setts. Hypothyroid control animals received a diet con­
taining 1 per cent cholic acid and 0.5 per cent 2-thioura­
cil; normal control animals were fed the stock diet. As 
noted previously (4), normal control rats gained weight 
steadily during the period of observation whereas hypo­
thyroid control and cholesterol-fed rats maintained 
their weights unchanged.
L i p i d  a n d  L i p o p r o t e i n  A n a l y s i s
Blood samples in ethylenediaminetetraacetic acid (1 
mg. per ml.) were obtained before starting the diet and 7 
days after and at the time of sacrifice. Plasma choles­
terol, triglyceride, and lipoprotein determinations were 
made as described previously (4).
E x p e r i m e n t a l  P r o c e d u r e
Right carotid endothelial injury was performed as 
described by Fishman, Ryan, and Kamovsky (8). In 
brief, after 10 days on the diet animals were anesthe­
tized with ether and the right common carotid artery 
was exposed through a longitudinal incision. The endo­
thelial injury was induced in an isolated 1.5-cm. seg­
ment of common carotid artery by an infusion of air 
through a needle cannula at 40 to 50 ml. per minute for 
3.5 minutes. The wound was closed with skin clips after 
blood flow was reestablished and hemostasis obtained. 
Animals were sacrificed at 6 months and 12 months, 
after an overnight fast (Table 1). Three hours before 
sacrifice, blood samples were taken and Evans blue dye 
(Fisher Scientific Company, Pittsburgh, Pennsylvania) 
in phosphate-buffered saline, pH 7.4, (60 mg. per ml.) 
was injected intravenously (60 mg. per kg.). Perfusion 
fixation was performed through an abdominal aortic 
cam ula as described by Fishman, Ryan, and Kamov­
sky (8). After 10 minutes of perfusion with 1 per cent 
paraformaldehyde and 1.25 per cent glutaraldehyde in 
0.1 m  cacodylate buffer, pH 7.4, the carotid arteries and
Table 1. E xperimental Protocol
Diet" Injured rat Uninjured rat
6 m o.
H ig h  cholesterol 11* 4
N orm olip em ic control 4 4
H ypothyroid  control 4
12 m o.
H ig h  cholesterol 4 4
N orm olip em ic control 2 2
a D ie t  w a s started  10 d a y s before carotid injury. 
* N u m b er o f  a n im a ls  sacrificed  a t  each  sta g e .
thoracic aorta were dissected free and examined imme­
diately for blue stain. These vessels were excised and 
placed in 2 per cent paraformaldehyde and 2.5 per cent 
glutaraldehyde in 0.1 m  cacodylate buffer, pH 7.4, for 4 
hours. Subsequently, the vessels were washed with 
buffer, postfixed with 2 per cent aqueous osmium tetrox- 
ide for 2 hours, and stained with uranyl acetate en bloc. 
Vessels were then dehydrated through graded solutions 
of alcohol and processed for light, scanning, and trans­
mission electron microscopy as described earlier (4, 8). 
Carotid arteries and aorta were embedded in Epon 812 
for longitudinal or seriated cross-sectioning at 500-pm. 
stages (2-pm. sections). The plaque size in the injured 
right carotid was measured as described earlier (4) by 
taking the ratio of the intimal thickness (luminal sur­
face to internal elastic lamina) to the adjacent media 
thickness (internal elastic lamina to most external elas­
tic lamina). The maximal plaque size was taken as an 
index of intimal cell proliferation.
RESULTS
L i p i d  a n d  L i p o p r o t e i n  A n a l y s i s
Rats developed marked hypercholesterolemia after 1 
week of cholesterol feeding, as noted earlier (4). At 
sacrifice cholesterol-fed animals had mean plasma cho­
lesterol levels of 1085 ± 84 mg. per 100 ml. (normoli- 
pemic control, 92 ± 11 mg. per 100 ml.; hypothyroid 
control, 143 ± 11 mg. per 100 ml.) and mean triglyceride 
levels of 80 ± 11 mg. per 100 ml. (normolipemic controls, 
148 ± 16 mg. per 100 ml.; hypothyroid controls, 53 ± 15 
mg. per 100 ml.). Lipoprotein electrophoresis was un­
changed from previous work (4); Normocholesterolemic 
rat plasma had a-bands and a faint pre-/3-band whereas 
hypercholesterolemic plasma had a normal a-region 
and a prominent /3-band.
P e r m e a b i l i t y  S t u d i e s
Neither control nor cholesterol-fed rats showed Evans 
blue stain in the injured right carotid artery, the left 
carotid artery, or the thoracic aorta at 6 months or 12 
months.
L i g h t  M i c r o s c o p y
Control Anim als. The air-dried right carotid arteries 
of normal and hypothyroid control animals examined at 
6 months and 12 months after injury showed residual 
intimal thickening composed of two or three layers of 
cells and large amounts of toluidine-stained extracellu­
lar material (Fig. 1A). As observed earlier (4), the inti-
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mal thickening tended to be asymetrieal. The maximal 
plaque size at 6 months was 0.9 (hypothyroid control, 
0.7) and at 12 months was 0.8 (Fig. 2); these values do 
not differ significantly from similar measurements at 3 
months (4). Uninjured right and left carotid arteries and 
aortas were unchanged in appearance; no spontaneous 
intimal thickening or accumulation of surface mononu­
clear cells was observed (Fig. 1C).
Hypercholesterolemic Animals. At 6 months, the 
thickening intimas of injured carotid arteries of choles­
terol-fed rats resembled those examined at 3 months 
and were composed of lipid-containing cells, extracellu­
lar lipid crystals, and large amounts of toluidine- 
stained extracellular material (Fig. IB). At 12 months, 
the number of lipid-containing cells was diminished; at 
this stage the intimal thickening in hypercholesterol­
emic and control injured carotid arteries was similar in 
size. In hypercholesterolemic rats, the maximal plaque 
size was 0.7 at 6 months and 1.0 at 12 months and did
not differ significantly from control animals (Fig. 2). 
These measurements were not significantly different 
from measurements made at 3 months (1.0) (4). Mitotic 
figures, previously seen at 2 weeks after injury, were 
not present in the thickened intima at 6 or 12 months. 
There was no evidence of necrosis, hemorrhage, calcifi­
cation, or thrombosis. The endothelial cells of the ca­
rotid arteries and the aorta contained small lipid vacu­
oles and occasional adherent mononuclear cells (4). 
However, uninjured carotid arteries did not develop 
lipid accumulations or intimal thickening. Thoracic aor­
tas from hypercholesterolemic animals showed striking 
changes in the intima and first layer of the media (Fig. 
ID) at 12 months and occasionally at 6 months. Intimal 
thickening due to large foam cells and extracellular 
lipid crystals was prominent. In addition, large num­
bers of mononuclear cells were adherent to the endothe­
lium at sites of foam cell accumulation. The majority of 
the adherent cells contained little or no lipid; however,
Fig . 1. A to D . H isto log ic  sec tio n s o f  injured r ig h t carotid  arter ies  
and thoracic  aortas o f  control and cholestero l-fed  rats a t  6  m onths: A , 
in tim a l th ic k e n in g  in  control in jured  carotid; B , in tim a l th ic k e n in g
in  injured carotid  seg m en t from  cholesterol-fed  a n im a l; C,  contro l 
thoracic aorta; D,  thoracic aorta  w ith  in t im a l foam  c e lls  from ch o les­
terol-fed  rat. L u m en  is  a t th e  top o f  ea ch  photograph. x340.











MONTHS AFTER RIGHT CAROTID INJURY
F ig . 2. B ar graph dep ic tin g  m ax im al p laq ue size  in th e  r igh t  
carotids o f  norm olipem ic control, hypothyroid  control, and ch o les­
terol-fed  rats a t  6 m onth s and 1 y ear  a fter injury. T he error b ars are  
th e  standard errors o f th e  m ean. T he d ifferences b etw een  control and  
exp erim en ta l p laq ue sizes are not s ig n ifica n t.
occasional adherent cells approximately twice the size of 
the others and containing many lipid vacuoles were 
noted. These aortic lesions lacked the large amounts of 
toluidine-stained extracellular material seen in the in­
jured right carotid arteries. In one 6-month rat with the 
highest cholesterol measured (1905 mg. per 100 ml.), an 
enormous plaque (maximal plaque size 7.0) containing 
actively dividing smooth muscle cells was found (Fig. 3). 
However, the aorta from this animal contained only 
foam cells.
S c a n n i n g  E l e c t r o n  M i c r o s c o p y
Control Animals. The scanning electron microscopy 
(SEM) observations in control animals at 6 and 12 
months confirmed the observations made by light mi­
croscopy and the SEM results at 3 months (4). In addi­
tion, the central part of many endothelial cells was 
noted to protrude and to be irregular. The appearance of 
carotid and aortic endothelium was similar in normal 
and hypothyroid control rats.
Hypercholesterolemic Animals. The over-all appear­
ance of arterial endothelium in hypercholesterolemic 
rats was similar to that of control animals, but with 
several important exceptions (Figs. 4A and B and 5A): 
(1) All of the vascular endothelium in hypercholesterol­
emic rats contained multiple small protuberances previ­
ously noted to be intracellular vacuoles by light micros­
copy. (2) The luminal surface of the injured and unin­
jured carotids had only occasional adherent cells; how­
ever, the aortas demonstrated tremendous numbers of 
cells adherent to focal raised lesions made up of endo­
thelium draped over bulbous structures (foam cells). 
There appeared to be two types of adherent cell; the 
more numerous smaller cells were approximately 4 to 6 
pm. in diameter whereas the less common cells (1 to 2 
per cent of adherent cells) measured approximately 7 to
12 pm. in diameter (Fig. 5B). No difference in function 
could be demonstrated for these cells (3). Finally, the 
amorphous particles, measuring 0.5 to 1.5 pm. in diam­
eter, were present, as noted earlier (4). There was no 
evidence of thrombosis or endothelial cell loss.
T r a n s m i s s i o n  E l e c t r o n  M i c r o s c o p y
Control Anim als. Observations by transmission elec­
tron microscopy confirmed the results of SEM and light 
microscopy at 6 months and 1 year. The intimal thicken­
ing of the injured right carotid was sparsely populated 
with cells and was composed largely of elastin and 
collagen. An unbroken endothelial layer formed the 
luminal surface. Associated with the endothelium was a 
single underlying layer of mature smooth muscle cells. 
No other cell types or lipid were noted. Uninjured ca­
rotid arteries and aorta had only a simple endothelial 
lining.
Hypercholesterolemic Animals. By transmission elec­
tron microscopy, the injured right carotid artery in hy­
percholesterolemic animals appeared remarkably simi­
lar to that in control animals. The intimal thickening 
contained proteoglycan, elastin, collagen and lipid, and 
very few cells. The surface endothelial layer was com­
plete and showed no evidence of injury. Unlike control 
arteries, small lipid vacuoles were present in the endo­
thelium and large intracellular and extracellular lipid
F ig . 3. H isto log ic  section  through  m arked ly  th ick en ed  in tim a  in  
th e  injured  r ig h t carotid  o f th e  rat w ith  th e  h ig h e s t  m easu red  p lasm a  
ch o lestero l a t  6 m on th s. x380.
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F ig . 4. A  a n d  B.  S ca n n in g  e lectron  m icrographs o f  th e  lu m in a l artery; n ote  cobblestone appearance o f  su rface  and adherent cells ^  
surface o f  thoracic aortas in  12-m onth h yp ercholestero lem ic  rats. A ,  L ow er pow er v iew  show s foam  cell le s io n s  around the orifice of 
Low pow er v iew  sh o w s thoracic a orta  a t  th e  or ig in  o f  th e  in n o m in a te  in tercosta l artery . F igu re 4A , x90; B , x 4 00 .
F ig . 5. A  and D.  S can n in g  e lectron  m icrographs o f les io n s in  pow er v iew  dem onstrates two ty p es o f ad h eren t cells, amorphous 
thoracic aortas from 12-m onth h yp erch olestero lem ic  rats. A,  D is- p articles , and  prom inent en d oth elia l vacu o les. Figure 5/1, x 300; fl, 
Crete foam  cell le s io n  is sh ow n in  ascen d in g  thoracic aorta. B , H igh  x  2,400.
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accumulations were present in the thickened intima 
and media. In the intima, mature smooth muscle cells 
and undifferentiated mononuclear cells were noted as in 
previous experiments (4). By comparison, the lesions 
found in the aortic arch contained massive lipid-con­
taining mononuclear cells with little surrounding extra­
cellular elastin and collagen. In every instance an over- 
lying attenuated endothelial layer could be distin­
guished (Fig. 6). Mononuclear cells, occasionally replete 
with lipid (Figs. 7 and 8), were adherent to the luminal 
surface of the endothelium and appeared to invade the 
intima. No mature smooth muscle cells could be identi­
fied in these aortic lesions.
DISCUSSION
In short term experiments (4), we demonstrated that 
hypercholesterolemia and hyperlipoproteinemia in the 
rat did not directly affect smooth muscle cell hyperpla­
sia in the intima of injured carotid arteries; we sug­
gested that in long term experiments cholesterol feeding 
might produce chronic endothelial injury leading to re­
newed intimal cellular hyperplasia and possibly the 
development of proliferative lesions.
Our long term experiments indicate that significant 
smooth muscle hyperplasia did not recur in arteries of 
hypercholesterolemic animals subjected to endothelial 
injury, except in one case. Instead, the arterial intima 
became slowly and progressively more fibrotic and less 
cellular. Furthermore, no chronic endothelial damage 
was noted. Hardin, Minick, and Murphy (14) have de­
scribed similar results in a rabbit model of coronary 
artery endothelial injury induced by immunologic 
means. They reported that injured rabbits, fed either a 
normal or a high cholesterol diet, developed the same 
number of coronary artery intimal fibromuscular le­
sions; they did not quantitate the size of these lesions. 
These results are in striking contrast to those of Nam et 
al. (19); they observed continued intimal thickening and 
the formation of complex lesions containing lipid, calci­
fication, hemorrhage, necrosis, and thrombosis in the 
balloon-injured aortas of swine that were fed cholesterol 
for 3 months or more. The differences in these results 
may be ascribed to variations in permeability of normal 
arterial endothelium in different animals, the location 
of the initial endothelial injury, and the endothelial 
response to hypercholesterolemia. For example, Fried-
F ig . 6. T ran sm ission  e lectron  m icrograph dem on stra tin g  in tim a l face  and ab sen ce o f m atu re  sm ooth  m u scle  ce lls  in  th e  intim i 
foam  cells (F) in  th e  thoracic  aorta  o f  a  6-m onth  h yp ercholesterol- L um en  (L) is  a t top. x7 ,400 . 
em ic  rat. N o te  con tin u ou s layer  o f en d oth eliu m  (E) a t lu m in a l sur-
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F ig . 7. T ran sm ission  electron  m icrograph of large , lip id -filled  cell 
(M) in serted  b etw een  adjacent e n d o th e lia l ce lls  (E) in  th e  thoracic  
aorta from  a  h yp ercholestero lem ic  rat a t  12 m onths. T h is cell corre­
sponds in  size to th e  large ad h eren t c e lls  (F ig. 5) se e n  by SEM . 
Arrows m ark th e  lim its  o f th e  e n d o th elia l cells . L um en (L) is  a t  the  
top. x4 ,830 .
man and Byers (9) showed that Evans blue stained 
normal rabbit aorta in discrete locations but did not 
stain normal rat aorta. They also showed that the prolif­
erative lesions occurred at the sites of staining in choles­
terol-fed rabbits. Similarly, Packham et al. (20) and Fry
(10) have shown blue stain and intimal cellular prolifer­
ation at vessel orifices in normal pigs and dogs. Fry (10) 
has emphasized that increased endothelial permeability 
to Evans blue may be found at sites of unstable stress 
(flow dividers such as vessel orifices) but not in locations 
of moderate and continuous stress (straight arterial 
segments). The results in the pig aorta model may be 
explained as follows: the marked intimal thickening is 
the result of mechanical injury to an endothelial layer 
that even in its natural state around the vessel orifices 
is permeable to albumin; furthermore, following balloon 
injury, the hypercholesterolemia may retard endothe­
lial regeneration at sites of perturbed blood flow if, as in 
the baboon (22), hypercholesterolemia is actually inju­
rious to endothelium. Lacking a proper endothelial bar­
rier, the aorta would then be exposed continuously to an 
influx of albumin and other blood components. In con­
trast, normal rat arterial endothelium in the common 
carotid artery is not permeable to albumin, is not sub­
jected to unstable stress, and appears to be unaffected 
by hypercholesterolemia. Hence, after an initial injury, 
carotid endothelium in cholesterol-fed rats would be 
expected to regenerate unimpeded and to reestablish a 
stable, relatively impermeable barrier. We have shown 
that in the first 2 weeks after right common carotid 
endothelial injury, but not later, Evans blue staining 
occurs in areas still lacking endothelium (A. W. Clowes 
and M. J. Kamovsky, unpublished observations); and 
Bjorkerud and Bondjers (3) have reported that in rabbit 
arteries subjected to extensive injury, Evans blue stain­
ing is present at sites of delayed endothelial regenera­
tion. We conclude that had there been further injury 
and perhaps loss of endothelium in the previously in­
jured right carotid, Evans blue staining would have 
been present. As well as the species differences in endo­
thelium, there may also be differences in smooth muscle 
cell behavior in response to hypercholesterolemia. For 
example, hyperlipemic low density lipoproteins have 
been reported to be mitogenic for rabbit smooth muscle 
cells (7). These lipoproteins might not be mitogenic for 
rat smooth cells as suggested in our earlier report (4). 
This possibility is supported by the recent observations 
that rat fibroblasts and probably rat smooth muscle cell 
membranes lack high affinity receptors for low density 
lipoproteins (J. L. Breslow, unpublished observations); 
these receptors have been demonstrated on human fi­
broblast and smooth muscle cell membranes (12) and 
may be present on cell membranes of other animal 
species.
Apart from the regression of injury-induced prolifera­
tive lesions, we have observed the development of foam 
cell lesions in the aortas of rats fed cholesterol for 6 
months and 1 year. These lesions contained large lipid- 
filled cells and extracellular cholesterol crystals and 
were often associated with adherent luminal mononu­
clear cells. Characteristic smooth muscle cells and their 
matrix of proteoglycans (29), collagen, and elastin were 
notably absent in these lesions; thus, foam cells in these 
lesions were probably macrophages and were derived 
from luminal mononuclear cells. This conclusion is in 
agreement with the work of others (1, 2, 18, 25) and in 
particular Spraragen et al. (23).
There has been some discrepancy between the de­
scriptions of the lesions found in rats on atherogenic 
diets. Although Page and Brown (21) tried a variety of 
dietary manipulations, they were unable to induce ath­
erosclerosis in the rat; some studies have reported only 
foam cell lesions (2, 26) whereas others have observed 
primarily proliferative lesions (6, 13, 17, 27, 28, 30). For 
the production of atherosclerosis in rats, emphasis has 
been placed on age, obesity, hypertension, and source of 
noncholesterol dietary fat. For example, Wexler, An­
thony, and Kittinger (28) have demonstrated that prolif­
erative intimal lesions occur spontaneously in retired 
breeder rats and Koletsky (16) has developed an obese, 
hyperphagic, hypertensive, and arteriosclerotic rat by 
cross-breeding. Our results demonstrate that the foam 
cell plaque is the dominant lesion in rat aortic arterio­
sclerosis induced by feeding cholesterol, thiouracil, and 
cholic acid; foam cell plaque develops as a result of the
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F ig . 8. T ran sm ission  e lectron  m icrograph d em o n stra tin g  m ono- o lem ic  rat a t 6 m onth s. T h is  ce ll corresponds in  s ize  to  th e  sm a ller  
nu clear  cell (M) w ith o u t lip id  vacu o les in ser ted  b etw een  tw o adja- ad h eren t ce lls  (F ig . 5) seen  b y  SE M . Arrows m ark th e  lim its  o f  th e  
cen t e n d o th elia l c e lls  (E) in  th e  thoracic aorta  from  a  hyp ercholester- en d o th elia l ce lls . L u m en  (L) is  a t  th e  top. x  18,200.
migration of lipid-containing mononuclear cells into the 
intima. In view of their initial size, these tissue macro­
phages must continue to accumulate lipid; as suggested 
by others (5,11,15, 24) cholesterol may be liberated into 
extracellular compartments by cell death and rupture.
We conclude that cholesterol feeding in hypothyroid 
rats produces marked hypercholesterolemia which, in 
time, leads to the accumulation of lipid in arterial walls. 
The lipid deposition is associated with the migration of 
mononuclear cells into the intima to form the foam cell 
lesion. The absence of smooth muscle cells, smooth mus­
cle cell excretory products, or increased endothelial 
permeability suggests that hypercholesterolemia does 
not produce the chronic endothelial injury needed for 
the formation of the proliferative fibrous plaque. Fur­
thermore, the regression and scarring of smooth muscle
cell intimal thickening in arteries previously subjected 
to endothelial injury indicates that hypercholesterol­
emia in the rat does not enhance or sustain es­
tablished proliferative fibrous lesions.
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Failure of Certain Antiplatelet Drugs to Affect 
Myointimal Thickening following Arterial 
Endothelial Injury in the Rat
A. W. C l o w e s , M.D., and M. J. K a r n o v s k y , M.B., B.Ch .
Department o f Pathology, H arvard Medical School, Boston, Massachusetts 02115
The effect of aspirin, reserpine, and flurbiprofen on in vivo platelet function and intimal smooth muscle 
cell hyperplasia in rat carotid arteries subjected to endothelial injury was investigated and related to the 
effect of these drugs on in vitro platelet aggregation. Endothelial injury was achieved by infusing air 
briefly into a segment of right common carotid artery. Beginning before or after surgery, experimental 
animals were given sufficient drug to suppress platelet aggregation in vitro in response to collagen, 
adenosine diphosphate, or thrombin. The carotid arteries were fixed by perfusion at 5 and 14 days after 
injury and examined by light, scanning electron, and transmission electron microscopy for platelet 
activity and intimal smooth muscle cell proliferation in the denuded segment. Platelets in platelet-rich 
plasma from control animals aggregated in response to collagen, adenosine diphosphate, and thrombin; 
platelets from aspirin-, flurbiprofen- and reserpine-treated rats showed markedly diminished aggregation 
in response to collagen and normal or slightly diminished aggregation in response to ADP and thrombin. 
At 5 days, platelets from control animals formed a dense layer in the denuded segment; at 14 days, marked 
intimal thickening due to smooth muscle cell hyperplasia was observed. In experimental animals, the 
platelets were morphologically identical with controls and covered the denuded segment; serotonin 
granules were missing in platelets of reserpine-treated rats. Intimal thickening at 14 days was the same as 
controls. We conclude that in the rat no correlation may be made between the effect of aspirin, reserpine, 
and flurbiprofen on in vitro platelet aggregation and the effect of these drugs on the function of platelets 
on an arterial wall denuded of endothelium, as judged by morphology; furthermore, even when these drugs 
are used in sufficient dose to inhibit in vitro aggregation of platelets, myointimal thickening is not 
inhibited.
Additional key words: Smooth muscle cell, Pseudoendothelium, Reserpine, Aspirin, Flurbiprofen, 
Dipyridamole.
Intimal thickening due to smooth muscle cell hyper­
plasia has been demonstrated after arterial endothelial 
injury in a variety of models, yet the mechanism re­
mains unclear (6, 9, 17, 18, 21, 35, 41, 45). Based on in 
vitro data various groups have postulated that lipopro­
teins, insulin, and platelet factors may provide the mi­
togenic stimulus for dormant smooth muscle cells in the 
arterial wall denuded of endothelium (16, 30, 37, 38, 46). 
Of all the mitogens, platelet factors appear to be the 
most likely candidates since platelet adherence and de­
granulation are regulated by the extent of the arterial 
endothelial injury. The specific role of platelets in the 
cellular proliferative response has been suggested re­
cently by work with drugs affecting platelet aggrega­
tion, although the general contribution of platelets and 
thrombosis in the development of atherosclerotic 
plaques has been acknowledged for a long time. Kin- 
caid-Smith (24) reported decreased intimal proliferation 
in the renal arteries of transplanted kidneys in patients 
treated with dipyridamole, and Harker et al. (21) have 
noted a similar effect in a model of chronic endothelial
injury in baboons. H. R. Baumgartner and R. K. Studer 
(personal communication), however, observed no effect 
in rabbits with dipyridamole and aspirin and a slight 
effect with sulfinpyrazone. Friedman et al. (19) have 
reported inhibition of aortic intimal thickening after 
balloon injury in rabbits made thrombocytopenic with 
antiplatelet antisera. Similarly, Moore et al. (29) have 
reported marked suppression of aortic intimal thicken­
ing of complicated atherosclerotic lesions caused by re­
peated endothelial injury.
We have developed a model of arterial endothelial 
injury in the rat which yields a reproducible localized 
intimal thickening in the affected artery (9, 17). In this 
model, air is infused into the lumen of a 1.5-cm segment 
of right common carotid artery isolated by ligatures. 
Blood flow is then reestablished in the injured artery. 
The dessicated endothelium is washed away and is re­
placed by a carpet of platelets. The platelets in turn are 
replaced by endothelial cells growing in from normal 
sources at the ends of the injured segment. Endothelial 
regeneration is complete between 7 and 14 days. Intimal
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thickening due to smooth muscle cell hyperplasia devel­
ops in the central part of the injured segment under the 
regenerating endothelium and is maximal at 14 days.
In this study we examine in rats the effect of anti­
platelet drugs on the formation of the platelet layer in 
the denuded artery and the development of the thick­
ened intima. These results are correlated with the in 
vitro response of platelets from drug-treated animals to 
collagen, adenosine diphosphate (ADP), and thrombin.
METHODS AND MATERIALS 
Eighty-one male Sprague-Dawley rats (Charles River 
Breeding Laboratories, Inc., Wilmington, Massachu­
setts), weighing between 150 and 250 gm., were fed 
standard rat chow and kept in cages (four in each cage).
E x p e r i m e n t a l  P r o c e d u r e  
Air injury of the right common carotid artery was 
performed as described previously (17). In brief, animals 
were anesthetized with sodium pentobarbital (Nembu­
tal sodium, Abbott Laboratories, North Chicago, Illi­
nois) and each rat was given an intraperitoneal injec­
tion of 5 mg. per 100 gm. of body weight. Through a 
longitudinal neck incision, a 1.5-cm. segment of right 
common carotid artery isolated by ligatures was infused 
with air through a 30-gauge needle cannula at 40 to 50 
ml. per minute for 3.5 minutes. Blood flow was reestab­
lished and hemostasis obtained before the wound was 
closed. In the first group of animals, the antiplatelet 
drugs were administered 26 hours and 2 hours before 
carotid injury; a second group of animals was started on 
drug treatment beginning 24 hours after carotid injury. 
The animals tolerated the drug treatment better if  the 
drugs were begun after carotid injury. Twenty-four 
hours after the first dose an effect of the drugs on 
platelet function could be demonstrated in vitro. The 
last dose of drug was given approximately 18 hours 
before sacrifice. Animals were sacrificed at 5 and 14 
days after surgery (Table 1). After satisfactory anesthe­
sia was obtained, 4.5 ml. of blood was drawn into a 
plastic syringe containing 0.5 ml. of 3.8 per cent sodium 
citrate through a sterile, disposable 18-gauge needle 
inserted retrograde into the abdominal aorta just below 
the renal arteries. Blood was then obtained for measure­
ment of the whole blood clotting time and clot retrac­
tion. Through the same needle cannula 100 units of 
heparin (Elkins-Sinn, Inc., Cherry Hill, New Jersey) 
per 100 gm. of body weight was injected. The jugular 
veins were divided and perfusion was begun through 
the needle with Hanks’ balanced salt solution (Microbi­
ological Associates, Inc., Bethesda, Maryland), pH 7.4, 
for 30 seconds followed by 1 per cent paraformaldehyde 
(Matheson, Coleman, and Bell, Norwood, Ohio) and
Table 1. E xperimental Protocol
Drug group Sacrificed at 5 days Sacrificed at 14 days
C ontrol 6“ 10
A sp irin 6 11
F lurbiprofen 6 10
R eserp ine 6 10
“ N u m b er  o f  r a ts  sacrificed  in  ea ch  tr e a tm e n t group a t  5 an d  14 
days a fter  carotid  injury.
1.25 per cent glutaraldehyde (Taab Laboratories, Read­
ing, England) in 0.1 m  cacodylate buffer, pH 7.4, as 
described previously (17). Both common carotid arteries 
were excised and fixed by immersion for an additional 4 
hours in 2 per cent paraformaldehyde and 2.5 per cent 
glutaraldehyde in 0.1 m  cacodylate buffer, pH 7.4. The 
vessels were washed in buffer, postfixed for 2 hours in 2 
per cent aqueous osmium tetroxide, and stained in 2 per 
cent aqueous uranyl acetate en bloc. They were then 
dehydrated through graded solutions of alcohol and 
embedded in Epon 812 for longitudinal or seriated cross- 
sectioning. Epon sections (2 /urn.) were stained with 
toluidine blue. Preparative methods for transmission 
and scanning (SEM) electron microscopy have been de­
scribed earlier (9, 17). Earlier work (9) with the carotid 
injury model has demonstrated that when arteries are 
cross-sectioned at 500-/nm. stages the maximal amount 
of intimal thickening occurs in almost every case in the 
center of the injured segment and correlates with the 
total amount of intimal smooth muscle cell hyperplasia. 
Hence, maximal plaque size was used as an indicator of 
smooth muscle proliferation and was recorded as the 
maximal ratio of the plaque thickness (distance from 
luminal surface to internal elastic lamina) to the adja­
cent media thickness (distance from internal elastic 
lamina) to the most external elastic lamina) (I to M 
ratio) as measured with an ocular graticule (Fig. 1).
I n  V i t r o  P l a t e l e t  S t u d i e s
Platelet-rich plasma (PRP) was prepared in plastic 
test tubes by centrifuging anticoagulated blood at 150 x 
g  for 25 minutes at room temperature. Platelet-poor 
plasma was obtained by centrifuging blood at 2000 x #  
for 15 minutes at room temperature. The platelet count 
of the PRP was measured in a hemocytometer and ad­
justed to 500,000 platelets per cubic millimeter with 
platelet-poor plasma. Platelet aggregation studies were 
performed in a platelet aggregometer (model 300, 
Chrono-Log Corporation, Broomall, Pennsylvania) by 
adding ADP (Sigma Chemical Company, St. Louis, Mis­
souri), collagen, or thrombin (Sigma Chemical Com­
pany) to cuvettes containing 500 g\. of PRP. The extent 
of aggregation was expressed as percentage of control 
and was measured for concentrations of ADP, collagen, 
or thrombin that produced submaximal aggregation of 
control platelets.
C l o t t i n g  T i m e s , C l o t  R e t r a c t i o n , a n d  M e s e n t e r i c
B l e e d i n g  T i m e s
Clotting times were measured on whole blood by the 
method of Lee and White (27). The clot retraction of 
dilute whole blood clots was measured as described by 
Taylor and Miiller-Eberhard (47). Mesenteric bleeding 
times were measured as described by Hovig et al. (22) in 
a separate group of 16 rats that were not used for other 
studies.
A s p i r i n
Aspirin powder (Sigma Chemical Company) (20 to 200 
mg. per kg. of body weight) was administered daily by 
stomach tube to rats lightly anesthetized with ether. 
Rats that were given doses greater than 200 mg. per kg.
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of body weight per day died within several days. Aspi­
rin-treated control rats were intubated daily under an­
esthesia. There was no difference in weight gain for 
aspirin-treated and control rats.
R e s e r p i n e
Reserpine (Serpasil, CIBA Pharmaceutical Company, 
Summit, New Jersey) (0.4 to 0.8 mg. per kg. of body 
weight) was diluted in phosphate-buffered saline, pH 
7.4, and was given to the rats daily by subcutaneous 
injection. Within 1 day animals treated with reserpine 
developed ptosis of the eyelid, lassitude, diarrhea, and 
weight loss. Animals subjected to doses of 1.0 mg. per 
kg. of body weight per day or greater died within 1 
week. Reserpine-treated control rats received daily sub­
cutaneous injections of phosphate-buffered saline.
F l u r b i p r o f e n
Flurbiprofen (Upjohn Company, Kalamazoo, Michi­
gan) was dissolved in batches of 50 mg. in several drops
F ig . 1. H isto log ic  cross-section  o f injured seg m en t in  r ig h t carotid  
artery  from  control a n im a l a t  14 days. To p erm it th e  E pon to en ter  
th e  lu m en  w ith o u t a lter in g  th e  an atom y, th e  v e sse l w a s d ivided  
lo n g itu d in a lly  in  th e  m id-portion  but no t n ear th e  lig a tu re  site s . The  
tw o half-section s com e from  th e  sam e location  a lo n g  th e  artery. N ote  
th e  asym m etric  d istr ib u tion  o f  th e  in tim a l th ick en in g; th e  in tim a l  
th ick en in g , a lth o u g h  co n sta n t in  its  position  a lo n g  th e  artery, varied  
in  its  c ircu m feren tia l location . T he plaque th ic k n e ss  (d istan ce  be­
tw e en  arrow s lab eled  I) to adjacent m ed ia  th ick n ess  (M ) ratio w as  
2.0 in  th is  section  and w a s th e  m a x im a l p laq ue s ize  for th is  carotid  
artery . x4 5 .
of 0.1 n  NaOH and diluted with Hanks’ balanced solu­
tion, pH 7.4, to a concentration of 4 mg. per ml. The pH 
was not adjusted and was approximately 8. Flurbiprofen 
(1 to 10 mg. per kg. of body weight) was injected subcu­
taneously every day; up to 10 mg. per kg. of body weight 
per day was given without adverse effect. Flurbiprofen- 
treated control rats received daily subcutaneous injec­
tions of Hanks’ solution. There was no difference in 
weight gain for flurbiprofen-treated and control rats.
RESULTS
I n  V i t r o  P l a t e l e t  A g g r e g a t i o n  S t u d i e s
The platelet counts of control and experimental ani­
mals did not differ significantly (Table 2). Platelets of 
control animals aggregated reversibly in response to 1 
/xM  ADP, 1 fig. of collagen, and 0.3 National Institutes 
of Health units of thrombin; no secondary wave of ag­
gregation was noted (28). Platelets from animals treated 
with a range of doses of aspirin, flurbiprofen, and reser­
pine showed markedly decreased aggregation in re­
sponse to collagen; platelets from aspirin-treated and 
reserpine-treated rats showed slightly decreased aggre­
gation in response to ADP whereas only platelets from 
aspirin-treated rats showed decreased response to 
thrombin (Table 2).
C l o t t i n g  T i m e s , C l o t  R e t r a c t i o n , a n d  M e s e n t e r i c
B l e e d i n g  T i m e s
The clotting times and clot retraction of dilute whole 
blood clots were not significantly different for control 
and drug-treated animals. The mesenteric bleeding 
times of aspirin-treated and reserpine-treated rats were 
slightly prolonged over controls when assayed at 18 
hours (Table 3).
L i g h t  M i c r o s c o p y
Control Animals. The observations at 5 and 14 days 
confirmed the results of previous studies in rats (9, 17). 
At 5 days, the proximal and distal endothelial growing 
edges had advanced over the ligature sites and had 
partly covered the injury zone. A thin layer of platelets 
was visible in the residual central zone of denudation
T able 2. In V itro P latelet Studies
Drug group0 Platelet count*




1.52 ±  0.11 100 100 100
A sp ir in  (4) 1.22 ±  0.05 2.5  ±  2.5 79.8 ±  22.8 58.7 ±  21.0
200 m g ./k g ./d a . p = 0.06 p  <  0.001 p  =  0.082 p  =  0.04
F lu rb ip rofen  (5) 1.38 ±  0.09 24.8 ±  12.5 95.4 ±  4.3 135.6 ±  16.7
5 m g ./k g ./d a . p  = 0.37 p  <  0.001 p  =  1.0 p  =  0.03
R eserp in e (5) 1.03 ±  0.20 2 .2  ±  1.7 79 ±  4.9 242.7 ±  98.3
0.8 m g ./k g ./d a . p  =  0.08 p  <  0.001 p  =  0.002 p  =  0.14
° N u m b er  o f  an im a ls in  group is  sh ow n in  p a ren th eses.
6 N u m b er  o f  p la te le ts  per cubic m illim eter  ±  stan d ard  error.
' P la te le t  aggregation  m easured  a s  p ercen tage o f  control ±  standard error. 
rf C o llagen  su sp en sion  (1 fig.) added to PRP. 
p A D P  (1 fin) in  PR P.
r N a tio n a l In stitu tes  o f  H ea lth  u n its  (0.3) o f  throm bin  added to PRP.
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Table 3. Clotting Tim es, Clot Retraction, and Mesenteric 
Bleeding Times
Drug group Clotting time® Clot retrac­tion6
Mesenteric 
bleeding timef
Control 3.9 ±  0.1 (9)d 85 ±  2 (4) 192 ±  8 (4)
A spirin
200 m g ./k g ./d a . 3 .8  ±  0.4 (6) 90 ±  3 (4) 206 ±  17 (4)
F lurbiprofen  
5 m g ./k g ./d a . 4.6 ±  0.4 (10) 86 ±  5 (5) 191 ±  38 (4)
R eserp ine  
0.8 m g ./k g ./d a . 4.7 ±  0.4 (10) 83 ±  5 (4) 525 ±  143 (4Y
“ C lo ttin g  tim e in  m in u tes  by th e  m eth od  of L ee and W hite  (27) ±  
standard error.
6 C lot retraction  as percen tage  o f  in it ia l vo lu m e ±  standard error 
at IV2 hou rs a fter  c lo ttin g  as described  by T aylor and M iiller- 
E berhard (47).
c M esen teric  b leed in g  tim e  in  seconds as described  by H ovig  et al. 
(22) ±  standard error.
rf N u m ber of rats in  each  group is  sh ow n in  paren th eses.
e p < 0.05; o ther d ifferences are not sign ifican t.
adherent to the internal elastic lamina (Fig. 2A). 
Edema was present in the inner layers of the media. 
Occasional single cells were present passing through 
clefts in the internal elastic lamina into the intima 
under the platelet layer. At 14 days, in some animals, 
endothelial regeneration was complete over the mark­
edly thickened intima (9, 17) (Fig. 2B). All carotids 
showed intimal thickening. Of particular note in two- 
thirds of controls was the lack of complete endothelial 
covering in the central part of the plaque. In place of 
normal endothelium, pseudoendothelium (41) was pres­
ent and it appeared to be enmeshed in the intima except 
for limited surface exposure to the lumen of the vessel 
(Fig. 3A and B). In every instance the pseudoendothe­
lium was present at the point of maximal intimal thick­
ening. Occasional mononuclear cells were seen adher­
ing to endothelium and pseudoendothelium. There were 
no changes in the uninjured left carotid artery.
Drug-Treated Animals. At 5 days, the right carotid 
arteries of both groups of animals treated with aspirin, 
flurbiprofen, and reserpine showed no difference from 
control injured carotids (Fig. 2C). Partial endothelial 
regeneration had occurred and the remaining central 
area of denudation was covered with a thin layer of 
platelets. Occasional microthrombi were seen in the 
denuded carotids of flurbiprofen-treated rats. At 14 
days, all right carotid arteries except one from an aspi­
rin-treated rat (group 2) showed intimal thickening. 
The maximal plaque size (I to M ratio) for groups 1 and 2 
together was as pronounced as in control animals (con­
trol, 1.5; aspirin, 1.3; flurbiprofen, 1.7; reserpine, 1.5) 
(Table 4). There were no significant differences between 
the plaque size of animals in group 1 (drug treatment 
started before surgery) and in group 2 (drug treatment 
started after surgery) except for the flurbiprofen-treated 
rats (group 1, 0.9; group 2, 2.3, p  = 0.05). However, the 
difference between each flurbiprofen group and the re­
spective control group was not significant. In most ani­
mals, the endothelial layer was incomplete and was 
substituted for by a pseudoendothelial layer (Fig. 2D). 
Left carotid arteries from experimental animals ap­
peared normal at all stages.
S c a n n i n g  E l e c t r o n  M i c r o s c o p y
Control Animals. The SEM confirmed observations 
made by light microscopy and contributed the following 
additional information: (1) at 5 days, two layers of plate­
lets could be distinguished—one composed of platelets 
which were spread and tightly adherent to the underly­
ing substructure and the other platelets round or 
slightly spread overlying or inserted between the first 
(Fig. 4A); (2) at 5 days, the endothelial growing edge 
was advancing toward the center of the injury zone as a 
broad front in continuity with proximal and distal endo­
thelium; (3) at 14 days, the endothelium was completely 
regenerated in some arteries and resembled normal 
uninjured endothelium; (4) in two-thirds of the control 
rats, pseudoendothelium could be distinguished; 
whereas normal endothelium tended to be smooth, fusi­
form, and elongated in the direction of blood flow, the 
pseudoendothelial cells were slightly ruffled, irregular 
or polygonal in outline, and were not organized in rela­
tionship to the blood flow (Fig. 5A and 5 ). The junctions 
between these cells appeared to be open and made up of 
multiple interdigitating processes from neighboring 
cells. Individual platelets, microthrombi, fibrin, and 
debris were found in the crevices between pseudoen­
dothelial cells. No platelets were seen adhering to the 
actual surface of the pseudoendothelium. Leukocytes 
adherent to the endothelium were also present in the 
unhealed central zone.
Drug-Treated Animals. By SEM, experimental in­
jured carotids at 5 days resembled controls, except for 
the presence of microthrombi in the right carotids of 
flurbiprofen-treated rats (Fig. 6A and B ).* The number 
of platelets and their appearance was unchanged (Fig. 
4B); the extent of the ingrowth of the endothelial grow­
ing edges was the same for experimental and control 
animals. At 14 days, endothelium had not regenerated 
over the central part of the injured segment in most 
drug-treated rats. Instead, pseudoendothelium was 
present as in controls.
T r a n s m i s s i o n  E l e c t r o n  M i c r o s c o p y
Control Anim als. The findings by light microscopy 
and SEM were confirmed by transmisson electron mi­
croscopy. In addition, at 5 days a range of platelet forms 
could be identified. Degranulated platelets were 
stretched thinly over most of the denuded surface; in 
places, adherent platelets retained their granules. 
Other rounded forms were in contact with the first layer 
(Fig. 7A). The platelets appeared to interact with the 
loose fibrillar material overlying the internal elastic 
lamina. Occasional cells were seen migrating through 
the internal elastic lamina; these cells had smooth mus­
cle cell characteristics (17, 20) (Fig. 8). At 14 days, the 
cell layer overlying the thickened intima had the ap­
pearance of normal endothelium with occasional Wei- 
bel-Palade bodies (50) and tightly opposed cell borders. 
As noted before (9, 17), the cells in the intima were 
either undifferentiated or mature smooth muscle cells 
and were surrounded by collagen and elastin. In some 
arteries, pseudoendothelium could be distinguished 
from normal endothelium (41) (Fig. 9A and B). In par­
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ticular, pseudoendothelial cells were ensconced in a ma­
trix of collagen and elastin, had a band of myofilaments 
under a flat luminal surface, and formed complex but 
interdigitating, loosely apposed cell borders. Normal 
endothelial cells were spread over the luminal surface of 
the intima, had basilar bands of myofilaments some­
times stretching diagonally across the cell and forming 
dense specializations with the basal attachments, and 
had junctions composed of tightly apposed membranes. 
No Weibel-Palade bodies were found in pseudoendothe­
lium. As was also shown by SEM, no transition forms 
between normal endothelium and pseudoendothelium 
were seen. Adjacent cells had some or all of the charac­
teristics of mature smooth muscle cells. Presumably, 
the pseudoendothelium derives from underlying smooth 
muscle cells (41).
Drug-Treated Anim als. At 5 days, platelets of drug- 
treated animals showed the same range of forms as
controls (Fig. IB and C). Serotonin granules (11, 48) 
were not identified in reserpine-treated rats. At 14 days, 
pseudoendothelium and intimal smooth muscle cells 
were observed as in controls.
DISCUSSION
Early after arterial endothelial injury, platelets ad­
here to the denuded wall; later, over a period of time, 
intimal smooth muscle cell hyperplasia occurs. Recent 
work has suggested that the two events are related and 
that platelet degradation may produce growth factors 
specific for smooth muscle cells (19, 21, 29, 38, 39). Based 
on this theory, one possible method for inhibiting 
smooth muscle cell proliferation after arterial injury 
might be to administer drugs that inhibit platelet ag­
gregation to collagen and other components of the arte­
rial wall. Numerous in vitro studies have shown that 
platelets taken from animals treated with antiplatelet
F i g . 2. H isto logic  sec tio n s o f injured r ig h t carotid  arter ies from  d em on stra tin g  m arked in tim a l proliferation; C, denuded carotid  
control and drug-treated  anim als; A , zone o f  d en u d ation  in  control from  reserp ine-treated  ra t a t  5 days; note s in g le  in tim a l cell under
carotid  a t 5 days a fter  in jury sh ow in g  th in  in tim a l la y er  o f p la te le ts  p la te le ts; D, in tim a l th ic k e n in g  a t  14 days in  carotid  o f  flurbiprofen-
and m ed ia l edem a; B,  cen tra l zone in  control carotid  a t 14 days trea ted  rat. F igu re 2A a n d C , X615; B and D, x320.
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F ig . 3. H isto log ic  section s from  th e  cen tra l zone o f  injured r ig h t carotids a t  14 days d em on stra tin g  app earance o f  reg en era tin g  norm al 
en d oth eliu m  (A ) and p seu d oen d oth eliu m  (B). x2 ,000.
Table 4. Maximal Plaque Size (I to M Ratio) in  Injured Right 
Carotid Arteries at 14 Days
Group 1“ Group 26 Total
Control
A spirin
1.8 ±  0 .6r (4)d 1.3 ±  0.4 (6) 1.5 ±  0.3
20-200 m g ./k g ./ 
da.
F lurbiprofen
1.5 ±  0.5 (6) 1.1 ±  0.4 (5) 1.3 ±  0.3
1-10 m g ./k g ./d a . 
R eserp ine
0.9 ±  0.4  (4) 2.3 ±  0.3  (6) 1.7 ±  0.3
0 .4 -0 .8  m g ./k g ./  
da.
1.6 ±  0.4  (4) 1.5 ±  0.2  (6) 1.5 ±  0.2
“ A n im a ls  in  group 1 received  d ru g  26 hou rs an d  2 hou rs before  
carotid injury and w ere sacrificed  14 d a y s fo llow in g  injury.
6 A n im a ls  in  group 2 received  d ru g  b e g in n in g  24 h ou rs a fter  
su rgery  an d  w ere sacrificed  a t  14 days.
‘ M ean m a x im a l p laq u e  size  (in tim a  to  m ed ia  ratio) a t  14 d a y s ±  
standard error. T he d ifferences are n o t s ig n ifica n t for p  =  0.05.
'' N u m b er o f  a n im a ls  in  each  group is  sh ow n  in  p aren th eses.
drugs aggregate less well in the presence of collagen 
than platelets from normal animals; however, it is not 
at all clear that platelet function in vivo at the surface of 
an injured artery is inhibited in the same way by these 
drugs. Thus, if platelets do liberate factors mitogenic for 
smooth muscle cells, it is uncertain whether these drugs 
could inhibit the intimal thickening due to smooth mus­
cle cell hyperplasia that follows upon endothelial injury. 
The antiplatelet drug, dipyridamole, has been shown to 
inhibit intimal smooth muscle cell hyperplasia in ba­
boons (21); however, platelet aggregation in vitro was 
not inhibited at the concentration of drug achieved in 
vivo.
In this study we have attempted to relate the in vitro 
activity of platelets from rats treated with aspirin, flur­
biprofen, or reserpine to in vivo deposition of similar 
platelets on the exposed carotid artery subendothelial 
layer. These drugs were employed because of their 
known long acting effect on platelets in vivo (3, 31, 42, 
51, 55) and their inhibition of collagen-induced platelet 
aggregation in vitro; reserpine was used not only be­
cause it inhibits platelet aggregation but also because it 
selectively depletes platelets of one factor, serotonin 
(42). Our results demonstrated that although collagen- 
induced aggregation was markedly inhibited in vitro 
there was no alteration in the in vivo pattern of platelet 
interaction with the carotid arterial subendothelial 
layer; however, the slight prolongation of the mesen­
teric bleeding time for aspirin-treated and reserpine- 
treated rats does suggest diminished platelet activity in 
vivo in these animals (13). We also found that at 14 days 
after injury there was no decrease in intimal thickening 
or inhibition of smooth muscle cell proliferation in the 
drug-treated groups. The intimal thickening in the in­
jured arteries of rats treated with flurbiprofen before 
surgery was decreased with respect to controls. How­
ever, the large biologic variability in plaque size in 
control and drug-treated groups rendered this difference 
not significant. We have found in other work that when 
treatment is successful the intimal thickening of the 
experimental group is unequivocally diminished with 
respect to controls (8). The failure of endothelium to 
regenerate by 14 days and the development of pseudoen­
dothelium (41) probably derived from smooth muscle 
cells were unexpected additional results in both control
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F ig . 4. S cann ing  e lectron  m icrographs d em o n stra tin g  th e  appear­
ance o f  p la te le ts  ad h eren t to th e  lu m in a l su rface o f  denuded r ig h t  
carotid  arter ies from control (A ) and reserp in e-trea ted  (B ) rats a t  5 
days. N o te  th e  d ense  p a ck in g  of th e  p la te le ts  in  both  m icrographs. 
X 5,000.
and drug-treated rats. They are perhaps related to the 
stress of frequent traumatic stimuli since previous re­
sults in unmanipulated animals (9, 17) with the same 
model showed complete endothelial regeneration at 14 
days.
P l a t e l e t s  a n d  S u b e n d o t h e l i u m
Baumgartner et al. (2-4) and Stemerman (44) have 
shown that platelets adhere to microfibrils and collagen 
in the subendothelial layer but not to elastin. Huang, 
Lagunoff, and Benditt (23) have demonstrated that 
when platelets interact with glomerular basal lamina 
they adhere and spread but do not aggregate or degran- 
ulate. Our results at 5 days are in agreement with these 
findings, although some of the fully spread platelets 
seemed to lack granules. The lack of visible granules 
may have been a consequence of the spreading and the 
resultant decrease in cross-sectional area. In the drug- 
treated animals, although platelet morphology ap­
peared to be unchanged in the injured carotid (except for 
the reserpine-treated rats), nevertheless platelet degra­
dation and turnover may have been affected. As yet no 
methods have been developed to measure the kinetics of 
platelet turnover in the area of endothelial denudation.
In rabbit arteries injured by the application of a liga­
ture Ts’ao (49) found that platelets adhered to injured 
endothelium and degranulated; if  the rabbits were 
treated with aspirin, platelet adherence still occurred 
but without degranulation, and platelet aggregates 
were more loosely constructed than in normals. Plate­
lets from aspirin-fed rabbits aggregated in vitro in the 
presence of ADP and thrombin but not collagen. Weiss, 
Tschopp, and Baumgartner (52) have examined the in 
vitro interaction of human platelets with the subendo­
thelial layer of the rabbit aorta and have reported that 
although the adhesion of platelets from patients given 
aspirin was normal, there were virtually no platelet 
thrombi present; Baumgartner and Muggli (3) reported 
that platelets from aspirin-treated rabbits showed nor­
mal adhesion to denuded rabbit aorta in vitro and in 
vivo but fewer microthrombi. On the other hand, Cazen- 
ave et al. (7), using washed, chromium-labeled platelets 
from aspirin-fed rabbits, showed reduced platelet adhe­
sion in vitro to the damaged intimal surface of everted 
segments of rabbit thoracic aorta. They point out that 
the use of citrated platelet preparations as employed by 
Baumgartner and Muggli reduces the amount of normal 
platelet adhesion to the level of aspirin-treated platelet 
adhesion. In other studies of arterial thrombosis, Re- 
naud and Godu (36) reported inhibition of experimen­
tally induced thrombosis in rats fed aspirin, and 
Danese, Voleti, and Weiss (10) have shown a similar 
effect in dogs. Our results indicate that even if  aspirin 
did acutely reduce the adhesion of platelets to carotid 
subendothelium following injury, over a period of time 
the aspirin effect was not sufficient to diminish grossly 
platelet deposition.
Reserpine (15, 34, 40, 42, 43, 55) and flurbiprofen (12, 
31) both have been used to inhibit platelet aggregation 
in in vitro and to a limited extent in in vivo models. 
These drugs seem to act by different pathways, al­
though diminished collagen-induced aggregation is the 
end result. Aspirin interacts with platelets by acetylat- 
ing the platelet membrane (1) and by inhibiting the 
platelet release reaction through suppression of prosta­
glandin synthesis (25, 32, 53, 54); although the mecha­
nism by which platelet aggregation is inhibited by re­
serpine is unclear reserpine is known to deplete the 
platelets of their serotonin stores sequestered in the 
osmiophilic granules by preventing serotonin uptake at 
the platelet membrane (34, 43). Reserpine also inhibits 
thrombus formation in vivo (55). Flurbiprofen does not 
bind to the platelet (31); it too may act by inhibiting 
prostaglandin synthesis. Our data suggest that al­
though both reserpine and flurbiprofen are potent inhib­
itors of collagen-induced platelet aggregation neither 
drug is potent enough to diminish platelet-arterial wall 
interaction in vivo.
I n t i m a l  S m o o t h  M u s c l e  C e l l  H y p e r p l a s i a
We have shown that myointimal thickening following 
arterial endothelial injuiy in the rat is not inhibited by 
the administration of aspirin, flurbiprofen, or reserpine. 
Our results support those of H. R. Baumgartner and R.
K. Studer (personal communication) who found that 
aspirin and dipyridamole did not suppress myointimal
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F ig . 5. S ca n n in g  electron  m icrographs illu s tra tin g  th e  d ifferen ces to pseu d oen d oth eliu m  (cells  w ith  p o lygon al outlines); B,  h igh er  
b etw een  e n d o th e lia l an d  pseu d oen d oth elia l c e lls  in  th e  injured r ig h t pow er v iew  o f  pseu d oen d oth eliu m  a t  14 d ays . F igu re  5A , x 2 ,1 0 0 ;B ,  
carotid  o f  reserp in e-trea ted  rats: A,  e n d o th e lia l g ro w in g  ed g e  o f  14 x  4,000.
d a y s (e lon gated  ce lls  a lig n ed  in  th e  d irection  o f  blood flow ) adjacent
F ig . 6. S ca n n in g  e lectron  m icrographs o f  th e  lu m in a l surface o f  in g  en d oth elia l cells; B , h ig h  pow er v ie w  o f  m icrothrom bu s contain- 
th e  injured r ig h t carotid  seg m en t in  flurbiprofen -treated  r a ts  a t  5 in g  p la te le ts  and stran d s o f  fibrin . F igu re  6A , x800; B , x 5 ,0 0 0 . 
days: A , low  pow er v iew  sh o w in g  m icrothrom bi b e tw een  regen erat-
proliferation in injured rabbit aortas. Baumgartner and 
Studer report that sulfinpyrazone produced some inhibi­
tion of intimal smooth muscle cell hyperplasia which 
was not statistically significant when compared to ap­
propriate controls. Harker et al. (21) have reported that 
the antiplatelet drug dipyridamole can affect platelet
survival time and intimal thickening; in vitro this drug 
has antiplatelet aggregation effects but only at concen­
trations not normally attained in vivo (21). They have 
reported that chronic endothelial injury and decreased 
platelet survival time may be produced by infusing 
homocystine intravenously into baboons and that the
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F ig . 7. T ransm ission  electron  m icrographs o f  p la te le ts  in  the  
denuded segm en t o f  injured r ig h t carotid ar ter ie s  a t  5 days from  
control (A ), flurbiprofen-treated  (B ), and reserp in e-trea ted  (C) rats. 
N o te  osm ioph ilic  (seroton in) g ra n u les (S )  p resen t in  p la te le ts  from  
control and flurbiprofen-treated  ra ts  b u t ab sen t in  p la te le ts  from
reserp in e-trea ted  a n im a ls . E m pty  vacuole  (arrow) m a y  b e  a  sero­
ton in -d ep leted  gran u le . P la te le ts  are ad h eren t to  m icrofibrils (M ) 
and am orphous m a ter ia l o v er ly in g  in tern a l e la s tic  la m in a  (IEL). 
F igu re  7A, x27 ,000;B,  x27,800; C, x36 ,000 .
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resultant intimal smooth muscle cell hyperplasia may 
be suppressed and the platelet survival time returned to 
normal by the oral administration of dipyridamole. 
Also, Didisheim (14) has reported inhibition of arterial 
thrombosis in the rat with this drug. Using a method for 
continuous intravenous infusion of dipyridamole, we 
attempted to reproduce Harker’s results in the rat. 
However, the drug precipitated about the catheter tip, 
and continuous infusion of dipyridamole at 20 mg. per 
kg. of body weight per day into a gastrostomy produced 
no change in in vitro or in vivo platelet function or 
intimal thickening at 14 days. In view of the short half- 
life of the drug in rats (5) and its paradoxical effects of 
rat platelets in some hands (33) it is possible that our 
negative results may reflect some intrinsic difference in 
platelet function in the two animals.
Although the work of Harker et al. (21) is supported 
by the in vivo studies of Friedman et al. (19) and Moore 
et al. (29) and the in vitro studies of Rutherford and Ross 
(39), Ross et al. (38), and Kohler and Lipton (26), our 
results and those of Baumgartner and Studer are in 
disagreement. In part, the discrepancies may be due to
the difference in animals and methods used for sup­
pressing platelet function as judged by conventional 
criteria. However, until methods are developed for as­
sessing the turnover of platelets and the accumulation 
of mitogenic factors in the arterial wall, only inferential 
conclusions can be drawn about the relationship of the 
drug experiments in vivo to the growth factor experi­
ments in vitro. It is possible that the agent responsible 
for stimulating smooth muscle cell proliferation in vivo 
is not as yet certain and might be shown in time to be a 
pool of factors generated possibly from plasma or plate­
lets or both at the site of endothelial denudation.
In summary, we have shown a distinct lack of correla­
tion between in vitro platelet aggregation and in vivo 
platelet interaction with arterial subendothelium in 
rats treated with a range of doses of aspirin, reserpine, 
and flurbiprofen. On the assumption that such drugs 
might suppress the release of growth factors from plate­
lets, we measured the amount of intimal thickening in 
the rat carotid artery injury model and in drug-treated 
animals and found no change in intimal smooth muscle 
cell proliferation.
F ig . 8. T ran sm iss ion  e lectron  m icrograph o f  m odified  sm ooth  N o te  la y er  o f  p la te le ts  ad h eren t to fib r illa r  m a ter ia l overly in g  
m u scle  c e ll (SMC) in  tr a n sit  th rou gh  fen estra  in  in tern a l e la s t ic  sm ooth  m u scle  ce ll. L um en (L) o f  v e sse l is  a t  th e  top. x  15,000. 
la m in a  (IEL) o f  denuded carotid  from  asp ir in -trea ted  ra t a t  5 days.
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F ig . 9. T ran sm ission  e lectron  m icrographs of en d oth eliu m  (A ) d o th e lia l ce ll (PE) in ser ted  in  in tim a  am on g sm ooth  m u scle  cells
and pseu d oen d oth eliu m  (B ) in  injured carotid  artery  a t  14 days: A , (SMC) w ith  lim ited  m em b ran e surface exposed  to lu m e n  (L); note
e n d o th e lia l cell (E) spread  over  in tim a  co n ta in in g  m atu re  sm ooth m y o fila m en ts (MF) un der lu m in a l surface. F igu re  9A , x9,500; B,
m u scle  ce ll (SMC); n ote  b a sila r  m yofilam en ts (MF); B,  pseudoen- x 9 ,900 .
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Suppression by heparin of smooth 
muscle cell proliferation in injured arteries
I ntim al smooth muscle cell (SMC) proliferation dominates 
the early phase of healing after arterial endothelial 
injury1' 6; what growth factors are responsible for this 
mitotic activity of an otherwise quiescent cell is not known. 
SMC growth in vitro is enhanced by platelet factors, insulin 
and lipoproteins7-11 and, according to some reports, can 
be diminished in vivo with various antiplatelet agents. 
Harker et al.6 have reported decreased myointimal 
thickening in homocystinaemic baboons treated with 
dipyridamole, and Friedman et al.n and Moore et al.13 
have reported suppression of SMC proliferation in the 
injured arteries of rabbits injected with anti-platelet serum. 
Intimal thickening was not diminished, however, in the 
injured carotid arteries of rats given various anti-platelet 
drugs13. Because the clotting system is inextricably linked 
to arterial injury and because thrombin is used to generate 
the platelet growth factor9 and may itself be a mitogen14’15, 
we speculated that heparin might inhibit myointimal 
thickening. We report here the use of heparin to suppress 
intimal SMC hyperplasia in a rat model of arterial 
endothelial injury and suggest possible mechanisms for the 
heparin effect.
Endothelial injury was achieved by infusing air into 
isolated segments of right carotid arteries of 45 young male 
Sprague-Dawley rats (250-300 g, Charles River Breeding 
Laboratories) as described earlier1 ,s. This procedure 
dessicated the endothelium. After blood flow was re­
established and haemostasis obtained, the wound was 
irrigated with Betadine solution. Using a sterile technique, 
a silastic catheter was inserted into the left jugular vein 
and connected to an infusion system as described by 
Steiger et a/.18. Initially all rats were infused with lactated 
Ringer’s solution (Abbott) at 0.91 ml h-1 using a syringe 
infusion pump. After 24 h, experimental rats were switched 
to an infusion of heparin (from pig intestinal mucosa, 
Elkins-Sinn). Control rats were infused continuously with 
Ringer’s solution. Animals were killed at 5, 10 and 14 d 
by perfusion fixation1,2 after blood had been collected for 
clotting times17 and platelet counts. Carotid arteries were 
: further fixed and processed as described earlier1,2 for light, 
scanning (SEM) and transmission electron microscopy 
(TEM).
Clotting times were prolonged in a predictable fashion; 
as noted before18, a linear relationship existed between the 
logarithm of the clotting time and the heparin dose. 
Heparin doses of 50 or 100U kg-1h_1 given intravenously 
yielded clotting times of 12.5 and 36 min (control 4.4 min). 
Platelet counts were not affected by heparin administra­
tion (control: 1.28 + 11x10* (+s.e.); 5 0 U k g '1h '1:
1.38+0.04X10*; 100U kg-I h'': 1.38 + 0.11 X 10*).
In earlier studies on uncatheterised control animals12, 
we showed that after carotid injury the dessicated endo­
thelium rapidly sloughed and was supplanted by a carpet 
of platelets. Endothelial regeneration proceeded from 
normal endothelium at the ends of the injured segment 
and was complete by 14 d; between 5 and 14 d smooth 
muscle cells migrated through the internal elastic lamina 
and proliferated in the intima. The intimal thickness was 
maximal at 14 d.
The right carotid arteries of catheterised control animals 
at 5 d demonstrated partial endothelial regeneration and a 
dense monolayer of platelets in the residual central denuded 
portion of the injured segment. Unlike uncatheterised 
controls, at 10 and 14 d, endothelial regeneration in 
catheterised control carotids was still incomplete in the
Fig. 1 H isto logical sections o f  injured right carotids in heparin- 
treated (right) and control (left) anim als at 14 d. T he m axim um  
I/M  ratio is 1.8 (control) and 0.2 (heparin). The m inim al intimal 
thickening sh ow n here in the right carotid o f  the heparin-treated  
rat is representative o f  findings in anim als with a  pronounced  
response to heparin; as can  be seen in  T able 1 there w as con­
siderable variation in intimal thickening under heparin treatment. 
T E M  o f  these sam ples dem onstrated on ly  sm ooth  m uscle  cells in  
the intim a o f  the control carotid and a  single layer o f  sm ooth  
m uscle cells covered by endothelium  in the intima o f  the  carotid  
from  the heparin-treated rat.
central zone; in place of endothelium and platelets, 
modified smooth muscle cells lined the luminal surface. A  
possible explanation for this failure of endothelial regenera­
tion is that in stressed animals or after long arterial 
injuries5’’3, rapidly growing SMC can temporarily form a 
luminal surface and impede endothelial regeneration. At 
10 d, all injured carotids showed marked intimal thickening 
due to SMC proliferation; at 14 d, the intimal thickening 
was even more pronounced. The injured right carotids of 
heparin-treated rats exhibited the same features as cathe­
terised controls at 5 d with partial endothelial regeneration 
at the ends and a dense carpet of platelets in the middle 
of the injured segment; the platelets in heparin-treated rats 
were morphologically (SEM and TEM) similar to controls. 
At 10 d, a small central residual zone of denudation 
covered by platelets remained and at 14 d endothelial 
regeneration was complete as in uncatheterised controls. At 
lOd, there was only slight evidence of intimal thickening 
which nevertheless was not significantly different from 
controls. But, at 14 d, because of increased intimal 
thickening in control carotids, the maximum ratio of 
intima to media (I/M) in carotids from heparin-treated 
rats was diminished significantly (Fig. 1 and Table 1). The
T able 1 M yointim al thickening at 14 d
I/M
C ontrol 1 .9 ± 0 .5 (5 )
H eparin (50 U  k g -1 h~*) 0 .4 ± 0 .2 ,  P = 0.02 (5)
(100 U  k g - 1 h ' 1) 0 .6 ± 0 .1 ,P  = 0.005 (10)
T otal 0.5  ± 0 .1 ,  P  = 0 .0 0 0 7 (1 5 )
I /M ± s .e .  w as m easured in right carotid arteries, 14 d after injup', 
which were cross sectioned at 500-gm  stages along their entire 
length2,13. Because the thickened intim a at 14 d is a lm ost entirely 
com posed  o f  sm ooth  m uscle cells1"* (Fig. 1), the m axim um  I/M  
ratio reflects the am oun t o f  SM C  proliferation and is m easured by 
using an ocular graticule by taking the ratio o f  the m axim um  intimal 
thickness (distance from  the lum inal surface to  the internal elastic 
lam ina) to  the adjacent m edia thickness (distance from  the internal 
elastic lam ina to  the m o st external elastic lam ina). Num bers o f  rats in 
each group are sh ow n in parentheses.
maximum I/M  ratios for high and low dose heparin were 
similar and both were significantly different from control 
values. At most, one to three SMC layers were seen at this 
stage in the intima under the endothelium. The normal 
rate of endothelial regeneration in heparin-treated animals 
may have been related to the absence of luminal SMC.
These results indicate that heparin in doses sufficient to 
prolong clotting markedly suppressed intimal SMC pro­
liferation after arterial endothelial injury even though 
endothelial regeneration (mitosis and migration) progressed 
unimpaired. Heparin did not seem to inhibit platelet- 
subendothelium interaction in the injured carotid.
This suppression of SMC proliferation may be the result 
of one or more effects of heparin because heparin is known 
to have many biological activities16'21. Heparin may act 
directly on the SMC19’21. Alternatively, because of its 
charge, heparin may bind and inactivate platelet growth 
factors generated by platelet activity on the denuded 
arterial wall; this is particularly plausible in view of Ross’s 
in vitro results demonstrating that the SMC platelet 
mitogen is a basic protein22. Heparin may achieve several 
effects indirectly through its action on the clotting system. 
Thrombin and the other serine proteases of the clotting 
system (XII, XI, IX, X and plasmin) are undoubtedly 
activated at the surface of the denuded segment and may 
accumulate in the arterial wall. One or more of these 
clotting factors may be mitogenic for SMC1415; thrombin, 
in particular, may generate mitogens from the adherent 
platelets as suggested by in vitro work9,22. Antithrombin III 
normally regulates the level of proteolytic activity by 
slowly inactivating the clotting proteases; this process is 
almost instantaneous in the presence of heparin22. Thus, 
heparin through antithrombin III may affect the degrada­
tion of platelets and generation of platelet SMC growth 
factors by thrombin24, and the direct activity of the clotting 
proteases on SMC. Arterial SMC proliferation may be just 
one example of the general phenomenon of wound healing 
suppressible by heparin; previous studies of wounds in
skin, bowel, artery and bone indicate that heparin can 
prevent scarring if given in doses large enough to produce 
a continuous and significant state of anticoagulation25-26.
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Inhibition of Rat Arterial Smooth Muscle 
Cell Proliferation by Heparin
In Vivo Studies with Anticoagulant and Nonanticoagulant
Heparin
J ohn R. Guyto n , R obert D. R o senberg , A lex a n d er  W. Clow es, and
M orris J. K arnovsky
SUMMARY Heparin inhibits the proliferation of intimal smooth muscle cells which occurs after 
denudation of endothelium by air-drying injury in the rat carotid artery. We determined (1) whether 
the antiproliferative effect of heparin is secondary to effects on platelet adherence to subendothelium 
or endothelial regeneration and (2) whether the antiproliferative and anticoagulant activities of heparin 
are related. Morphometric observations by scanning electron microscopy showed that heparin did not 
alter platelet adherence 5 days after arterial injury and had little or no effect on endothelial regener­
ation at 5 and 10 days. To study the relationship between the antiproliferative and anticoagulant 
effects, we fractionated heparin by affinity chromatography on antithrombin-Sepharose into purified 
anticoagulant and nonanticoagulant fractions. These heparin fractions were administered to rats in 
doses which were equivalent either in terms of anticoagulant activity or in terms of mass to the dosage 
of unfractionated heparin known to inhibit myointimal growth. Additionally, some rats received 
nonanticoagulant heparin at a dose which was greater in terms of mass than the highest dose of 
unfractionated heparin which could be administered without inducing fatal hemorrhage. Inhibition of 
myointimal growth, determined by morphometric analysis of total plaque volume 2 weeks after arterial 
injury, correlated with total mass of heparin administered but not with anticoagulant activity. Non­
anticoagulant heparin given at high dose caused 77% inhibition of myointimal growth (P  «  0.02 vs. 
controls). Heparin inhibition of arterial smooth muscle cell proliferation does not appear to be mediated 
either by effects on other cells at the level of the arterial wall or by antithrombin. This study 
should direct attention toward a potential growth regulatory role for arterial glycosaminoglycans. 
CircRes 46: 625-634, 1980
IN A RECENT study on intimal smooth muscle 
cell proliferation in the rat carotid artery denuded 
of endothelium, we reported that intravenous hep­
arin in doses large enough to cause continuous 
anticoagulation markedly inhibited myointimal 
proliferation (Clowes and Karnovsky, 1977). Sev­
eral hypotheses for the mechanism of this antipro­
liferative effect of heparin have been considered. 
First, heparin may have little direct effect on 
smooth muscle cells in vivo, but may change plate­
let function (Zucker, 1974) or endothelial regener-
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ation in a manner such that smooth muscle cell 
proliferation is secondarily inhibited. Second, acti­
vation of clotting factors may be necessary for 
smooth muscle cell proliferation, either directly, as 
in thrombin stimulation of fibroblast division in 
tissue culture (Chen and Buchanan, 1975), or indi­
rectly, since thrombin evolved at an injured vessel 
wall could potentiate platelet aggregation and 
release of platelet-derived growth factors (Ross et 
al., 1974). The discovery in the laboratory of one of 
us (R. D. Rosenberg) that heparin can be separated 
into anticoagulant and nonanticoagulant fractions 
(Lam et al., 1976) has made possible investigations 
of the hypothesized link between humoral clotting 
and smooth muscle cell proliferation in vivo as well 
as in vitro. Finally, heparin may interfere with the 
action of growth factors other than clotting factors, 
or it may act directly on the cell to inhibit division.
In this paper we report in vivo studies of the 
mechanism of the antiproliferative action of heparin 
on arterial smooth muscle cells. It is shown, first, 
that this effect is unlikely to be caused by anteced­
ent changes in endothelial regeneration or platelet 
function. Second, because nonanticoagulant hepa­
rin is capable of inhibiting myointimal proliferation,
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the antiproliferative effect probably is not related 
to changes in the humoral clotting system.
Methods
Preparation of Experimental Animals
We studied 69 male Sprague-Dawley rats (CD 
strain, Charles River Breeding Laboratories) weigh­
ing between 250 and 320 g. Arterial air-drying injury 
was induced using the technique of Fishman et al.
(1975) modified with a higher air flow rate and 
longer drying time to ensure complete endothelial 
denudation. Briefly, the rat was anesthetized with 
intraperitoneal pentobarbital (Nembutal, Abbott 
Laboratories, 50 mg/kg body weight) and the right 
common carotid artery was exposed and ligated at 
two points 1.5 cm apart. A 30-gauge hypodermic 
needle was inserted into the proximal end of the 
segment. An exit hole was punctured at the distal 
end of the segment either by passing the same 
needle down the lumen and out through the wall or 
by puncturing with an additional needle from out­
side. After the lumen had been rinsed with phos­
phate-buffered saline, dry (compressed) air was al­
lowed to flow through the segment for 3.5 minutes 
at a rate of 50-60 ml/min. Ligatures then were 
removed and hemostasis was obtained by pressure.
Within minutes to a few hours after reestablish­
ment of blood flow in the arterial segment, desic­
cated endothelial cells detach from the arterial wall 
and are swept away. To monitor the completeness 
of endothelial denudation between the ligature 
sites, perfusion silver staining (Fishman et al., 1975) 
was performed 24 hours after operation in nine rats 
taken from various cohorts during the course of the 
study.
The intravenous infusion technique was the same 
as that described previously (Clowes and Kamov- 
sky, 1977), except that the swivel connector was 
found to be unnecessary. A Silastic catheter was 
placed in the left jugular vein and passed through 
the skin at the back of the neck beneath a shoulder 
saddle, where it connected to an external catheter 
of Tygon tubing. The external catheter was pro­
tected by a stainless steel flexible coil which was 
anchored 14 or more inches above the animal. The 
animal’s cage was turned daily to relieve any torque 
in the coil caused by the animal’s net rotational 
movement. A syringe pump delivered fluid at a rate 
of 0.91 ml/min. Ringer’s lactate (Abbott) was in­
fused into control rats and served as diluent for the 
heparin solutions.
Preparation of Heparin Fractions
Human thrombin and human antithrombin were 
isolated in physically homogeneous form by meth­
ods previously reported (Rosenberg and Damus, 
1973).
The anticoagulant potency of mucopolysaccha­
ride fractions was estimated by quantifying their 
ability to accelerate the interaction of antithrombin
with thrombin and comparing the extent of enzyme 
neutralization to that attained with a heparin stan­
dard of known USP potency (Lam et al., 1976).
The concentration of antithrombin was deter­
mined by absorbance measurements at 280 nm as­
suming an extinction coefficient of 6.5. Mucopoly­
saccharide concentrations were estimated colori- 
metrically by assay of uronic acid at 530 nm accord­
ing to the carbazole method of Bitter and Muir 
(1962). The relationship between this parameter 
and the dry weight of heparin fractions was deter­
mined experimentally.
A single lot of commercial heparin (Upjohn, lot 
082ED) was used to prepare the heparin fractions. 
Heparin was mixed with a 2-fold molar excess of 
antithrombin to form complexes in a buffer consist­
ing of 0.15 M NaCl in 0.01 M Tris-HCl at pH 7.5 and 
24° C. Thereafter, heparin bound to inhibitor as 
well as uncomplexed mucopolysaccharide were iso­
lated free of antithrombin by techniques analogous 
to those reported previously (Rosenberg et al., 1978; 
Jordan et al., 1979). The heparin that bound to 
antithrombin, called purified anticoagulant heparin, 
exhibited a specific anticoagulant activity of 317- 
352 USP units/mg. The mucopolysaccharide that 
did not complex with antithrombin, termed non­
anticoagulant heparin, had a specific anticoagulant 
activity of 17-18 USP units/mg.
Chemical differences between anticoagulant and 
nonanticoagulant heparin are subtle. Analysis of 
low molecular weight fractions (~6000 daltons) has 
demonstrated that anticoagulant heparin contains 
1.1 more residues of glucuronic acid and 1.5 fewer 
residues of N-sulfated glucosamine than nonanti­
coagulant heparin (Rosenberg et al., 1978). Recent 
studies have demonstrated the unique presence in 
anticoagulant heparin of a tetrasaccharide sequence 
with the unusual features of nonsulfated iduronic 
and glucuronic acid residues and an N-acetylated 
glucosamine (Rosenberg and Lam, 1979).
Platelet Deposition and Endothelial 
Regeneration
The inner surface of the right carotid artery was 
studied by scanning electron microscopy at 5 and 
10 days after air-drying injury in 34 rats. Arteries 
from 10 heparin-treated and 9 control rats were 
fixed at 5 days, and from 9 heparin-treated and 6 
control rats were fixed at 10 days. Only unfraction­
ated heparin was given to these animals. To avoid 
hemorrhage, heparin administration was not begun 
until 24 hours after the operation. The initial infu­
sion rate was at least 50 units/kg body weight per 
hour, and this was increased to 100 units/kg body 
weight per hour on the 6th postoperative day. The 
minimal regimen had been shown previously to 
inhibit myointimal proliferation effectively (Clowes 
and Kamovsky, 1977). For the last 5 rats in each 
group fixed at 5 days and the last 3 rats in each 
group fixed at 10 days, whose arteries were studied, 
heparin was administered according to the schedule
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for unfractionated heparin shown in Table 1. Two 
commercial brands of porcine intestinal heparin 
(Elkin-Sinn and Upjohn) were used at various 
times, both of which were equally effective in in­
hibiting rat arterial smooth muscle cell proliferation 
in vitro (data not shown).
After blood had been drawn for Lee-White clot­
ting times, hematocrits, and platelet counts (he- 
matocytometer method), rats were fixed by retro­
grade perfusion via the abdominal aorta at 120 mm 
Hg pressure with 1% paraformaldehyde and 1.25% 
glutaraldehyde in 0.1 M cacodylate buffer.
Excised tissues, including right and left common 
carotid arteries, were further fixed by immersion in 
2% paraformaldehyde and 2.5% glutaraldehyde for 
2-4 hours. Arteries were postfixed in osmium te- 
troxide and dehydrated using alcohols. They were 
sectioned at the midpoint, cut longitudinally, criti­
cal point dried in CO2 using a Samdri PVT-3 (Tou- 
simis Research Corporation), and coated with gold- 
palladium using a Technics Hummer sputter-coat­
ing device (Technics). All observations were made 
on an ETEC Autoscan scanning electron micro­
scope (ETEC Corporation) on coded randomly se­
quenced specimens by a single observer (J. R. Guy­
ton).
To quantify platelet adherence to the arterial 
wall at 5 days, three fields from each artery selected 
at low magnification were photographed at 3000X. 
The photographs were coded and shuffled, and 
platelets were counted visually, marking those 
counted on a plastic overlay. Eight photographs 
were counted twice, showing good reproducibility 
with an intraclass correlation coefficient of 0.97 
(Snedecor and Cochran, 1956).
Endothelial regeneration was quantified in 5- and 
10-day specimens in the following manner. The 
specimens were oriented at a right angle to the 
electron beam. An average location for the advanc­
ing endothelial edge, which was often irregular 
around the circumference of the artery, was esti­
mated visually. The sum of lengths of endothelial 
regrowth from the two ends divided by the total 
length of the original ligated segment, as measured 
on the microscope viewing screen, was taken to 
represent fractional endothelial regeneration.
Effect of Heparin Fractions on Plaque 
Volume
Twenty-six rats were divided into two control 
and three experimental groups, as shown in Table
1. Control rats received either no heparin or unfrac­
tionated commercial heparin (Upjohn) according to 
a progressive schedule. Gradual onset of heparin 
administration postoperatively was necessary to re­
duce the incidence of hemorrhage. Two experimen­
tal groups received purified anticoagulant or non­
anticoagulant heparin in dosages which matched 
the control unfractionated heparin infusion in terms 
of anticoagulant activity (for those receiving puri­
fied anticoagulant heparin) or mass (for those re­
ceiving nonanticoagulant heparin). In order to 
study the response to a mass dose greater than that 
of control infusion, a third experimental group re­
ceived a relatively high constant dose of nonanti­
coagulant heparin beginning immediately after the 
operation.
Myointimal growth was determined 2 weeks after 
air-drying carotid injury, because previous work 
(Fishman et al., 1975) showed that plaque size was 
maximal at this time. Blood for tests was drawn 
and animals were fixed by perfusion as described 
earlier. Carotids were sectioned midway between 
the original needle puncture sites and embedded in 
Epon 812. Two-micron sections were cut perpendic­
ular to the vessel axis at 500-jum intervals to a depth 
of 5 mm in each half of the original carotid segment, 
thus yielding 22 sections for plaque volume analysis. 
Because the plaque tended to grow largest in the 
midportion of the denuded segment and because of 
shrinkage of tissue during processing, essentially all 
of the intimal plaque volume was contained within 
this distance.
Sections were stained with toluidine blue, then 
projected at approximately 200-fold magnification 
onto bond quality typing paper which varied in 
weight per unit area by ± 1%. The outlines of intima 
and media were traced, and the paper was cut and 
weighed. Repeated area determinations for individ­
ual samples of intima and media from 20 sections 
showed good reproducibility, with an intraclass cor­
relation coefficient of 1.00. The total weight of
T able  1 Schedules of Heparin Administration in the Plaque Volume Study
Heparin fraction infused
Dose schedule
1 2-4 5-6 7-14 Days post-op
N on e (7)* 0 0 0 0
U nfractionated (U F) (7) 0 60 75 100 u n its/k g  per hrf
0 0.39 0.49 0.65 m g/k g  per hr
A nticoagulant (AC) (4) 0 60 75 100 u n its/k g  per hr
N onanticoagulant (NAC1) 0 0.39 0.49 0.65 m g/k g  per hr
N onanticoagulant (NAC2) 0.78 0.78 0.78 0.78 m g/kg  per hr
* Numbers in parentheses = numbers of rats.
f The dosage schedule for the group receiving unfractionated heparin is given in terms of both anticoagulant 
activity and mass.
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tracings of intima was divided by the total weight 
of tracings of media to give an index of plaque 
volume in each animal.
Autopsies
After perfusion fixation, viscera in all rats were 
inspected grossly for abnormality. In 21 represent­
ative animals, paraffin sections of various organs 
were stained with hematoxylin and eosin and with 
alcian blue and neutral red.
Statistical Methods
Reproducibility of morphometric technique was 
shown by the intraclass correlation coefficient, 
which yields values near 1.00 when the variance 
among replicated measurements is small compared 
to the variance among measurements on different
specimens (Snedecor and Cochran, 1956). To dem­
onstrate the lack of difference between heparinized 
and control groups in endothelial regeneration and 
platelet adherence, Student’s t-test with confidence 
intervals for the differences between means was 
used. Analysis of variance was used to assess differ­
ences in plaque volume, with data from each animal 
transformed to the fourth root to give comparable 
variances within groups. Transformation to a root 
was more suitable than either the use of untrans­
formed data or log transformation, because the 
variance could be expected to increase with increas­
ing values, yet values near zero (i.e., almost no 
migration of smooth muscle cells into the intima) 
were possible and did occur. Scheffe analysis was 
chosen for a posteriori comparison of results, be­
cause it corrects for multiplicity of comparisons
Figure 1 Scanning electron micrograph showing platelets adherent to arterial wall 5  days after air-drying injury 
and 4 days after institution of heparin therapy, in a healthy animal without bleeding. Bar = 5  pm. 5800X .
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(more conservatively than other methods) and at 
the same time allows combinations of groups to be 
compared (Brownlee, 1965).
Results
Completeness of Endothelial Denudation
Silver stains performed the day after air-drying 
carotid injury showed 98-100% endothelial denu­
dation within the ligature marks in all nine rats. 
Three rats showed 100% denudation; in the other 
six a small tag of endothelium remained intact at 
the end of the segment next to a ligature mark, 
where it presumably was protected from drying by 
moisture trapped in crevices or beneath the needle 
tip.
Weight Gain, Blood Findings, Histology
There were no significant differences among ex­
perimental and control groups for weight gain (av­
erage was 21 g), platelet counts, or hematocrits. 
Routine hematoxylin and eosin staining of various 
organs showed no unusual findings. Alcian blue 
applied to the paraffin sections stained mucus, bone 
marrow cell granules, aortic media in all animals, 
and bony matrix variably. In one rat given high- 
dose nonanticoagulant heparin, alcian blue staining 
was seen in scattered large cells in the spleen.
Platelet Adherence
Figure 1 is a typical scanning electron micrograph 
of adherent platelets, from which visual counting 
was performed. Six rats which remained healthy 
after operation and heparinization gave results that 
were sharply different from those of three rats 
which bled massively and were moribund at the 
time of fixation. The former group showed a mean 
( ±  s e m ) of 199,000 ±  14,000 platelets per square 
nillimeter adherent to the arterial wall, which is 
lot significantly different from the mean of 216,000 
t  13,000 found in unheparinized controls (Fig. 2). 
The three rats which bled had a range of platelet 
idherence from 10,000 to 55,000 per square milli- 
neter (not shown in Fig. 2). This latter group could 
lot be considered representative of rats which were 
ubmitted to studies lasting longer than 5 days, 
>ecause in the longer studies rats which showed 
teck swelling and pallor at 5 days always died when 
he heparin dose was increased.
Endothelial Regeneration
A typical view of endothelium regenerating as a 
ontinuous sheet of cells is shown in Figure 3. 
leparin appeared to have little effect on the frac- 
ion of denuded surface reinvested by endothelium 
t 5 and 10 days (Fig. 4). Heparin-treated animals 
tad slightly less endothelial regeneration at 5 days, 
>ut the differences between heparin-treated and 
ontrol groups were not significant at either time 
eriod.
Figure 2 Platelet adherence to the luminal surface of 
carotid artery 5 days after air-drying injury in control 
and heparinized rats. Counts were obtained from scan­
ning electron micrographs similar to Figure 1. Mean 
counts were 199,000/mm2 for heparinized group and 
216,000/mm2 for control group. The 95% confidence in­
terval for the difference between means, heparinized 
minus control, was —31,000 to +9,000/mm2.
Anticoagulant Activity and Myointimal 
Thickening
Clotting times were prolonged to approximately 
2.5 times control values after administration of 
either unfractionated heparin or the anticoagulant 
fraction (Fig. 5). Two of the eight rats given non­
anticoagulant heparin had clotting times slightly 
outside the normal range (7.5 and 7.8 minutes vs. a 
range of 3.7 to 5.8 minutes in control rats), but the 
mean log clotting times of nonanticoagulant heparin 
groups were not significantly different from con­
trols.
Figure 6 shows light micrographs of myointimal 
thickening in a control rat and a rat given nonan­
ticoagulant heparin. Determinations of intima-me- 
dia volume ratios (Fig. 7 A and B) clearly showed 
inhibition of myointimal thickening in the high- 
dose nonanticoagulant heparin group (77% reduc­
tion in plaque size, P  =  0.02 vs. controls) as well as 
in the unfractionated heparin group (64% reduction 
in plaque size, P  =  0.02 vs. controls). There was also 
a significant difference between the group given the 
anticoagulant heparin fraction and the high-dose 
nonanticoagulant heparin group (P  =  0.04). Scheffe 
analysis also allows a posteriori comparisons of 
combinations of groups; results are given in the 
legend to Figure 7.
Figure 7a presents data on intima-media volume 
ratios in individual arteries, plotted against the total 
cumulative dose of heparin in terms of mass. A 
negative correlation between mass dose of heparin 
and plaque growth is evident on visual inspection.
As shown in Figure 7b, the unfractionated hepa­
rin group tended to show greater inhibition of
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Figure 3 Scanning electron micrograph of endothelial regeneration in a heparinized rat 5 days after air-drying 
arterial injury. Bar — 20 pm. 900x.
plaque growth than the nonanticoagulant heparin 
group given the same mass dose (NAC1) and less 
inhibition than the group given a higher dose of 
nonanticoagulant heparin (NAC2). However, these 
trends did not reach statistical significance.
Discussion
Our results confirm earlier work (Clowes and 
Karnovsky, 1977), in demonstrating an inhibitory 
effect of heparin on intimal smooth muscle cell 
proliferation, which can account for as much as 77% 
inhibition of growth in terms of plaque volume. 
With the same progressive dosage regime used to 
demonstrate this effect, heparin had little or no 
effect on platelet adherence or endothelial regen­
eration. Experiments with heparin fractions differ­
ing in their binding to antithrombin showed that
the antiproliferative effect of heparin is not related 
to its anticoagulant activity.
Role of Platelets
It is likely that platelets did play a role in initi­
ating smooth muscle cell proliferation in this study, 
as has been demonstrated in other models of arte­
rial endothelial denudation (Moore et al., 1976; 
Friedman et al., 1977). Heparin conceivably could 
interfere with platelet-mediated activation of 
smooth muscle cells either by inhibiting platelet 
attachment to subendothelium and granule release 
or by preventing platelet release products from 
exerting their effects on the smooth muscle cells. 
There are several reasons to believe that the anti­
proliferative effect of heparin in vivo is not me­
diated through the former mechanism—i.e., de-
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DAYS
Figure 4 Endothelial regeneration in control and 
heparin-treated rats assessed by scanning electron mi­
croscopy 5 and 10 days after air-drying injury to the 
right carotid artery. Mean ± SEM are shown. Numbers 
of rats in each group are in parentheses. Means for the 
heparin-treated groups (yji) and control (xc) and 95% 
confidence intervals (C.I.) for the difference between 
means were as follows: A t 5 days, xh = 0.43, xc = 0.54, 
C.I. = —0.28 to +0.08. At 10 days, xh = 0.72, xc = 0.73. 
C.I. = -0.22 to + 0.21.
HEPARIN FRACTION INFUSED 
Figure 5 Whole blood clotting times after 2 weeks of 
continuous infusion of various forms of heparin. The 
scale is logarithmic, and geometric means ± S E M  are 
shown. Groups are as in Table 1. U F  = unfractionated 
heparin, A C  = anticoagulant heparin, N ACl = nonan­
ticoagulant heparin at equivalent mass dose, NAC2 = 
high-dose nonanticoagulant heparin. Using Student’s t- 
test with correction for unequal variances, a significant 
difference from control was found for U F  (P  = 0.003), 
but not for A C  (P  = 0.07) or any other group. Filled 
circles represent anticoagulated groups; unfilled circles 
represent nonanticoagulated groups.
Figure 6 Appearance of intimal plaque near the mid­
point of injured arterial segment. A : Control rat. Arrow 
indicates internal elastic lamina. B: Rat given high- 
dose nonanticoagulant heparin. Arrow indicates inter­
nal elastic lamina. Toluidine blue, 490X ;  bar = 20  pm.
rangement of platelet function. First, heparin in­
hibits smooth muscle cell growth in vitro in the 
presence of platelet products (R.L. Hoover, R.D. 
Rosenberg, and M.J. Kamovsky, unpublished ob­
servation). Second, heparin was not administered 
in this study until 24 hours after carotid air-drying 
injury, with the exception of the high-dose nonan­
ticoagulant heparin group. Endothelial desquama­
tion and platelet adherence are actually seen within 
minutes after air-drying injury to the rat carotid 
artery and reestablishment of blood flow. Complete 
coverage of the denuded surface and degremulation 
of platelets follow within a few hours (unpublished 
observations). Subsequent turnover of platelets at 
the arterial surface probably is relatively slow, as 
shown by Groves and co-workers (1979) after bal­
loon catheter endothelial denudation in the rabbit. 
Friedman (1977) has reported that severe throm­
bocytopenia initiated 1 day after endothelial denu­
dation in the rabbit aorta does not inhibit the 
smooth muscle cell proliferative response. This fact 
suggests that platelets may trigger the smooth mus­
cle cell response, but are not necessary to sustain it. 
Together, all these observations suggest that the 
major antiproliferative effect of heparin is likely to 
occur at some step subsequent to platelet degranu­
lation.
In the absence of massive hemorrhage, heparin 
did not appear to affect platelet adherence to the 
arterial wall, observed 5 days after endothelial de­
nudation and 4 days after the onset of heparin 
administration. This is in accord with the finding of 
Essien and co-workers (1978) that heparin did not
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Figure 7 Intima-media volume ratios 2 weeks after 
air-drying carotid injury in rats continuously infused 
with various forms of heparin. A : Intima-media volume 
ratios for individual rats are shown plotted against total 
cumulative mass dose of heparin administered. Filled 
circles represent anticoagulated rats, which received 
either purified anticoagulant heparin (84 mg/kg) or un­
fractionated heparin (177 mg/kg). These two groups had 
equal mean log clotting times (Fig. 5). Unfilled circles 
represent nonanticoagulated rats that received either no 
heparin or nonanticoagulant heparin. Inspection shows 
that inhibition of plaque growth correlates with mass 
dose of heparin and not with anticoagulant activity. B: 
Groups of rats are as shown in Table 1 and Figure 5. 
Numbers of rats in groups are shown in parentheses. 
Means ± SE M  were obtained after transformation of 
individual data to the fourth root. P  values for signifi­
cant differences between groups, corrected for multiplic­
ity of comparisons by the Scheffe method, are as follows: 
Control vs. UF, P  = 0.02; control vs. NAC2, P  = 0.02; 
A C  vs. NAC2, P  = 0.04; control vs. N A C l + NAC2, P  =
0.03; control + A C  vs. N A C l + NAC2, P  = 0.01; control 
+ A C  vs. U F  + N A C l + NAC2, P  = 0.002.
affect in vitro platelet adherence to rapidly isolated 
aortic subendothelium.
Endothelial Regeneration
Preliminary experience with the air-drying rat 
carotid injury model had suggested that, if a certain
small amount of viable endothelium, perhaps 10- 
20%, remained within the ligature sites after the 
injury, smooth muscle cell proliferation would be 
inhibited markedly, presumably because of rapid 
re-endothelialization. This is the reason that silver 
stains 1 day after injury were performed repeatedly 
during the course of the study. It also was necessary 
to determine whether heparin might accelerate en­
dothelial regrowth and thereby inhibit smooth mus­
cle cell proliferation indirectly. Figure 4 shows that 
this clearly was not the case.
Effectiveness of Nonanticoagulant Heparin
The most important conclusion of this study is 
that inhibition of smooth muscle cell proliferation 
by heparin does not require anticoagulant activity. 
Our in vitro data support this conclusion, and it is 
also consistent with the studies of Lippman and 
Mathews (1977) on L-M cells in tissue culture. They 
demonstrated a lack of correlation between antico­
agulant and antiproliferative effects of various types 
of heparin. It may be inferred that thrombin, de­
spite its potent mitogenic effect in fibroblast tissue 
culture (Chen and Buchanan, 1975), probably does 
not play a major or necessary role in the smooth 
muscle cell proliferative response. A modulating 
role for thrombin is not ruled out by the data, 
particularly in view of the trend toward a greater 
nonproliferative effect of unfractionated heparin as 
opposed to nonanticoagulant heparin at the same 
mass dose (NACl group in Fig. 7).
The data from this in vivo study do not answer 
the question of whether the purified anticoagulant 
heparin fraction might inhibit myointimal prolifer­
ation as effectively as the nonanticoagulant heparin 
fraction. Recent in vitro work in our laboratory 
suggests that, in fact, the two fractions have equal 
antiproliferative potency (R.L. Hoover, R.D. Ro­
senberg, and M.J. Kamovsky, unpublished obser­
vation). The maximum mass dose of purified anti­
coagulant heparin that could be administered safely 
in vivo appears to be below the threshold necessary 
for a distinct antiproliferative effect, as shown in 
Figure 7b.
Although heparin is a mast cell product and has 
not been found in the intima or media of arteries, 
other glycosaminoglycans, including the closely re­
lated compound, heparan sulfate, are pesent at high 
concentrations (Smith, 1973). Some of these glycos­
aminoglycans may be inhibitory for smooth muscle 
cell growth, as suggested by Eisenstein and col­
leagues (1979). Wasteson and co-workers (1977) 
have demonstrated that platelets contain an en­
zyme that specifically degrades heparin and he­
paran sulfate. It is possible that this platelet enzyme 
might act as a growth factor in concert with the 
well-known small cationic polypeptide growth fac­
tor (Ross and Vogel, 1978). Whatever the initial 
stimulus for medial smooth muscle cell activation, 
we may speculate that those cells which migrate to 
the intima might be exposed to an environment
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which lacks the usual inhibitory influence of certain 
medial glycosaminoglycans on cell division and 
therefore might continue to proliferate for some 
time after the initial stimulus (perhaps platelet 
factors) has subsided. Exogenous heparin adminis­
tration in our study may have acted to restore the 
physiological inhibitory influence.
An alternative hypothesis for the action of hep­
arin, that it may bind the cationic platelet-derived 
growth factor before it can contact smooth muscle 
cells, is considered doubtful. For reasons discussed 
above, it seems likely that the greatest quantity of 
platelet-derived growth factor would have reached 
the surface of smooth muscle cells during the first 
24 hours, before heparin was given in most of our 
experiments. Also, in vitro work suggests that con­
tact between heparin and the cell surface is a critical 
step in the antiproliferative effect (R.L. Hoover, 
R.D. Rosenberg, and M.J. Kamovsky, unpublished 
observation).
Possible Effects of Heparin on 
Atherosclerosis and Other Conditions
Studies on the inhibition of dietary atheroscle­
rosis by heparin or heparin-like compounds have 
yielded variable results (Hess, 1964). Those with 
positive results have generally regarded plasma 
lipid changes due to heparin as the ameliorating 
factor in the atherosclerotic process. Interestingly, 
two recent studies with positive results [Besterman 
(1970) and Grossman et al. (1971)] utilized heparin­
like compounds chosen for their lack of anticoagu­
lant activity—a sulfated polysaccharide from sea­
weed and a heparan sulfate by-product from the 
commercial manufacture of beef lung heparin, re­
spectively.
It would be dubious to propose nonanticoagulant 
heparin as a treatment for atherosclerosis. In cer­
tain clinical circumstances, however, intimal 
smooth muscle cell proliferation may occur much 
more rapidly than in ordinary atherosclerosis and 
thus be amenable to pharmacological inhibition. 
This situation may occur in some patients after 
saphenous vein coronary artery bypass grafting 
(Kern et al., 1972; Lawrie et al., 1976) or after 
arterial embolectomy by Fogarty balloon catheter 
(Chidi and DePalma, 1978).
This study suggests that heparin inhibition of 
arterial smooth muscle proliferation occurs through 
a direct process and is not mediated by effects on 
other cells or by antithrombin. Thus the antipro­
liferative effect of heparin should direct attention 
toward a potential growth regulatory role for arte­
rial glycosaminoglycans, but not toward such a role 
for the humoral clotting system.
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Inhibition of Rat Arterial Smooth Muscle 
Cell Proliferation by Heparin
II. In Vitro Studies
R.L. H o o v e r , R. R o s e n b e r g , W. H a e r i n g , a n d  M.J. K a r n o v s k y
S U M M A R Y  W e  s tu d ie d  in  v i t r o  th e  e f fe c t s  o f  h e p a r in  o n  t h e  g r o w th  o f  r a t  a o r t ic  s m o o th  m u s c le  c e l ls .  
M e a s u r e m e n ts  o f  g r o w th  w e r e  m o n ito r e d  b y  [3H ]th y m id in e  u p ta k e  a n d  c h a n g e s  in  c e l l  n u m b e r  o v e r  a  
p e r io d  o f  3 d a y s . O u r  r e s u l t s  s h o w  t h a t  h e p a r in — h ig h ly  a n t ic o a g u la n t  o r  n o n a n t ic o a g u la n t— s ig n if i ­
c a n t ly  in h ib it s  g r o w th  o f  s m o o th  m u s c le  c e l ls .  W e  a ls o  s h o w  th a t  t h i s  i s  a  h ig h ly  s p e c if ic  in te r a c t io n  
w ith  r e g a r d  to  m o le c u le  a n d  c e l l  ty p e :  i .e ., o th e r  p o ly a n io n s ,  e x c e p t  fo r  a  lo w  m o le c u la r  w e ig h t  d e x tr a n  
s u lfa te , d o  n o t  h a v e  th e  sa m e  e f fe c t  o n  g r o w th , a n d  n o t  a ll  c e l l s  a r e  in h ib ite d  b y  h e p a r in ;  e .g ., e n d o th e l ia l  
c e l l  g r o w th  a c tu a l ly  i s  e n h a n c e d . A fte r  r e m o v in g  a n tith r o m b in  fr o m  o u r  m e d ia , w e  c a r r ie d  o u t  
e x p e r im e n ts  w h ic h  s h o w  th a t  h e p a r in  i s  e f fe c t iv e  e v e n  th o u g h  th r o m b in , a  p o te n t  m ito g e n ic  a g e n t , i s  
s t i l l  p r e s e n t  a n d  a c t iv e .  W e  a ls o  fo u n d  th a t  p a s s in g  th e  p la te le t  e x tr a c t  o v e r  a  h e p a r in  c o lu m n  d id  n o t  
r e m o v e  a ll  o f  th e  m ito g e n ic  a c t iv ity  o f  th e  p la t e le t  p r e p a r a t io n . B o th  e x p e r im e n ts  in d ic a te  a n  in h ib ito r y  
r o le  fo r  th e  h e p a r in  m o le c u le ,  p e r  s e .  O ur r e s u l t s  su p p o r t  t h e  f in d in g s  o f  a  r e c e n t  p a p e r  (G u y to n  e t  a l., 
1980) s h o w in g  t h a t  h e p a r in  c a n  l im it  th e  s iz e  o f  m y o in t im a l p la q u e s  in  r a t s  a f te r  c a r o t id  in ju r ie s  b y  
in h ib it in g  s m o o th  m u s c le  c e l l  p r o life r a t io n . Circ Res 47: 578-583, 1980
THE proliferation of smooth muscle cells in blood 
vessels after endothelial injury contributes to the 
formation of a myointimal plaque which may play 
an important role in atherosclerosis (Ross and 
Glomset, 1973). Regulation of this proliferation, 
therefore, may help prevent the formation of ath­
erosclerotic plaques or at least reduce their size. 
Clowes and Karnovsky (1977) have shown that if 
heparin is administered to rats whose carotid arter­
ies have been injured in order to produce a myoin­
timal plaque, the size of the myointimal thickening 
is dramatically reduced. In a recent paper, Guyton 
et al. (1980) have shown that the effect of heparin 
on the injured arterial wall is primarily to inhibit 
smooth muscle cell growth, and that this effect is 
not related to anticoagulant activity. Molecules 
similar to heparin also have inhibited the growth of 
a variety of cells in tissue culture (Goto et al., 1979; 
Lippman and Mathews, 1977).
The mechanism by which heparin and heparin­
like molecules affect cell proliferation is not known. 
It is possible that because of the high affinity for 
antithrombin, anticoagulant properties may be in­
volved. It also has been shown that heparin binds 
to the surface of cells (Hiebert and Jacques, 1976), 
and this may alter permeability to ions necessary 
for growth, change conformation of molecules to
From the Departm ent of Pathology, Harvard Medical School, Boston, 
and the Sidney Farber Cancer Institute, Boston, Massachusetts.
This work was supported by National Institutes of Health Grants HL 
17747 and HL 19131.
Dr. Rosenberg is affiliated with the Sidney Farber Cancer Institute.
Address for reprints: Richard Hoover, Departm ent of Pathology, 
Harvard Medical School, 25 Shattuck Street, Boston, Massachusetts 
02115.
Original manuscript received September 7, 1979; accepted for publi­
cation May 8, 1980.
which it binds (Villanueva and Danishefsky, 1977), 
or affect cell volume (Norman and Norrby, 1971). 
Since heparin is a highly charged molecule, it also 
could be interacting with other charged molecules 
which affect growth. For example, Ross et al. (1974) 
have shown that the addition of material released 
from platelets enhances cell growth; therefore, it is 
possible that the antiproliferative action of heparin 
is caused when it binds to these factors and prevents 
their interaction with the cell surface.
In this paper we examine, in vitro, the effects of 
heparin on rat aortic smooth muscle cell growth. 
We consider whether there is a specificity with 
regard to the molecule and to the cell type, in 
particular, smooth muscle cells, and whether inter­
action with antithrombin plays a role. We also 
investigate what role the interaction with a platelet 
extract may play and whether the mechanism of 
action is mediated through the cell surface. Our 
results support the findings of the in vivo study in 
an earlier paper (Guyton et al., 1980) which show 
that heparin inhibits smooth muscle cell growth 
and limits the size of myointimal plaques.
Methods
Isolation and Culture of Smooth Muscle Cells
Smooth muscle cells are isolated from aorta of 
Sprague-Dawley (Charles River, CD strain) rats by 
carefully stripping pieces of the intima and inner 
media and incubating in RPMI-1640 media supple­
mented with 20% fetal calf serum (FCS) plus peni­
cillin (100 U/ml), streptomycin (100 jug/ml), and 
amphotericin (0.25 /xg/ml). After 1-2 weeks in cul­
ture, the smooth muscle cells migrate out of the 
tissue and begin to proliferate. Enzymes are not
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used initially to separate the cells. Once confluent, 
the cells are passaged and incubated in a special 
medium in which D-valine has been substitued for 
L-valine. Based on our own experiments and those 
of Gilbert and Migeon (1975), fibroblasts will not 
grow but smooth muscle cells will. These cells have 
been examined by electron microscopy and appear 
identical to the vascular smooth muscle cells de­
scribed by others (Gimbrone and Cotran, 1975; 
Jones et al., 1979), i.e., numerous myofilament bun­
dles and vesicles near the surface membrane. After 
this, the cells are maintained in RPMI-1640 me­
dium + 20% FCS and passaged every 3-4 days. 
Cultures beyond the 15th passage are not used.
Growth Measurements
Cells are plated sparsely at 30,000-50,000 cells/ 
ml in growth medium in 35-mm Petri dishes or Co 
Star cluster dishes (#3524). After 24 hours at sub- 
confluency, the cells are washed and RPMI-1640 
medium and 0.4% serum are added to arrest cell 
growth. The cells then are incubated for another 
24-48 hours. At the end of this incubation, the 
medium is replaced by the experimental solutions 
prepared in RPMI-1640 medium + 0.4% FCS. 
Growth is measured after 1, 2, and 3 days by direct 
cell counts and uptake of [3H]thymidine, as out­
lined by Chen and Buchanan (1975). These same 
procedures were used to look at the growth of calf 
aortic endothelium and BHK fibroblasts, the only 
difference being that the BHK cells were incubated 
with Dulbecco’s modified essential medium 
(DMEM) supplemented with 0.1% FCS, as the se­
rum requirements for BHK cells are lower than for 
smooth muscle and endothelium. In these experi­
ments, as with those of the smooth muscle cells, the 
endothelium and the BHK cells were tested at 
subconfluency.
All data have been subjected to a two-way anal­
ysis of variance for the purpose of determining 
statistical significance between the test groups. The 
analyses compared the growth values of the controls 
to those of the experimental groups. The analyses 
take into account not only experimental manipula­
tion but also the time element; i.e., each value is 
compared to measurements made at the same time 
and then compared with the data from the other 
time points. In all experiments, we found that time 
was not a factor and that significance depended 
only on treatment to cells. All significant values 
have a P  value of at least 0.01.
Preparation of Platelet Extract
Platelets are isolated by the methods of Tollefsen 
et al. (1974) from Sprague-Dawley rats. The with­
drawn blood is added to a solution of ethylenedia- 
minetetracetic acid (5 mM final cone.) and centri­
fuged for 3 minutes at 1400 g. The supernatant is 
removed and spun at 2250 g  for 15 minutes. The 
pellet of this centrifugation is suspended in phos­
phate-buffered saline (pH 6.5) containing no mag­
nesium or calcium but including 5.5 mM glucose and
5 mg/ml bovine serum albumin. The suspension is 
centrifuged at 120 g  for 10 minutes, and the pellet 
containing the leukocytes and erythrocytes is dis­
carded. The platelet suspension then is washed 2X 
in the above-described phosphate saline and resus­
pended at a concentration 108/m l in RPMI-1640 
containing no serum. Under these conditions, ac­
cording to Tollefsen et al. (1974), the platelets do 
not release their granules, as monitored by the 
absence of serotonin in the medium. The growth 
factor(s) then is released by freezing and thawing 
6X. This solution is centrifuged for 20 minutes at 
2250 g  and sterilized by filtration through a Milli- 
pore filter, 0.22 jupore size, which also removes any 
remaining particulate matter. In all experiments 
using this extract, 5 ml were added to 95 ml of 
medium.
Preparation of Purified Anticoagulant and 
Non-anticoagulant Heparins
Commercial heparin is separated into two major 
fractions based on anticoagulant activity by passing 
the material over a Sepharose-antithrombin col­
umn. The procedure is that described by Lam et al.
(1976) and is outlined extensively by Guyton et al. 
(1980). In summary, the anticoagulant fraction 
which has a high affinity for antithrombin stays on 
the column while the nonanticoagulant fraction of 
low affinity passes through.
Results
Figure 1 shows results of a typical experiment 
involving controls (RPMI-1640 medium + 0.4% 
FCS), platelet extract, platelet extract plus heparin,
Figure 1 Growth of smooth muscle cells in the pres­
ence of RPMI-1640 medium + 20% fetal calf serum (□  ); 
RPMI-1640 + 0.4% FCS (O); RPMI-1640 + 0.4% FCS + 
5% platelet extract (A); and RPMI-1640 + 0.4% FCS + 
5% platelet extract -l- heparin, 10 jig/ml (%).
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T a b l e  1 Growth of Smooth Muscle Cells in the Presence of Heparin as Monitored by 
f 3HJThymidine Uptake
Cell growth with following heparin concentration
5/ig/m l 10/tg/ml 15 ng/ml 20 jtg/ml
R e la tiv e  g row th  v a lues 0.79 ±  0.13 0.63 ±  0.18 0.63 ±  0.01 0.52 ±  0.07
Values (means ±  S E) are expressed as a fraction of controls containing RPMI-1640 medium plus 0.4% FCS and 
ra t platelet extract (5%). Number of measurements for each concentration of heparin, n >  18, which represents a t 
least three separate experiments (n per experiment >  6).
and 20% FCS, and provides the parameters for all 
subsequent experiments. The presence of heparin 
reduces the cell number, whereas growth in 20% 
FCS produces the greatest number of cells. We also 
found that [3H]thymidine uptake mimicked these 
results and was used in conjunction with the data- 
monitoring change in cell number. In both methods, 
due to the variability in the cultures with increasing 
passage number, size of inoculum, differences in 
serum batches, etc., the data have been based on 
controls with RPMI-1640 +  0.4% FCS.
The addition of heparin to smooth muscle cul­
tures inhibits growth (Table 1). As the concentra­
tion is increased from 5 jug/ml up to 20 jug/ml, the 
inhibitory effect increases. All values are signifi­
cantly different from one another (P  <  0.01) except 
at 10 and 15 jug/ml. All subsequent experiments 
were carried out using heparin at a concentration 
of 10 jug/ml because this corresponds to the in vivo 
situation, where this concentration is achieved 
readily.
Heparin can be separated into anticoagulant and 
non-anticoagulant fractions. When these are tested 
in our system, they produce similar effects on 
growth (Table 2). In each case, growth is inhibited 
by 50-60%. Because of variability in cultures, 
growth has been normalized to control conditions. 
Also, in all experiments, samples were tested with
Table 2 [ 3H]Thymidine Uptake of Smooth Muscle 
Cells When Grown in the Presence of Various 
Glycosaminoglycans
Control 1.00
— W ithout p latelet extract 0.55 ±  0.09*
N  onanticoagulant-heparin 0.63 ±  0.07*
A nticoagulant heparin 0.60 ±  0.04*
Chondroitin sulfate^ 1.07 ±  0 .05f
D erm atan sulfatej: 1.08 ±  0 .04t
Low m olecular wt§ 0.61 ±  0.04*
dextran sulfate
H igh m olecular wt* 0.99 ±  0 .07f
dextran su lfate
Protam ine sulfate* 0.99 ±  0 .05f
All values are based on controls containing 5% platelet extract, con* 
centrations are 10 /ig/ml for all compounds in RPMI-1640 medium +  0.4% 
FCS.
* Values which are significantly different from controls, P  <  0.01. 
Number of experiments for each glycosaminoglycan is a t least 3, repre­
senting 18 measurements.
t  Values which are not significantly different from controls, P  >  0.10. 
n >  18, representing a t least three separate experiments.
\  Standards obtained from Dr. Anthony Cifonelli, University of Chi­
cago.
§ Obtained from Dr. P. Petracek, Riker Lab., Minneapolis, MN.
|| Obtained from Sigma Chemical Co., St. Louis, MO.
RPMI-1640 medium plus 20% fetal calf serum (nor­
mal growth medium) to indicate the health and 
growth potential of the cells (see Fig. 1).
We have tested other sulfated polyanions, and 
none, with the exception of a small dextran sulfate 
(mol wt 25,000), inhibited growth like heparin 
(Table 2). The small dextran sulfate resembles hep­
arin in the degree of sulfation and charge, whereas 
the others are sulfated to a lesser extent (R. Rosen­
berg, unpublished observations).
We have also considered whether heparin affects 
other cells besides smooth muscle. We have tested 
bovine aortic endothelium and BHK fibroblasts and 
found contrasting results (Table 3). In the case of 
the fibroblasts, heparin inhibited growth to the 
same extent as the smooth muscle, but with endo­
thelium, there is no inhibitory effect—rather, the 
heparin significantly stimulates growth. Platelet ex­
tract alone had no significant effect on the uptake 
of [3H]thymidine by endothelium.
Thrombin has been shown to be mitogenic for 
several cell types in vitro (Chen and Buchanan, 
1975; Bohjanpelto, 1977) and, in preliminary exper­
iments, it enhanced [3H]thymidine uptake in our 
smooth muscle system. Therefore, by adding hep­
arin, which binds to antithrombin and complexes 
with thrombin, we may be inhibiting growth be­
cause the thrombin is now inactive. However, two 
different experiments indicate that this is not the 
case (Table 4). First, if serum is depleted of anti­
thrombin by passing over a heparin column and 
tested for growth with and without heparin, inhi­
bition occurs only in the heparin cultures. In this 
case, thrombin still should be active. Second, the 
addition of antithrombin, which would complex the 
thrombin, to the system does not enhance the hep-
Table 3 The Effects of Heparin (10 jig/ml) on 
Growth of Calf Aortic Endothelium and B H K  
Fibroblasts
BHK Endothelium
N o  platelet extract 1.00 1.00
P late let extract (5%) 1.00 ±  0.08* 0.90 ±  0.11*
H eparin 0.63 ±  0 .07f 1.44 ±  0 .06f
H eparin and p late let ex­
tract
0.63 ±  0 .07f 0.92 ±  0.14*
Basic medium for BHK cells was DMEM +  0.1% FCS and for 
endothelium, RPM I +  0.4% FCS.
Number of experiments is a t least 3 with a total of 18 measurements 
for each cell type and condition.
t  Values significantly different from controls, P  <  0.01.
* Values not significantly different from controls, P >  0.10.
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T able 4 The Effects on Growth of the Addition of 
Antithrombin (0.1 pg/ml) to Cultures of Smooth Muscle 
Grown with and without Heparin (10 pg/ml)
R PM I +  0.4% FC S +  platelet extract (PE) 1.00
R PM I +  0.4% FC S +  PE  +  antithrom bin 0.97 ±  0.09* 
R PM I +  0.4% FC S +  PE  +  heparin +  anti- 0.77 +  0.07f
throm bin
R PM I +  0.4% FC S +  PE  +  heparin 0.71 ±  0.08t
Fetal calf serum had been passed through a heparin-Sepharose column 
(equilibrated with 0.15 M NaCl/0.01 M Tris-HCl, pH 7.5) to remove the 
antithrombin.
* Values not significantly different from controls, P  a  0.10, n a  18 
representing a t least three different experiments with six or more mea- 
surements/experiment.
t  Values significantly different from controls, P  -- 0.01.
arin effect. It also should be remembered that non­
anticoagulant heparin, which has a low affinity for 
antithrombin, inhibits growth as well as the highly 
anticoagulant form.
Our test medium contains a platelet extract that 
causes stimulation of growth of the smooth muscle 
cells. It is possible that the heparin, because of its 
charge, may bind to these factors and prevent 
growth. Table 5 presents data which indicate that 
this probably is not the case. The platelet extract 
was passed over a heparin-Sepharose column and 
then tested for stimulatory effects on growth. Under 
these conditions, any molecule with a high affinity 
for heparin will be retained on the column; e.g., this 
is the same manner in which antithrombin was 
removed from the plasma. If the heparin column 
treatment removed growth factors, then a differ­
ence between the growth potential of the treated 
and untreated samples would be expected. As our 
results show, there is no inhibition with the treated 
sample and, statistically, it is the same as the un­
treated.
It is possible that the heparin is binding to the 
cell surface and in doing so is interfering with the 
interaction between the platelet extract and the 
cell, thereby inhibiting growth. In an attempt to 
investigate this possibility, we preincubated the 
cells in heparin followed by two washes with Hanks’ 
balanced salt solution before adding the platelet 
extract. If the preincubation is done for 1 hour, 
there is a slight inhibition, but by extending the 
preincubation time to 24 hours, the inhibitory effect 
increases, almost to the same extent as if heparin
Table 5 The Effect on Growth of Smooth Muscle 
Cells using Platelet Extract (PE) Passed over a 
Sepharose-Heparin Column
R P M I+  0.4% FC S 1.00
R P M I +  0.4% FC S +  5% p latelet extract 1.44 ±  0.03*
R PM I +  0.4% FC S +  5% platelet extract from 1.40 ±  0.06*
heparin colum n
Because the platelet extract was diluted after passage through the 
heparin-Sepharose column, the control PE was diluted to the same extent 
with the equilibration buffer, 0.15 M NaCl/0.01 m Tris-HCl, pH  7.5.
* Values significantly different from controls, P  £  0.01, n a  18, repre- 
senting-at least three separate experiments with six measurements/exper- 
iment.
had been added to the medium from the beginning 
(Table 6). The results suggest that heparin need 
not be free in solution in order to inhibit growth, 
and that it may be binding to the cell surface and 
thus blocking access to receptors for the platelet 
extract.
Discussion
In a previous paper, Clowes and Kamovsky
(1977) have shown that heparin inhibits the size of 
plaques formed in a rat carotid artery that has been 
injured. It also has been shown that the heparin 
effect is not related to its anticoagulant properties 
(Guyton et al., 1980). In this study, we have shown: 
(1) that these same heparins will inhibit the prolif­
eration of smooth muscle cells in vitro (2) that the 
only other polyanion to have an effect was a small 
dextran sulfate similar to heparin in charge and 
degree of sulfation, (3) that there is an inhibitory 
effect on fibroblasts but not on endothelium, (4) 
that the mechanism of action is not mediated 
through an interaction with antithrombin, (5) that 
interaction with platelet growth factors is not solely 
responsible for the heparin effect, and (6) that there 
is probably an interaction of the heparin with the 
cell surface.
Factors isolated from platelets can cause prolif­
eration of several cell types (Rutherford and Ross, 
1976). In this paper, we show that this stimulation 
is also true for growth of rat smooth muscle cells. It 
would follow from this, that interfering with these 
factors could result in an inhibition of growth; there­
fore, heparin might be inhibiting proliferation by 
complexing with the platelet growth factors. Our 
results show that after the platelet extract is passed 
through a column to remove heparin-binding mol­
ecules and added back to cell cultures, growth still 
continues. This indicates that heparin does not bind 
tightly to all factors necessary for growth and that 
the inhibition is not mediated merely through a 
depletion of these factors. However, the results do 
not rule out the possibility that heparin might be 
binding to the cell surface and preventing access to 
receptors. In fact, cells preincubated with heparin 
before addition of the platelet extract exhibit an 
inhibition, suggesting the above mechanism nay be
T a b l e  6  The Effects of Preincubation of Heparin 
(10 pg/ml) on Growth of Smooth Muscle Cells as 
Monitored by Cell Number
R P M I +  0.4% FC S +  P E  
R P M I +  0.4% FC S
R P M I +  0.4% FC S +  P E  preincubated 1 hr
w ith  heparin (10 pg/m l)
R P M I +  0.4% FC S +  P E  preincubated 24 hr
w ith  heparin (10 jag/ml)
Values are based on a  comparison between controls with platelet 
extract (PE) which had been incubated concurrently with each of the 
experimental conditions.
* Values significantly different from controls, P  <  0.01. Number of 
measurements for each condition is a t least 18, representing three separate 
experiments with six measurements each.
1.00
0.74 ±  0.01* 
0.88 ±  0.07*
0.68 ±  0.06*
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true. In preliminary experiments, however, we have 
found that incubating the cells first with platelet 
extract and then adding heparin (from 1-12 hours 
later) inhibits growth. Furthermore, the in vivo 
studies of Clowes and Kamovsky (1977) and Guy­
ton et al. (1980) show that heparin, when adminis­
tered to animals beginning 24 hours after carotid 
injuries, inhibits the size of the myointimal thick­
ening. This suggests that the heparin and the plate­
let growth factor(s) bind quickly and prime the cells 
for division (Pledger et al., 1977); yet, the addition 
of heparin to cultures that had been incubated with 
platelet extract still inhibited growth.
The results in Figure 1 also indicate that the 
inhibition caused by heparin occurs in the first 24 
hours and that no growth occurs after that point. 
At approximately the same time, growth of cells in 
0.4% fetal calf serum (with and without platelet 
extract) also subsides. Cells in 20% fetal calf serum, 
however, continue to grow until confluency, or to 
at least 48 hours. The addition of heparin to cultures 
with 20% serum does not affect growth during the 
first 24-48 hours, at which time a steady decline in 
growth rate begins (John Castellot, personal com­
munication). Although we do not know the reason 
for this difference in the kinetics of the heparin 
effects, we suggest that it may be related to the 
interactions between heparin and the serum com­
ponents, and at present are carrying out experi­
ments to test this possibility.
Antithrombin binds very easily to heparin (Ro­
senberg, 1977) which, in turn, combines with throm­
bin to inhibit proteolytic activity. It is possible that 
this interaction has an effect on smooth muscle 
proliferation because of the known mitogenic prop­
erties of thrombin (Chen and Buchanan, 1975; Car­
ney et al., 1978). However, our results, in which 
serum was depleted of antithrombin and growth 
continued, indicate that this is not the case. In the 
absence of antithrombin (active thrombin), heparin 
limited cell growth, and with the reintroduction of 
antithrombin into heparin-treated cultures, there 
was no enhanced inhibition. Apparently, the action 
of heparin is not mediated through thrombin inac­
tivation.
We also know that, even though we use the term 
“depleted” with respect to antithrombin, a very 
small amount of antithrombin remains after the 
heparin column treatment—by our calculations, 
about 1%. This measurement is based on the neu­
tralization of thrombin as outlined by Damus and 
Rosenberg (1976). Briefly, the sample is incubated 
with thrombin and the activity quantified by mea­
suring the time needed to clot a fibrinogen solution. 
If one considers there are approximately 250 fig of 
antithrombin per ml at the start, then the final 
concentration would be 2.5 jug/ml. This is then used 
at a concentration of 0.4% in our media, giving a 
final concentration of 10 ng/ml; however, because 
of molecular size, antithrombin does not bind to
heparin at a ratio of 1:1, rather 3:1. This means 
that the heparin-antithrombin complex would ac­
count for about 3-4 ng of heparin and would have 
essentially no effect in our experiments. Further­
more, the concentration of the antithrombin is so 
low in our medium and the binding constants such, 
that there is little chance of interaction with hepa­
rin. There is always the possibility that other mol­
ecules besides antithrombin are removed, but even 
if it were true, this does not affect the growth 
responses to heparin or platelet extract.
The specificity of the heparin molecule is dem­
onstrated by the fact that all other polyanions 
tested have no effect, except a small dextran sulfate. 
It is interesting to note that this compound is sim­
ilar in molecular weight and sulfation to heparin, 
whereas the others are not. The lack of inhibition 
by these other molecules also indicates that an 
interaction due to charge per se between the cell 
and heparin or between growth factors and heparin 
is probably not the mechanism involved in this 
effect. If it were, then the other molecules of similar 
charge would show inhibition. Apparently, the sec­
ondary structure or charge distribution of the mol­
ecules plays an important role. Goto et al. (1977) 
also have indicated that the specific structure of 
polyanions may play a part in determining satura­
tion density.
The inhibition of growth by heparin in our ex­
periments appears specific for smooth muscle cells 
and BHK fibroblasts because, in contrast to this, 
the growth of calf aortic endothelium is stimulated 
in the presence of heparin. These differential 
growth effects may be very important in the for­
mation of atherosclerotic plaques because, once en­
dothelium covers the smooth muscle cells, prolif­
eration decreases (Schwartz et al., 1978). The effects 
of heparin, therefore, are amplified by increasing 
the growth of the endothelium and inhibiting that 
of smooth muscle which, as a result, reduce the size 
of the plaques. Indeed, we have found in prelimi­
nary experiments that conditioned media from en­
dothelial cultures inhibit the growth of smooth mus­
cle cells, suggesting a regulatory role for endothe­
lium (Castellot et al., 1979).
This heparin-induced increase of endothelial 
growth differs from the results in the in vivo study 
(Guyton et al., 1980), which showed no endothelial 
enhancement. Clowes and Kamovsky (1977) simi­
larly had found no endothelial growth increase and 
suggested that endothelial regeneration requires 
migration and mitosis; therefore, in the in vivo 
situation, migration may have been affected, re­
stricting endothelial overgrowth, whereas in in vitro 
experiments, no such restrictions occurred.
The interaction of heparin with the cell surface 
probably initiates the inhibitory effects observed. 
Evidence for this comes from our data which show 
that if the cells were preincubated in heparin for as 
short a time as 1 hour and were washed before
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addition of the growth extract, inhibition occurred. 
In addition, we have found, in preliminary experi­
ments, that heparin bound to Sepharose beads (Jor­
dan et al., 1979) causes an inhibition of growth, 
although the response is not as great as when the 
heparin is added directly. We also have found re­
cently that radiolabeled heparin binds readily to 
the cell surface of smooth muscle cells. At present 
we are considering whether there are specific recep­
tors on the cell surface for heparin and whether 
there are any changes in morphology and physiol­
ogy of the cells after binding of heparin.
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VIII
Cultured Endothelial Cells Produce a Heparinlike 
Inhibitor of Smooth Muscle Cell Growth
JOHN J. CASTELLOT, J r., MARY L. ADDONIZIO, ROBERT ROSENBERG, and MORRIS J.
KARNOVSKY
Department o f Pathology, Harvard M edical School, Boston, Massachusetts 02115, and the Sidney Farber 
Cancer Institute, Boston, M assachusetts 02115
A bstract Using cultured cells from bovine and rat aortas, we have examined the possibility 
that endothelial cells might regulate the growth of vascular smooth muscle cells. Conditioned 
medium from confluent bovine aortic endothelial cells inhibited the proliferation of growth- 
arrested smooth muscle cells. Conditioned medium from exponential endothelial cells, and 
from exponential or confluent smooth muscle cells and fibroblasts, did not inhibit smooth 
muscle cell growth. Conditioned medium from confluent endothelial cells did not inhibit the 
growth of endothelial cells or fibroblasts. In addition to the apparent specificity of both the 
producer and target cell, the inhibitory activity was heat stable and not affected by proteases. 
It was sensitive to Flavobacterium heparinase but not to hyaluronidase or chondroitin sulfate 
ABC lyase. It thus appears to be a heparinlike substance. Two other lines of evidence support 
this conclusion. First, a crude isolate of glycosaminoglycans (TCA-soluble, ethanol-precipitable 
material) from endothelial cell-conditioned medium reconstituted in 20% serum inhibited 
smooth muscle cell growth; glycosaminoglycans isolated from unconditioned medium (i.e., 
0.4% serum) had no effect on smooth muscle cell growth. No inhibition was seen if the 
glycosaminoglycan preparation was treated with heparinase. Second, exogenous heparin, 
heparan sulfate, chondroitin sulfate B (dermatan sulfate), chondroitin sulfate ABC, and hyalu­
ronic acid were added to 20% serum and tested for their ability to inhibit smooth muscle cell 
growth. Heparin inhibited growth at concentrations as low as 10 ng/ml. Other glycosamino­
glycans had no effect at doses up to 10 /xg/ml. Anticoagulant and non-anticoagulant heparin 
were equally effective at inhibiting smooth muscle cell growth, as they were in vivo following 
endothelial injury (Clowes and Karnovsk. Nature (Eond.). 265:625-626,1977; Guyton et al. C/rc. 
Res. 46:625-634, 1980), and in vitro following exposure of smooth muscle cells to platelet 
extract (Hoover et al. C/rc. Res. 47:578-583, 1980). We suggest that vascular endothelial cells 
may secrete a heparinlike substance in vivo which may regulate the growth of underlying 
smooth muscle cells.
A  ch a ra cteristic  featu re  o f  th e  n o rm a l, h e a lth y  arteria l w a ll is 
that th e  in tim a l e n d o th e lia l c e lls  form  a c o n tin u o u s  q u iesc e n t  
m o n o la y e r , a n d  th e  u n d e r ly in g  m ed ia l sm o o th  m u sc le  c e lls  
a lso  rem ain  in a q u iesc e n t g ro w th  state . I f  th e  e n d o th e liu m  is 
d a m a g e d , sm o o th  m u sc le  c e ll  p ro lifera tio n  occu rs u n til  th e  
e n d o th e liu m  reg en era tes (9 , 2 9 ). T h e  reg u la tio n  o f  c e ll  grow th  
in  th e  v a scu la r  w a ll is p o o r ly  u n d ersto o d . R o ss  (1 5 , 2 8 ) an d  
o th e r s  (1 0 , 2 5 ) h a v e  sh o w n  th at p la te le t-d e r iv e d  gro w th  factors  
are req u ired  fo r  sm o o th  m u sc le  c e ll g ro w th  in  v iv o  a n d  in  v itro. 
R e ce n tly , c o n d it io n e d  m e d iu m  from  m a c ro p h a g e s  h a s  b een  
fo u n d  to  s t im u la te  sm o o th  m u sc le  c e lls  (2 3 ). G a jd u sek  e t  al.
(1 1 )  h a v e  sh o w n  th a t e n d o th e lia l ce lls  p ro d u ce  a  factor  w h ich  
stim u la te s  th e  g ro w th  o f  sm o o th  m u sc le  c e lls . E isen ste in  et al. 
(8 ) h a v e  fo u n d  th a t ex tracts from  th e  in n er  arteria l w a ll c a n  be  
fra ctio n a ted  to  p ro d u ce  b o th  stim u la to rs a n d  in h ib ito rs o f  
sm o o th  m u sc le  c e ll g row th .
W e  p resen t e v id e n c e  d em o n stra tin g  th at cu ltu red  e n d o th e lia l  
c e lls  p r o d u ce  b o th  p o s it iv e  a n d  n e g a tiv e  e ffe c to rs  o f  sm o o th  
m u sc le  c e ll  gro w th . T h e  in h ib ito r y  a c tiv ity  ap p ears to  b e  h ep ­
arin  or  a  h e p a r in lik e  m o le c u le . T h e se  resu lts su g g est a p o ssib le  
ro le  fo r  h ep a r in  in  th e  reg u la tio n  o f  va scu la r  sm o o th  m u scle  
c e ll  g r o w th  in  v iv o .
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MATERIALS AND METHODS
Purification of Heparinase
Flavobacterium heparinum were either grown as described by Linker and 
Hovingh (22) or were provided by Dr. R. Langer (Massachusetts Institute of 
Technology, Boston, Mass). The cells were sonicated at a cell protein concentra­
tion o f —8 mg/ml for 12 min with a Branson Sonifier set at 125 W. The sonicate 
was centrifuged at 20,000 g at 4°C for 30 min. The resulting supemate was 
treated with protamine sulfate at a level of 15 mg/ml and then exhaustively 
dialyzed against distilled water.
The crude preparation was subsequently chromatographed on hydroxylapatite 
and cellulose-phosphate as outlined by Linker and Hovingh (22). We purified 
the enzyme further by concentrating with ultrafiltration, and then by filtration 
on Sephacryl S-200 equilibrated in 0.5 M NaCl in 0.01 M Tris-HCl, pH 7.5. The 
elution profile exhibited a major protein peak at a molecular weight of —60,000 
daltons, as well as several minor protein peaks of lower molecular size. Direct 
analysis of the first peak with respect to heparin-cleaving potency (22) revealed 
a constant specific activity of —3,000 U /m g across the initial two-thirds of the 
profile. The remaining two components of lower molecular size possessed essen­
tially no glycosaminoglycan (GAG)-cleaving ability. The final enzyme prepara­
tion exhibited no capacity to degrade chondroitin sulfate, dermatan sulfate, or 
hyaluronic acid when employed at concentrations as high as —200 ftg/ml (24). 
There was no detectable protease activity in this preparation as measured by the 
radiolabeled casein assay (17).
Isolation of Bovine Aortic Heparan Sulfate
Glycosaminoglycans were obtained from blood vessels by extensive proteolytic 
digestion of the intima and media of calf aortas (26). Heparan sulfate was isolated 
free of other G AGs by chromatography on DEAE-Sephadex A-25 and Sepharose 
4B (30). The resulting product was identified by the two-dimensional electropho­
retic system of Hata and Nagai (16) in conjunction with appropriate standards. 
The nature of the heparan sulfate was confirmed by its sensitivity to digestion 
with bacterial heparinase and its resistance to the action of chondroitinase ABC 
and testicular hyaluronidase (24).
Cell Culture
Bovine aortic endothelial cells (BAEC) were isolated from freshly slaughtered 
calves, as previously described (2, 13, 19). The cells obtained from one aorta are 
grown in a single 75-cm2 tissue culture flask in RPMI-1640 medium containing 
20% fetal calf serum (FCS), 4 mM glutamine, penicillin (100 U/ml), streptomycin 
(100 jug/ml). amphotericin (0.25 jug/ml), and gentamicin (50 /ig/ml) at 37°C in 
a humidified, 10% CO* atmosphere. At confluence, >95% of the cells are 
endothelial, as determined by their distinctive morphology and the presence of 
factor VIII antigen on the cell surface.
Rat aorta smooth muscle cells (rat SMC) from Sprague-Dawley (Charles 
River, Wellesley, Mass.; CD strain) rats were isolated (18) as previously described. 
Cells were grown in the same medium and incubation conditions described for
BAEC.
Calf aorta smooth muscle cells (calf SMC) were isolated as previously de­
scribed (27). Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% calf serum (CS), penicillin (100 U/ml), streptomycin (100 fig/ 
ml), amphotericin (0.25 /xg/ml), and gentamicin (50 Mg/ml) at 37°C in a humid­
ified, 10% CO2 atmosphere.
Baby hamster kidney—2 1/clone 13 cells (BHK) were obtained from the 
American Type Culture Collection (Rockville, Md.). Cells were grown in DMEM 
containing 10% FCS, penicillin (100 U/ml), streptomycin (100 Mg/ml), and 
gentamicin (50 /zg/ml) at 37°C in a humidified, 10% CO* atmosphere. This 
fibroblast line was used because many laboratories have shown that these cells 
can be readily growth-arrested, and that the growth of the cells is dependent on 
serum factors. Thus its growth characteristics are similar to those of smooth 
muscle cells.
Conditioned Medium
A week or more after reaching confluence, BAEC were washed and 10 ml (— 1 
ml/10tt cells) of RPMI containing 0.4% FCS was added. 48 h later, this medium 
was removed and immediately filtered through a 0.22 |j.m filter. Conditioned 
medium (CM) from exponential BAEC and from exponential and confluent 
cultures of other cell types was collected in the same manner. Before adding it to 
cells, CM was mixed 1:1 with medium containing twice the usual serum concen­
tration (e.g., RPMI + 40% FCS, or DMEM + 20% CS), thus yielding a final 
serum concentration of 20% and 10%, respectively.
Growth Arrest of SMC
Sparsely plated rat or calf SMC were washed and placed in RPMI + 0.4% 
FCS or DMEM +  0.2% CS for 72 h. Flow microfluorimetry (32) and [3H]- 
thymidine uptake into DNA were used to determine that the cells were arrested
in G0 (Gl).
Inhibition Assay
To assay for inhibitory activity, 6 x  I03 cells were plated into 16-mm multiwell 
plates and growth-arrested as described above. Control cultures were released 
from the G„ block by placing them in RPMI +  20% FCS. Other cultures were 
placed in the 1:1 mixture of CM and RPMI +  FCS (final concentration FCS 
20%). Cell numbers were measured in duplicate samples at daily intervals by 
washing the cells once in a trypsin-EDTA solution (Grand Island Biological Co., 
Grand Island, N. Y.), then incubating the cells for several minutes in trypsin- 
EDTA solution to dislodge the cells. The dislodged cells were collected and 
counted in a Coulter counter. Trypsinized cultures were routinely checked by 
direct microscopic examination to ascertain that the trypsinization procedure had 
not lysed the cells (as determined by the presence of cell debris) and to ensure 
that all cells were removed from the multiwell. The cells were not fed during the 
experiment.
Mitogenesis Assay
To assay for mitogenic activity, exponential BAEC-CM was fractionated and 
concentrated 50-fold using Amicon XM100 and UM10 filters (Amicon Corp., 
Scientific Sys. Div., Lexington, Mass.). A concentrated fraction was mixed 1:1 
with RPMI +  FCS (final concentration FCS 1%) and added to growth-arrested 
rat SMC. In some control experiments, cells were exposed to a 1:1 mixture of 50- 
fold concentrated RPMI +  0.4% FCS and RPMI +  FCS (final concentration 
FCS 1%). In other control experiments, cells received RPMI +  20% FCS. Cell 
numbers were measured in duplicate samples at daily intervals using a Coulter 
counter as described above.
Chemicals
Chondroitin sulfate ABC lyase and Streptomyces hyaluronidase were pur­
chased from Miles Laboratories Inc., Miles Research Products (Elkhart, Ind). 
Unless otherwise stated, heparin was obtained from Upjohn Co., Agricultural 
Prods. MKT (Kalamazoo, Mich.) or Elkins-Sinn, Inc. (Cherry Hill, N. J.); other 
G AGs were kindly supplied by Drs. M. Mathews and J. Cifonelli (University of 
Chicago). All other chemicals were obtained from Sigma Chemical Co. (St. 
Louis, Mo.).
RESULTS
Crowth Arrest of SMC
SMC were plated and exposed to low serum as described in 
Materials and Methods. We used flow microfluorimetry and 
[3H]thymidine uptake into DNA to determine the cell cycle 
distribution of exponentially growing and serum-deprived 
SMC (32). The results will be published in detail elsewhere.1 
In brief, >90% of the growth-arrested rat SMC cells have the 
G l DNA content. These cells are most likely arrested at the 
same point in the cell cycle (G0), because growth-arrested cells 
placed in fresh complete medium undergo a synchronous round 
of DNA synthesis, with the earliest cells beginning S phase 16- 
18 h after the addition of serum. The peak of DNA synthesis 
occurs —28 h after release. Flow microfluorimetry confirms the 
time course of this release from G0. Calf SMC behaved simi­
larly, except that the onset of S phase began 12-14 h after 
release, and peaked at —20 h.
Effect of Confluent Primary BAEC-CM on SMC
Rat and calf SMC were growth-arrested as described in 
Materials and Methods. Control cultures were released from 
the G0 block by replacing the low serum medium with RPMI
' Castellot, J., and M. J. K am ovsky. Manuscript in preparation.
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+ 20% FCS. Other cultures were exposed to the 1:1 mixture of 
confluent primary BAEC-CM and RPMI + FCS (final con­
centration FCS 20%). Cell growth after exposure to CM is 
presented in Fig. 1.
Rat SMC exposed to CM go through one to one and a half 
doublings at the same rate as control cells. After this initial 
growth, rat SMC stopped proliferating. Control cultures reach 
confluence at day 4 or 5 under these conditions. If the CM was 
replaced with normal growth medium at day 4 or 5, the cells 
proliferated to confluence.
Calf SMC exposed to CM also go through one or two rounds 
of division at about the same rate as control cells. At this point 
(usually day 3), the cells in CM often began to round up and 
slowly detach. Very few cells remained by day 5. Once the cells 
began to round up, replacing the CM with normal growth 
medium did not reverse this effect. In approximately one-third 
of the experiments, the calf SMC did not round up, but their 
growth plateaued, as shown in Fig. 1. The inhibitory effect was 
reversible, as the cells in these experiments proliferated to 
confluence if the CM was replaced with normal growth me­
dium.
Direct observation of cells undergoing mitosis in CM-ex- 
posed rat and calf SMC cultures revealed that both daughter 
cells remained attached and spread normally after cytokinesis. 
Neither visual inspection nor Coulter counting of the medium 
indicated the presence of detached cells in CM-treated rat 
SMC and calf SMC cultures in which the cells did not round 
up. Flow microfluorimetry data indicate that both CM-treated 
and control SMC were arrested mainly in G0 (Gl) at the 
endpoint of the experiment (data not shown). CM-treated SMC
Figure 1 Effect of CM from confluent primary BAEC on growth- 
arrested SMC. Rat and calf SMC were arrested in C 0 by serum- 
deprivation as described in Materials and Methods. The effect of 
confluent primary BAEC-CM on SMC growth was assayed as de­
scribed in Materials and Methods. In approximately two thirds of 
the experiments, calf SMC exposed to CM began to round up and 
detach at day 3 (A— —A ). The other third of the time, the calf SMC
did not round up (A-------A). A----- A , calf SMC in RPMI + 20% FCS;
O-----O, rat SMC in RPMI + 20% FCS; # -----• ,  rat SMC exposed to
CM. Data for each cell type are the average of ten or more experi­
ments.
did not stain with trypan blue at any time during the course of 
the experiment. Finally, the possibility that the detachment of 
calf SMC is related to something present in the serum is 
suggested by experiments in which CM was mixed 1:1 with 
lower concentrations of FCS (final FCS concentrations, 10% 
and 5%). In these experiments, growth of control calf SMC 
(i.e., no CM) is reduced to three to four doublings in 10% FCS 
and two to three doublings in 5% FCS. CM-treated calf SMC 
did not go through even one doubling, and they did not round 
up and detach. Because of the potential difficulties in quanti­
fying results of experiments in which calf SMC detached, 
subsequent data on calf SMC in this paper are based on 
experiments in which calf SMC did not round up and detach.
To test the possibility that simple nutrient depletion was 
causing growth inhibition, some experiments were done using 
a 1:1 mixture of CM and RPMI containing twice the normal 
nutrient concentration +  FCS (final concentration FCS 20%). 
The results were the same as those in Fig. 1.
Specificity of the CM Effect
CM was collected from exponential and confluent cultures 
of BAEC, rat and calf SMC, and BHK cells as described in 
Materials and Methods. The volume of medium used for 
conditioning was 1 m l/106 cells. All cell types tested for their 
responsiveness to CM were plated as described in Materials 
and Methods, except that BHK cells were arrested using 0.2% 
CS for 60 h. Rat SMC used in these experiments were second 
or third passage; calf SMC were first or second passage. BAEC 
were first through fifth passage, except that the confluent 
BAEC-CM was always collected from primary cultures. Cell 
numbers in duplicate cultures were measured at daily intervals 
after exposing cells to CM. The data are presented in Table I 
as the maximum percent inhibition. We obtain this figure by 
first subtracting the starting cell number (i.e., the cell number 
at the time the cells are released from G0) from the cell number 
at day 5, when growth has essentially ceased in both control 
and CM-exposed cells, and any growth inhibition was therefore 
maximal. The net growth in control cells is set at 100%, and 
the net growth in CM-treated cells is expressed as a percentage 
of the control. The difference is the maximum percent inhibi­
tion. We used this method of expressing our data to (a) compare 
more readily growth inhibition in experiments using different 
cell types or different types of CM, (b) to compare more easily 
the effect of various physical and biochemical treatments on 
the inhibitory activity, and (c) to calculate an ED50 for heparin 
and other substances with inhibitory activity.
Confluent, primary BAEC-CM preferentially inhibited rat 
and calf SMC; BHK and BAEC were much less affected (Table 
I). Other CM did not substantially inhibit SMC growth. It 
should be pointed out that when exponential cells are put in 
0.4% serum they begin the transition from proliferation to 
quiescence. We cannot rule out the possibility that a growth 
effector(s) secreted by truly exponential cells is lost or masked 
during this transition. With this reservation in mind, the data 
demonstrate an apparent specificity of the inhibitory activity 
for both the producer and the target cell.
Serum Requirements for Release and 
Effectiveness of the Inhibitory Activity
When we allowed confluent primary BAEC to condition 
serum-free medium for 48 h, the inhibitory activity decreased 
to 10-20% of the activity found in CM containing 0.4% serum.
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Table  I
Specificity o f the BAEC-CM Effect
Maximum percent inhibition
Rat Calf
Type of CM BHK BAEC SMC SMC
None (normal growth me­
dium)
0 0 0 0
Exponential BHK 2 11 8 4
Confluent BHK 13 3 16 10
Exponential rat SMC 9 11 16 7
Confluent rat SMC 8 15 1 12
Exponential calf SMC 0 6 7 9
Confluent calf SMC 0 8 13 18
Exponential BAEC 7 0 0 1
Confluent BAEC 6 2 63 >80
Cells were tested for their response to CM as described in Materials and 
Methods and Results. The data are presented as maximum percent inhibition. 
0 means only that there was no inhibitory effect of CM. Exponential BAEC- 
CM (described in text) stimulated cell growth when compared to normal 
growth medium. Experiments involving BHK cells or BHK-CM were done 
twice. All other combinations were done four or more times. In all cases, cells 
in normal growth medium doubled four or more times before reaching 
confluence.
T able II
Serum Requirement for BAEC-CM Effect
Maximum percent inhibition
10% CS +
10% CS 20% CS 10% FCS 20% FCS 10% FCS
-C M 0 0 42 20 12
+CM 34 30 91 87 80
Calf SMC were plated and growth-arrested as described in Materials and 
Methods. The cells were exposed to the indicated final concentrations of sera 
with or without BAEC-CM. The data are from a representative experiment in 
which the calf SMC exposed to CM did not round up and detach.
The overall metabolic rate of confluent BAEC in serum-free 
medium as measured by the rate of protein synthesis was 
decreased by only 30% (data not shown). This suggests that 
production of the inhibitory activity by BAEC depends to a 
large extent on the presence of serum. FCS and CS were 
equally effective in releasing the inhibitory activity.
If growth-arrested calf SMC were exposed to a 1:1 mixture 
of BAEC-CM and RPMI + FCS (final FCS concentration, 
20%), the growth inhibition shown in Fig. 1 occurred. However, 
if growth-arrested calf SMC were exposed to a 1:1 mixture of 
BAEC-CM and DMEM + CS (final CS concentration, 10%), 
much less inhibition was observed (Table II). Calf SMC are 
usually grown in DMEM +10% CS; when grown in RPMI + 
20% FCS, they grow at a slightly slower rate and reach 80-90% 
of the final cell density of calf SMC grown in DMEM + 10% 
CS. Mixing CS and FCS does not block the inhibitory activity 
(Table II). Growth-arrested calf SMC released into DMEM 
+ 20% CS grow at the same rate as they do in DMEM +  10% 
CS; the inhibitory effect of BAEC-CM when the final CS 
concentration is 20% is similar to the effect when the final CS 
concentration is 10% (Table II). When G0 calf SMC are 
exposed to RPMI + 10% FCS, they reach ~60% of the final 
cell density of calf SMC grown in DMEM + 10% CS. The 
inhibitory effect of BAEC-CM when the final FCS concentra­
tion is 10% is slightly greater than in 20% FCS because the 
cells do not go through even one doubling. These data suggest
that BAEC-CM interacts with something present in greater 
concentrations in FCS than in CS to generate the inhibitory 
activity. However, we cannot rule out the possibility that 
substances present in CS compete with the SMC for the 
inhibitor. Similar experiments cannot be done with rat SMC 
because these cells do not grow well in CS. In summary, the 
release of inhibitory activity by BAEC requires the presence of 
a small amount of either FCS or CS; however, the inhibitory 
effect is greater in the presence of FCS than in CS.
Effect of Passage Number
CM from confluent BAEC at different passages was collected 
as described in Materials and Methods. It was tested for 
inhibitory activity on second or third passage rat SMC as 
described in Materials and Methods. The results are presented 
in Fig. 2 A as the maximum percent inhibition. The data 
demonstrate that the inhibitory activity in confluent BAEC- 
CM decreases rapidly as the passage number of the BAEC 
increases.
Fig. 2 B shows the results of experiments in which confluent 
primary BAEC-CM was tested on rat SMC at different pas­
sages. These data show that the inhibition by BAEC-CM 
decreases as the passage number of rat SMC increases. Calf 
SMC were always used between passages one and three because 
they tended to become pleiomorphie at later passages. We have 
generally noted that third passage calf SMC were slightly less 
responsive to BAEC-CM (not shown).
Figure 2 Effect of passage number on BAEC-CM effect. (A ) The 
effect of confluent BAEC-CM from the indicated passage numbers 
on the growth of second or third passage rat SMC was assayed as 
described in Materials and Methods. (B ) The effect of confluent 
primary BAEC-CM on the growth of rat SMC at the indicated passage 
numbers was assayed as described in Materials and Methods. All 
passage number data are the average of three or more experiments, 
except for BAEC-CM at passages 6, 8 and 10, which were done 
twice.
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Biochemical Characterization o f the 
Inhibitory Activity
We subjected the CM obtained in 0.4% serum to a variety of 
treatments to characterize it. To test the heat sensitivity of the 
inhibitory activity, aliquots of CM were heated at 60°C for 30 
min, or at 90°C for 5 min. CM treated this way lost <20% of 
its activity (Table III).
To determine whether the inhibitory activity was a 
protein(s), we treated it with 30 jag/ml trypsin for 2 h at 37 °C. 
A tenfold excess of soybean trypsin inhibitor in a small volume 
was added 30 min before mixing the CM with RPMI + FCS 
(final concentration FCS 20%). Separate aliquots of CM were 
treated with 30 jag/ml chymotrypsin for 2 h at 37 °C, or with 30 
/Tg/ml subtilisin (Carlsberg) for 60 min at 37°C. A tenfold 
weight excess of chick egg white ovoinhibitor was added to the 
chymotrypsin-treated CM at least 30 min before mixing the 
CM with RPMI + FCS (final concentration FCS 20%). Sub- 
tilisin-treated CM was heated at 90°C for 5 min to kill the 
enzyme activity. Less than 10% of the inhibitory activity was 
lost after these protease treatments (Table III). To control for 
nonspecific protease or inhibitor effects, the same concentration 
of proteases and inhibitors (or boiled enzyme in the case of 
subtilisin) were mixed together for 30 min, then added to 
RPMI + 20% FCS or the 1:1 CM-RPMI + FCS (final concen­
tration FCS 20%) mixture. The inhibitory activity was unal­
tered by these treatments.
BAEC-CM was incubated with 1 U/ml of chondroitin ABC 
lyase for 90 min at 37 °C. Separate aliquots of BAEC-CM were 
treated with 15 U/m l hyaluronidase for 90 min at 37 °C. The 
samples were then boiled for 5 min, a treatment which kills the 
enzyme activity but does not affect the inhibitory activity. 
These enzyme treatments resulted in little or no loss of activity 
(Table III). Boiled hyaluronidase or chondroitin ABC lyase 
added to RPMI + 20% FCS did not affect SMC growth.
When BAEC-CM was incubated with 10 U/ml purified 
Flavobacterium heparinase for 90 min at 37 °C, 80% of the 
inhibitory activity was lost (Table III). The heparinase prepa­
ration has no detectable protease activity, even when tested in 
a sensitive assay system (17). In addition, the inhibitory activity 
in BAEC-CM was insensitive to digestion by a broad range of 
proteases, as described above. The heparinase is specific for a 
heparin or heparinlike substrate, in that it requires a 1—>4 
linkage between sugar residues and also requires sulfated idu- 
ronic acid or N-sulfated glucosamine as a substrate. Thus, it 
will not degrade chondroitin sulfates, dermatan sulfate, or 
hyaluronic acid. The inhibitory activity in BAEC-CM therefore 
appears to be heparin or a heparinlike molecule.
Two other lines of evidence support this conclusion. First, a 
crude isolate of glycosaminoglycans from BAEC-CM was pre­
pared by the method of Dietrich and de Oca (7). The TCA- 
soluble, ethanol-precipitable material obtained was reconsti­
tuted in the starting volume of RPMI +  20% FCS. When rat 
or calf SMC were exposed to this medium, their growth was 
inhibited with the same kinetics displayed in Fig. 1, although 
the calf SMC did not round up and detach in these experiments. 
Treating the crude isolate of GAGs with heparinase destroyed 
the inhibitory activity. GAGs isolated in the same manner 
from unconditioned medium (i.e., RPMI +  0.4% FCS) had no 
effect on SMC growth.
The second approach was to examine the effect of.exogenous 
GAGs on SMC growth. When chondroitin sulfate ABC, der- 
. matan sulfate, hyaluronic acid, or two types of heparan sulfate
T able III
Biochemical Properties o f the BAEC-CM Inhibitory Activity
Maximum percent inhibi­
tion
Treatment Calf SMC Rat SMC
None 84 ± 8 58 ± 5
60°C, 30 min 76 ± 9 53 ± 10
90°C, 5 min 93 + 4 62 ± 5
Trypsin
(30 Mg/ml, 2 h, 37°C) 82 ± 5 60 ± 10
Chymotrypsin 
(30 jug/ml, 2 h, 37°C) 85 54
Subtilisin
(30 fig/ml, 60 min, 37°C) ... 51
Hyaluronidase
(15 U/ml, 90 min, 37°C) 94 + 4 50
Chondroitin S 0 4 ABC lyase 
(1 U/ml, 90 min, 37°C) 88 ± 7 58 ± 2
Heparinase
(10 U/ml, 90 min, 37°C) 19 9 ± 6
CM from BAEC was subjected to the indicated treatments and then assayed 
for its ability to inhibit growth-arrested calf and rat SMC when mixed 1:1 with 
RPMI + FCS (final concentration 20% FCS). SD are given in those instances 
when the treatments were performed three or more times. In other cases, the 
treatments were performed twice.
LG AG]/ml
Figure 3 Effect of GAGs on rat SMC growth. (A ) Rat SMC were 
plated and growth-arrested as described in Materials and Methods. 
The cells were then exposed to RPMI + 20% FCS containing the 
indicated concentrations of GAGs. Cell number was measured at 
daily intervals. Data are expressed as maximum percent inhibition. 
(8 ) Rat SMC were plated at 6 x  103/16-mm well. After 24 h, the 
medium was aspirated and replaced with fresh RPMI + 20% FCS 
with or without the indicated concentrations of GAGs. Data are
expressed as maximum percent inhibition. • -----• ,  heparin;
□ -----□ , bovine aortic heparan sulfate; ■-----■, beef lung heparan
sulfate; A -----A , dermatan sulfate; A-----A , chondroitin ABC sulfate;
O-----O, hyaluronic acid. Data for the heparan sulfates are the
average of three experiments; data for other GAGs are the average 
of five or more experiments.
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were added to either growth-arrested or exponential cultures 
of rat SMC, no inhibition of growth occurred at concentrations 
up to 10 jug/ml (Fig. 3). At 100 jug/ml, slight inhibition (up to 
20%) of growth-arrested cells was observed with these GAGs 
(Fig. 3). In contrast, heparin inhibited SMC growth by 50% at 
1-2 jug/ml in growth-arrested SMC, and at 90-100 jug/ml in 
exponential SMC (Fig. 3). Anticoagulant and non-anticoagu­
lant heparin (21) were equally effective in inhibiting SMC 
proliferation.
Note that growth-arrested SMC are nearly 100 times more 
sensitive to heparin than exponential SMC (Figs. 3 and 4). 
Although the ED50 for heparin is rather variable from experi­
ment to experiment, the 100-fold difference in sensitivity to 
heparin was very consistent.
We also examined the effect of heparin on BAEC growth. 
Exponential and growth-arrested BAEC were not inhibited by 
heparin at doses <100 jug/ml (Fig. 4). There was actually a 
slight stimulation of BAEC, which ranged from 10-30% in 
different experiments. This is in sharp contrast to the effect of 
heparin on SMC. Heparin did not affect the growth of either 
exponential or growth-arrested BHK cells at doses <100 jag/ 
ml (data not shown).
Mitogenic Activity in BAEC-CM
When we attempted to fractionate BAEC-CM on Amicon 
filters, nearly all the inhibitory activity was lost. However, we 
noticed a small but consistent increase in cell number when 
the 10,000- to 100,000-dalton and > 100,000-dalton fractions 
were added to RPMI + 20% FCS. In light of the recent 
observations by Gajdusek et al. (11) that BAEC secrete a SMC 
mitogen, we fractionated CM from exponential BAEC at pas­
sages five through seven. The mitogenic potential of these 
Amicon fractions was assayed on rat SMC as described in 
Materials and Methods. The >  100,000-dalton fraction sup­
ported two rounds of SMC division, whereas the 1% FCS (final 
concentration) control supported less than one doubling (Fig. 
5). The 10,000- to 100,000-dalton fraction had even greater 
mitogenic activity, but the background from this fraction of
Figure 4 Effect of heparin on BAEC and rat SMC growth. Expo­
nential cultures of BAEC, and exponential and growth-arrested 
cultures of rat SMC were obtained as described in Materials and 
Methods. Growth-arrested BAEC were obtained by placing 6 x  103 
BAEC growing in 16-mm wells in RPMI + 0.4% FCS for 72 h. These 
cells were exposed to the indicated concentrations of heparin as
described in Fig. 3. O---- O, growth-arrested rat SMC; • ------• ,
exponential rat SMC; A--- A, growth-arrested BAEC; A------ A , ex­
ponential BAEC. Data are the average of five or more experiments.
DAYS AFTER RELEASE FROM G0
Figure 5 Mitogenic activity in fractionated BAEC-CM. CM from 
exponential BAEC (passages 5-7) was fractionated using Amicon 
filters. The ability of a concentrated >100,000-dalton fraction
( • -----• )  to stimulate the growth of G0-arrested rat SMC was
assayed as described in Materials and Methods, and compared to
growth in 20% FCS (O-----O) and 1% FCS (final concentration) +
concentrated 0.4% FCS (A-------A; see Materials and Methods). Data
are from a representative experiment.
concentrated RPMI + 0.4% FCS was also higher and more 
variable. This is probably the result of concentrating the low 
molecular weight growth factors, e.g., platelet factors, known 
to be present in serum. The results from this fraction are thus 
more difficult to interpret. These results confirm the observa­
tions of Gajdusek et al. (11) on the production of an SMC 
mitogen by BAEC.
DISCUSSION
We have shown that cultured BAEC are capable of secreting 
both positive and negative effectors of SMC growth. The 
mitogen is probably similar to the one described by Gajdusek 
et al. (11). The inhibitor appears to be heparin or a heparinlike 
molecule. Using CM from confluent cultures of primary BAEC, 
we observed a slow-onset inhibition of proliferation of growth- 
arrested SMC (Fig. 1). The difference between our observations 
of an inhibitory activity in BAEC-CM and those of Gajdusek 
et al., in which a mitogenic activity dominates, are due likely 
to one or more of the following differences in the systems used: 
(a) we collected CM only from primary BAEC that have been 
confluent for at least a week, whereas Gajdusek et al. used later 
passage BAEC to collect CM; (b) we collected our CM in the 
presence of serum, whereas Gajdusek et al. used plasma-de­
rived serum; and (c) we used growth-arrested SMC to assay for 
inhibitory activity, whereas Gajdusek et al. used exponential 
SMC to assay for mitogenic activity.
The issue of cytotoxicity is difficult to address directly. 
Several observations suggest that the inhibitory effect of 
BAEC-CM is not strictly cytotoxic: (a) the rat SMC never 
detach, and the calf SMC detach only two-thirds of the time in 
experiments using 20% FCS; (b) experiments in which the final 
concentration of FCS was varied suggest that the detachment 
of calf SMC may be an artefact of serum concentrations; (c)
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the medium does not contain detached cells (except in those 
calf SMC experiments in 20% FCS in which cells detach); (d) 
daughter cells are able to spread normally after cytokinesis; (e) 
flow microfluorimetry shows that both control and CM-ex- 
posed SMC have the same cell cycle distribution at the end of 
the experiment; (f) the CM-treated SMC never take up trypan 
blue; and (g) the BAEC-CM effect is reversible. Even if the 
growth inhibition is due to cytotoxicity, however, it is still 
important, because the inhibitory activity is specific for both 
producer and target cell (Table I). This type of specificity could 
be important in; (a) the normal vessel, in which this mechanism 
of SMC growth regulation may be involved in maintaining the 
SMC in a quiescent growth state; (b) the injured vessel, where 
the cessation of myointimal proliferation occurs after re-en- 
dothelialization of the damaged area (9); and (c) regulation of 
blood vessel morphogenesis during development and remod­
eling of the vasculature. The lack of inhibition of B AEC growth 
by BAEC-CM is corroborated by the observation that com­
mercially-prepared heparin, while inhibiting SMC prolifera­
tion, did not inhibit BAEC (Fig. 4) or BHK cells.
Serum is required for production of the heparinlike inhibitor 
by BAEC. The nature of the serum requirement is not known, 
but at least two general possibilities exist: (a) serum provides a 
necessary biosynthetic precursor or cofactor for heparin syn­
thesis; and (b) serum provides a substance that releases heparin 
from the endothelial cell surface. Because heparan sulfate has 
been shown to cause release of more heparan sulfate from the 
cell surface (4, 5), it is possible that the serum provides either 
heparan sulfate or an enzyme which liberates heparin. These 
possibilities remain to be tested.
The secretion of a heparinlike inhibitor of SMC by BAEC 
fits in well with observations made in this and other laborato­
ries. Buonassisi (3), Gamse et al. (12), and Busch et al. (5) have 
shown that cultured BAEC secrete heparan sulfates (of which 
heparin may be considered a subclass). Indeed, about half of 
all the GAGs synthesized by BAEC are heparan sulfates 
secreted into the medium. In contrast, SMC and fibroblasts 
secrete only ~10% of their GAGs as heparan sulfates (12, 20, 
31). In addition, Gamse et al. (12) found that the heparan 
secreted by BAEC was more heparinlike (i.e., more highly 
sulfated) than the heparan made by bovine aortic SMC.
The BAEC must be confluent before the inhibitory activity 
can be detected. Indeed, exponentially growing BAEC produce 
a SMC mitogen (Fig. 5). We suggest that the cessation of 
BAEC growth may be an important step in the regulation of 
vascular smooth muscle cell growth in vivo. This idea is 
supported by recent observations that in a nonregenerating 
(i.e., quiescent) vascular bed, heparan sulfates are the predom­
inant cell-associated GAGs, whereas in an actively regenerat­
ing vascular bed, the amount of heparan sulfate is greatly 
diminished (1).
When purified GAGs were added to growth-arrested SMC 
cultures, heparin was by far the most potent inhibitor of growth 
(Fig. 3). Preliminary experiments (not shown) suggest that the 
degree of sulfation plays an important role in the antiprolifer­
ative effect of heparin. This idea is supported by the fact that 
the inhibitory activity of GAGs correlates with their degree of 
sulfation; heparin has 2.5-3 sulfate groups per hexosamine; 
lung heparan sulfate, dermatan sulfate, and chondroitin ABC 
sulfate have about one sulfate per hexosamine; aortic heparan 
sulfate and hyaluronic add contain 0.3 and zero sulfates per 
hexosamine, respectively.
The effect of heparin on SMC proliferation in vivo has been
studied in this laboratory for several years. Clowes and Kar- 
novsky (6), using an air-dry model for vessel injury (9), showed 
that heparin markedly suppressed myointimal proliferation 
when infused in rats 24 h after the injury. More recently, 
Guyton et al. (14), also using the air-dry model for vessel 
injury, found that heparin prevented myointimal proliferation, 
and that anticoagulant and non-anticoagulant heparin were 
equally effective. In a series of parallel studies, Hoover et al. 
(18) demonstrated that heparin blocked the stimulation of 
cultured rat SMC growth by platelet extract, and showed that 
the inhibition was probably not mediated via a direct interac­
tion with platelet-derived growth factor. Again, anticoagulant 
and non-anticoagulant heparin were equally effective. The 
experiments using exogenous heparin and other GAGs re­
ported here confirm and extend these previous studies.
Based on the in vivo and in vitro demonstrations that non­
anticoagulant heparin is as potent as anticoagulant heparin in 
inhibiting SMC growth, it is possible that non-anticoagulant 
heparin might be useful in those clinical situations (balloon 
embolectomy, endarterectomy, vein grafting, etc.) in which 
suppression of myointimal proliferation is important to the 
patient, because the problem of increased bleeding that accom­
panies the use of anticoagulant heparin would be avoided. 
Synthetic, non-anticoagulant analogs of heparin which retain 
their SMC antiproliferative capacity might also be useful. The 
growth-arrested SMC assay would provide a good screening 
system for developing such compounds.
Experiments are now underway to examine the nature of the 
serum requirement for production and release of heparin from 
BAEC, the chemical structure of antiproliferative heparin, and 
the mechanism of heparin-induced inhibition of SMC prolif­
eration. This system should prove useful in elucidating the 
molecular mechanisms involved in the regulation of vascular 
cell growth.
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Bovine aortic endothelial cells release a heparin-like 
substance in the presence of 0.4% fetal calf serum. This 
substance inhibited the growth of smooth muscle cells 
in vitro by about 70%. Substitution of platelet-poor 
plasma for serum resulted in minimal liberation of 
inhibitory activity from the cells unless at least 10-fold 
higher concentrations of platelet-poor plasma were uti­
lized. This suggested that a platelet product was in­
volved in the release process. Therefore, we examined 
the ability of the platelet heparitinase described in the 
preceding communication to release heparin-like spe­
cies from cultured endothelial cells. Our results show 
that when endothelial cells were exposed to serum-free 
medium containing 1 ng/ml of the purified platelet 
endoglycosidase, at least as much inhibitory activity 
was released as was obtained with 0.4% serum. Dose 
response experiments indicated that only 10 pg/m l of 
the enzyme were necessary to liberate 50% of the inhib­
itory activity from endothelial cells. The heparin-like 
nature of the inhibitory substance was demonstrated 
by its sensitivity to Flavobticterium heparinase. Utiliz­
ing appropriate controls, the release of heparin-like 
material by the endoglycosidase was shown to be en­
zyme-specific and was not due to artifacts of experi­
mented manipulations. In addition, this enzyme did not 
convert prereleased material to an active component, 
but directly liberated the active heparin-like species 
from endothelial cells. A simple model describing the 
possible role of heparin-like components and the en­
doglycosidase in the normal and injured wall is pre­
sented.
The healthy arterial wall consists of the intimal endothelial 
cells which line the lumen, and the underlying medial smooth 
muscle cells. Both these cell types are in a quiescent growth 
state (1). In vivo and in vitro experiments indicate that 
endothelial cells may function as important regulators of 
smooth muscle cell growth within the vascular wall. However, 
little is known of the cellular and molecular mechanisms that 
govern this process.
Ross et al. (2), Harker et al. (3), and others (4, 5) have 
demonstrated that platelet-derived factors are required for
* T his work was supported by N ational Institutes o f  H ealth  Grants 
HL28625 and HL17747, as w ell as by funds from the N ational F oun­
dation for Cancer Research. T h e  costs o f  publication o f  th is article  
were defrayed in part by th e  paym ent o f  page charges. T h is article  
m ust therefore be hereby m arked “advertisement" in accordance  
w ith 18 U .S.C . Section  1734 solely  to  indicate th is fact.
|| T o  w hom  reprint requests should  be addressed at M assachusetts  
Institute o f  T echnology, E 25-229, 77 M assachu setts A ve., Cambridge, 
M A 02139.
smooth msucle cell growth in vivo and in vitro. Macrophages 
(6) and endothelial cells (7) have also been shown to produce 
mitogens for smooth muscle cells. Earlier work from our 
laboratory has demonstrated that exogenous heparin can al­
most completely suppress the in vivo myointimal smooth 
muscle cell proliferation that occurs after endothelial injury 
(8). We have found that nonanticoagulant heparin was as 
effective as anticoagulantly active material in preventing 
myointimal hyperplasia (9). Hoover et al. (10) demonstrated 
that heparin blocked the stimulation of cultured aortic smooth 
muscle cell growth by platelet-derived growth factor. Nonan­
ticoagulant fractions of heparin exhibited the same degree of 
potency as anticoagulantly active material. Furthermore, we 
have recently demonstrated that conditioned medium from 
bovine aortic endothelial cells inhibited the growth of aortic 
smooth muscle cells in vitro (11). The inhibitory component 
was identified as a heparin-like substance, which suggests a 
physiological role for the glycosaminoglycan within the vas­
cular wall. We have previously demonstrated that low concen­
trations of serum are required to release this substance from 
bovine aortic endothelial cells (11). In this communication, we 
present data which suggests that the serum factor required 
for release of heparin-like components from the bovine aortic 
endothelial cell surface is the platelet heparitinase (endogly­
cosidase) described in the preceding communication (12), and 
propose a simple model for growth regulation in the vascular 
wall.
MATERIALS AND METHODS
Cell Culutre— E ndothelia l cells w ere isolated from th e thoracic  
segm ent o f  aortas o f  fresh ly slaughtered calves, a s previously de­
scribed (13,14). T h e aortas w ere d issected  free o f  fascia and incubated  
in a 1 m g /m l o f  collagenase so lution  for 20 m in at 37 °C. T h e  cell 
suspension obtained from one aorta w as added to  a  single 75-cm2 
tissue culture flask th at contained R P M I 1640 m edium  w ith  fetal calf 
serum  (final concentration, 20%), 4 mM glutam ine, 100 u n its /m l o f  
penicillin, and 100 /ig /m l o f  streptom ycin at 37 °C in a hum idified 10% 
CO2 atm osphere. A fter 1-3  h, the  bulk o f the  cells had attached and 
were thoroughly rinsed w ith  4 m l o f R PM I 1640 m edium  supple­
m ented as described above. Subsequently, the m edium  was exchanged  
at 48-h intervals and the  cultures were incubated at 37 °C in a 
hum idified 10% C 0 2 atm osphere. A t confluence, m ore than 95% of  
th e  cells are o f  endothelial origin. T h is was verified by their distinctive  
m orphology and th e  presence o f  V on W illebrand’s antigen on the cell 
surface.
Sm ooth  m uscle cells were isolated from the aortas o f  Sprague- 
D aw ley rats (Charles R iver Breeding Laboratories, Inc., W ilm ington, 
MA; C D  strain) as previously described (10). T h e abdom inal segm ent 
of the  aorta was rem oved and th e  fascia cleaned away under a 
dissecting m icroscope. T h e aorta was cut longitudinally, and sm all 
pieces o f m edia were carefully stripped from th e vessel wall. T w o or 
three such strips w ith  average dim ensions o f 2 X 2 m m  were placed  
in 60-m m  diam eter tissue culture d ishes th a t contained R PM I 1640 
m edium  w ith  fetal calf serum  (final concentration, 20%), 100 u n its /
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m l o f  penicillin , and  100 p g /m l o f  streptom ycin. W ithin  7 to  14 days, 
large patches o f  m ultilayered cells had m igrated from  th e  explants. 
Approxim ately 1 w eek later, sm ooth  m uscle cells from  a 60-m m  
diam eter tissue culture dish were briefly exposed to  a  .05% trypsin: 
.02% ethylened iam inetetraacetic  acid  so lu tion  (G ibco Laboratories, 
Grand Island B iological Co., Grand Island, N Y ), subcultured in to  a  
75-cm2 tissue culture flask (~ 4  to  6 X 105 ce lls /fla sk ) th a t contained  
R P M I1640 culture m edium  w ith  feta l ca lf serum  (final concentration, 
20%), 100 jug/ml o f  penicillin , 100 jug/ml o f  streptom ycin, and 0.25 p g /  
m l o f  am photericin, and th en  incubated at 37 °C in a hum idified 10% 
C 0 2 atm osphere. A t confluence, th e  resultant cells w ere exam ined by  
electron m icroscopy and appeared identical w ith  th e  vascular sm ooth  
m uscle ce lls  described by others (15). In particular, num erous m yofil­
am ent bundles were noted  in the  cytoplasm  and v esicles w ere ob­
served near surface m em branes.
Platelet-poor Plasma— Platelet-poor hum an plasm a w as gener­
ously  provided by C. D . S tiles  (S idney Farber Cancer In stitute, 
B oston , M A). It w as prepared essentia lly  a s previously described (16). 
Briefly, titrated  hum an p lasm a is  centrifuged a t  3,500 X g. T h e  
supernatant w as harvested and defibrinated by heating a t  56 °C for 
30 min. T h e plasm a w as centrifuged a t  28,000 X g, dialyzed against 
0.15 m  N aC l, and sterile filtered prior to  use.
Conditioned Medium— Five to  seven  days after reaching conflu­
ence, a 75-cm 2 flask o f  prim ary bovin e aortic endothelia l cells  was 
washed, and 10 m l (approxim ately 1 m l/1 0 6 cells) o f  R P M I 1640 
m edium , w ith  or w ithout additions, w ere placed on th e  cells. Specific  
conditions for the  various incubations are described under “R esu lts .” 
A ll incubations were carried out a t  37 °C in a hum idified 10% CO2 
atm osphere. In som e instances, the  conditioned m edium  collected  
was subjected to  further treatm ents prior to  testin g  it  on cells. In all 
cases, the  conditioned m edium  w as passed through a 0.22-/im filter at 
th e  end o f  the  incubation period. C onditioned m edia containing either  
Flavobacterium heparinase or p late let heparitinase w ere boiled for 5 
m in prior to filtering. Subsequently, conditioned m edium  w as m ixed  
w ith R P M I 1640 m edium  and feta l calf serum  (final serum  concentra­
tion, 20%) before adding it  to  cells.
Inhibition Assay— T o quantitate inhibitory activity, 6 -8  X 103 rat 
sm ooth m uscle cells obtained after no m ore than  tw o serial passages 
were plated  into 16-mm m ultiw ell p lates in norm al growth m edium . 
After 24 h, th ey  w ere growth-arrested in G0 (Gj) by placing them  in  
R P M I 1640 +  platelet-poor plasm a (final concentration, 2%) for 96 h. 
Control cultures were released from th e  Go block by placing them  in  
R P M I 1640 +  feta l calf serum  (final serum  concentration, 20%). Other 
cultures were placed in a 1:1 m ixture o f conditioned m edium  and  
R P M I 1640 +  feta l calf serum  (final serum  concentration, 20%). D aily  
estim ates o f  cell num bers were obtained in duplicate by w ashing the  
cells in  a trypsim ethylenediam inetetraacetic acid so lution (see above), 
incubating th e  cells for several m inutes in the sam e reagent, and 
quantitating the  dislodged cells in  a Coulter counter. T o  ascertain  
th a t th e  procedure had not lysed th e  cells (as determ ined by the  
presence o f cell debris) and to ensure th a t all cells were rem oved from  
th e  m ultiw ells, trypsinized culture dishes Were routinely checked by 
direct m icroscopic exam ination. T h e n e t grow th of sm ooth  m uscle  
cells in  th e  control cultures w as obtained by subtracting th e  starting  
cell num ber (at the  tim e the  cells are released from  G 0) from  th e cell 
num ber at th e  end  o f  th e  experim ent. T h e net growth o f  sm ooth  
m uscle cells in  conditioned m edia w as com puted in a sim ilar fashion. 
T h e degree o f  inhib ition w as determ ined from th e follow ing relation­
ship:
n et growth in conditioned m edium  ___
% inhibition »  1 ---------- --------- - 7 — :-----------: — :--------t-------------- x  1 0 0n et growth in control m edium
T h e sam ple standard deviation for heparin concentrations or con­
ditioned m edium  w ith in  a single experim ent or betw een  different 
experim ents in w hich the  source o f heparin, conditioned m edium , 
sm ooth  m uscle cells, and serum  is the sam e as s  ±  6% inhibition. A ll 
data have been subjected to  an analysis o f  variance for the  purpose  
o f determ ining statistical significance betw een  te st  groups. D ifferences 
in  percentage o f  inhib ition o f  >7% have a p  value o f  sO.Ol. T h e paired  
difference te st indicates th at w ithin  a single experim ent, tw o concen­
trations o f  heparin w hich produce >4% inhib ition are significantly  
different (p <  0.01). T h e sam ple standard deviation  for heparin  
concentrations or conditioned m edium  am ong experim ents in w hich  
different sources o f  heparin, conditioned m edium , cells, or serum  were  
used w as S  ±  14%. A ll th e  data presented  are th e  average o f  three or 
m ore experim ents in w hich the  sources o f  conditioned m edium , cells, 
heparin, or serum  were different.
Enzymes—Flavobacterium heparinase w as purified by hydroxyl- 
apatite  chrom atography, cellu lose phosphate chrom atography, and 
Sephadex gel filtration, a s previously described (11). T h e  final prep­
aration exhib ited  a  heparin-cleaving potency  o f  ~3000  u n its /m l and  
did not degrade chondroitin su lfate, derm atan sulfate, or hyaluronic 
acid  w h en em ployed a t  concentrations as h igh as 500 u n its /m l (11). 
Furtherm ore, there w as n o  detectable protease activ ity  in th is prep­
aration, as quantitated  b y  th e  radiolabeled casein  assay (17). E nzy­
m atic activ ity  o f  the  Flavobacterium heparinase w as destroyed by  
boiling for 5 min.
H eparitinase w as purified from hum an p la te lets a s described in the  
preceding com m unication (12). T h is  enzym e is a  lysosom al endogly­
cosidase w hich  specifically  degrades heparin or heparan sulfate. T h is  
enzym e did not degrade other glycosam inoglycans or proteins (12). 
E nzym atic activ ity  o f  th e  p la te let heparitinase w as destroyed by 
boiling for 5 min.
Chemicals— H eparin w as obtained from  T h e  U pjohn Co. or Elkins- 
Sinn (Cherry H ill, N J ). A ll other chem icals w ere from  Sigm a.
RESULTS
Role of Platelet Products in Serum-mediated Release of 
Inhibitory Activity—We have previously demonstrated that 
a heparin-like species is released from confluent, primary 
endothelial cells, and that this heparin-like material inhibited 
the growth of smooth muscle cells (11). A small amount of  
fetal calf or calf serum was required for release of the heparin­
like material; in serum-free medium, little inhibitory activity 
was released from endothelial cells (Table I). Substituting 
0.4% human platelet-poor plasma for 0.4% fetal calf serum 
resulted in only a small release of inhibitory activity above 
that released by RPMI 1640 alone (Table I). We tested the 
ability of platelet-poor human plasma to release inhibitory 
activity from endothelial cells (Fig. 1). Approximately 10 times 
as much platelet-poor plasma was required to release the 
same amount of inhibitory activity as 0.4% serum. These 
observations suggest that a platelet product is involved in 
releasing inhibitory activity from endothelial cells. However, 
to ensure that any differences observed between platelet-poor 
plasma and fetal calf serum were due to the absence of platelet 
products rather than the difference in species, human whole 
blood serum was prepared and tested for its ability to release 
inhibitory activity from confluent endothelial cells (Fig. 1). 
Human serum and fetal calf serum were equally effective at 
releasing inhibitory activity.
The heparin-like nature of the inhibitory activity was shown 
by its sensitivity to Flavobacterium  heparinase (Table I). 
Appropriate controls showed that the elimination of inhibitory 
activity by this enzyme is not caused by either boiling or pH
T a b le  I
Ability o f different media to release inhibitory activity from bovine 
aortic endothelial cells
Confluent primary cultures o f  endothelial cells were incubated w ith  
the  indicated m edia. In  som e instances, the  conditioned m edia were 
subjected to further treatm ent. T h e resulting conditioned m edia were 
m ixed w ith  R P M I 1640 and feta l calf serum  (final concentration, 20%) 
and tested  for their ability  to inhibit sm ooth  m uscle cell growth. For 
further details, see  “M aterials and M ethods” and “R esu lts.”
Treatment Inhibition (±S.D.)_
R P M I 1640 +  0.4% fetal calf serum  68 (±11)
R PM I 1640 alone 12 (±5)
R PM I 1640 +  0.4% platelet-poor plasm a 15 (±4)
R PM I 1640 +  0.4% fetal ca lf serum; conditioned 15 (±8) 
m edium  th en  treated w ith  Flavobacterium h e ­
parinase
R PM I 1640 +  0.4% fetal calf serum; conditioned 73 (±9) 
m edium  th en  boiled 5 m in
R P M I 1640 alone (pH 6.5) 10 (±4)
R P M I 1640 +  0.5 m g /m l bovine serum  7 (±5)
R PM I 1640 +  10 m g /m l bovine serum  albumin 11 (±6)
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artifacts (Table I). We thought it likely that the platelet 
product responsible for cleaving heparin-like components 
from the endothelial cells is the platelet heparitinase described 
in the preceding communication (12). For this reason, endo­
thelial cells were exposed for 4 h at 37 °C to RPMI 1640 +  1 
ng/ml of purified platelet heparitinase. During the condition­
ing period, the pH was maintained at 6.5, roughly the midpoint 
of the optimum pH range for the platelet endoglycosidase
(12). When smooth muscle cells arrested in G0 were exposed 
to a 1:1 mixture of this conditioned medium +  RPMI 1640 
and fetal calf serum (final serum concentration, 20%), signifi­
cant inhibition of cell proliferation was observed (Table H). 
We have shown that at pH 6.5, RPMI 1640 alone liberates 
little inhibitory activity from the endothelial cells after 48 h
CONCENTRATION, Percent
Fig. 1. Ability of fetal calf serum, human serum, and plate- 
let-poor plasma to release inhibitory activity from bovine 
aortic endothelial cells. T h e endothelial cells  from three bovine  
aortas were pooled and plated into 60-m m  dishes. C onfluent primary 
cultures were w ashed and incubated in R P M I 1640 containing the
indicated concentrations o f  fetal calf serum  ( • ------ • ) ,  hum an serum
(O------ O), or platelet-poor plasm a (■ ------ ■ ) for 48 h. T h e resulting
m edium  was m ixed w ith R PM I 1640 and fetal calf serum  (final serum  
concentration, 20%) and tested  for its ability to  inhib it sm ooth  m uscle  
cell growth. Error bars indicate standard deviations. For further 
details, see “M aterials and M ethods.”
T a b le  II
Ability o f platelet heparitinase to release inhibitory activity from 
bovine aortic endothelial cells
Confluent primary cultures o f  endothelial cells were incubated w ith  
the  indicated m edia. In som e instances, the conditioned m edia were 
subjected to further treatm ent. T he resulting conditioned m edia were 
m ixed w ith R PM I 1640 and fetal calf serum  (final serum  concentra­
tion, 20%) and tested  for their ability to  inhibit sm ooth  m uscle cell 
growth. For further details, see “M aterials and M ethods” and  
“R esults.”
Treatment Inhibition (±S.D.)
R PM I 1640 +  p latelet heparitinase
%
71 (±3)
R PM I 1640 +  platelet heparitinase; conditioned  
m edium  then  treated w ith  Flavobacterium h e ­
parinase
13 (±7)
R PM I 1640 alone; endothelial cells then incu­
bated w ith platelet heparitinase
60 (±10)
R PM I 1640 +  0.4% platelet-poor plasma; endo­
thelial cells then  incubated w ith platelet hepar­
itinase
57 (±12)
R PM I 1640 alone; endothelial cells then incu­
bated with platelet heparitinase; p latelet hepar- 
itinase-conditioned m edium  then  treated w ith  
Flavobacterium heparinase
9 (±6)
R PM I 1640 +  0.4% platelet-poor plasma; endo­
thelial cells then  incubated w ith platelet hepar­
itinase; p late let heparitinase-conditioned me-
12 (±7)
dium then treated w ith  Flavobacterium hepar­
inase
R PM I 1640 alone; conditioned m edium  then  
treated w ith  p latelet heparitinase
18 (±3)
of conditioning (Table I). To ensure that the lack of release in 
serum-free medium was not due to the absence of protein, we 
conditioned endothelial cells with RPMI 1640 containing up 
to 10 mg/ml of bovine serum albumin. No additional release 
of inhibitory activity was observed (Table I).
Several experiments were performed to demonstrate the 
heparin-like nature of the inhibitory substances liberated from 
the endothelial cells by platelet heparitinase and to ensure 
that this release process is enzyme-specific. We initially con­
ditioned endothelial cells with medium containing platelet 
heparitinase as above, and then treated this conditioned me­
dium with 10 units/ml of Flavobacterium heparinase for 60 
min at 37 °C. This material was subsequently boiled for 5 min 
to destroy the enzymatic activities of Flavobacterium hepar­
inase as well as platelet heparitinase, and passed through a 
0.22-pm filter. Treating the platelet heparitinase-produced 
conditioned medium with Flavobacterium heparinase elimi­
nated most of the inhibitory activity (Table II). Thus, it 
appears that this substance is heparin-like in nature. It was 
critical to rule out artifacts that might occur due to the boiling 
procedure. It should be noted that heparin and heparin-like 
molecules are not significantly altered by boiling. We dem­
onstrated that the boiled 0.4% fetal calf serum-produced con­
ditioned medium did not lose inhibitory activity (Table I). We 
have also found that boiled RPMI 1640, RPMI 1640 + fetal 
calf serum (final serum concentration, 0.4%), or RPMI 1640 
+ platelet-poor plasma (final concentration, 0.4%) did not 
inhibit smooth muscle cell growth when each was mixed 1:1 
with RPMI 1640 +  fetal calf serum (final serum concentration, 
20%) (data not shown).
To show that heparin-like material was indeed present 
under those conditions in which inhibitory activity was not 
released, endothelial cells conditioned with serum-free RPMI 
1640 or with RPMI 1640 + platelet-poor plasma (final concen­
tration, 0.4%) were subsequently exposed to RPMI 1640 con­
taining 1 ng/ml of platelet heparitinase. The results showed 
that the platelet heparitinase treatment released an equivalent 
amount of the inhibitory activity as would occur had the 
endothelial cells been initially exposed to the endoglycosidase 
(Table II). When these platelet heparitinase-produced condi­
tioned media were incubated with Flavobacterium  hepari­
nase, 80% of the inhibitory activity was destroyed (Table II). 
It is possible tbat serum-free conditioned medium releases 
heparin-like substances, but that platelet heparitinase is re­
quired to convert it to an active form. We investigated this 
possibility by incubating serum-free conditioned medium with 
platelet endoglycosidase. Only a small increase in inhibitory 
activity occurred (Table II).
Amount of Platelet Heparitinase Required for Release of 
Inhibitory Activity—To determine the potency of the purified 
platelet heparitinase, we incubated replicate cultures of con­
fluent, primary endothelial cells with various concentrations 
of the platelet endoglycosidase. Endothelial cells from three 
bovine aortas were pooled and plated into 60-mm2 tissue 
culture dishes. The cells grew to confluence (2-3 x  10s cells/ 
dish) and were allowed to remain in this state for 1 week. 
Subsequently, the cells were washed and incubated in 2.5 ml 
of RPMI 1640 (pH 6.5) containing platelet heparitinase at 
concentrations ranging from 100 fg/ml to 100 ng/ml for 4 h at 
37 °C. The conditioned medium obtained was boiled for 5 min 
and passed through a 0.22-/im filter. It was mixed 1:1 with 
RPMI 1640 + fetal calf serum (final serum concentration, 
20%), and the effect on smooth muscle cell growth was as­
sayed. The results are shown in Fig. 2. From these data, we 
calculate that the concentration of platelet heparitinase re­
quired to release 50% of the inhibitory activity from the 
endothelial cells is approximately 10 pg/ml.
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PLATELET HEPAR/T/NASE, g/mt
Fig. 2. A b ility  o f  p la te le t  h e p a r it in a s e  to  r e le a s e  in h ib ito r y  
a c t iv ity  fr o m  b o v in e  a o r t ic  e n d o th e l ia l  c e l ls .  Confluent, primary 
cultures o f  endothelial cells were incubated in serum -free R P M I 1640 
containing the  indicated concentrations o f  platelet heparitinase for 4 
h at 37 °C. T h e resulting m edium  w as m ixed w ith  R P M I 1640 and  
fetal calf serum  (final serum  concentration, 20%) and tested  for its 
ability to  inhibit sm ooth m uscle cell growth. Error bars indicate  
standard deviations. For further details, see  “M aterials and M ethods.”
DISCUSSION
Work from several laboratories has demonstrated that en­
dothelial cells in vitro secrete much more heparan sulfate into 
the medium than smooth muscle cells and fibroblasts (18-22). 
In addition, Gamse et al. (20) found that the heparan sulfate 
secreted by endothelial cells was more heparin-like than the 
heparan sulfate synthesized by bovine aortic smooth muscle 
cells. Clowes and Kamovsky (8) and Guyton et al. (9) showed 
that exogenous heparin markedly suppressed myointimal pro­
liferation following injury to intimal endothelial cells. Hoover 
et al. (10) and Castellot et al. (11) demonstrated that heparin 
could block smooth muscle cell growth in vitro. Fishman et 
al. (23) and Schwartz et al. (24) have observed tbat smooth 
muscle cell proliferation in balloon-catheterized or air-dried 
arteries ceases as soon as the damaged area is re-endothelial- 
ized. It should be noted that large amounts of glycosamino- 
glycan, including heparan sulfates, are found beneath newly 
regenerated endothelium (25). Furthermore, Ausprunk et al. 
(26,27) have recently observed that in a nonregenerating (i.e. 
quiescent) vascular bed, heparan sulfates are the predominant 
cell-associated glycosaminoglycans, while in an actively regen­
erating vascular bed, the levels of this complex carbohydrate 
are greatly reduced.
We have previously shown that conditioned medium from 
bovine aortic endothelial cells prevented the growth of aortic 
smooth muscle cells in vitro, and that serum is required for 
release of inhibitory activity (11). Utilizing several criteria, we 
showed that the inhibitory activity released from endothelial 
cells is unlikely to be due to a cytotoxic effect. The inhibitory 
activity was identified as a heparin-like molecule by its sen­
sitivity to purified Flavobacterium  heparinase (11). This en­
zyme is an endoglycosidase which randomly cleaves heparin- 
like molecules at the relatively common glucosamine-iduron- 
ate bonds within sulfated regions to yield small oligosaccha­
rides with an average M, = 700 to 1400 (2 to 4 residues). We 
have demonstrated that components obtained by this degra­
dation process do not possess the ability to inhibit smooth 
muscle cell growth.1 In contrast, it must be emphasized that 
the platelet heparitinase scissions heparin-like species at the 
relatively rare glucuronsyl-glucosamine bonds outside the
1J. J. C astellot, Jr., D . B eeler, M . J. K am ovsky, and R . D . R osen ­
berg, m anuscript in preparation.
highly sulfated regions to yield a mixture of highly sulfated 
oligosaccharides with an average Mr =  4000 (~12 residues). 
We have shown that species of this size possess substantial 
inhibitory activity.1
In this communication, we have attempted to identify the 
serum component responsible for the release of heparin-like 
substances from endothelial cells. Our data show that much 
less inhibitory activity was liberated by platelet-poor plasma 
than by serum (either human or fetal calf; Table I). Indeed, at 
least ten times as much platelet-poor plasma was required to 
release the same amount of inhibitory activity as was liberated 
with 0.4% serum. It is well known that small numbers of 
platelets undergo release reactions unless special precautions 
are taken during the blood collection process. Thus, it seemed 
likely that a platelet factor was required to release the inhibit­
ing substance from endothelial cells. When these cells were 
incubated with RPMI 1640 containing platelet heparitinase, 
the inhibitory activity was liberated (Table II). Utilizing ap­
propriate controls, we have shown that the material released 
is a heparin-like substance, and that the, inhibitory effect is 
not an artifact of experimental manipulations. In addition, we 
have demonstrated that the liberation process is enzyme- 
specific. Furthermore, we have shown that the platelet hepar­
itinase does not convert prereleased material to an active 
component, but directly liberates the active heparin-like spe­
cies from the endothelial cells. Thus, our data suggest that 
the inhibitory activity emanating from endothelial cells is 
released from those cells by the platelet heparitinase present 
in serum. However, given the complexity of platelet products, 
we cannot exclude the possibility that other platelet compo­
nents are also involved. Dose response experiments indicate 
that only 10 pg/ml of platelet heparitinase are necessary to 
liberate 50% of the inhibitory activity from the endothelial 
cells (Fig. 1). RPMI 1640 + 0.4% fetal calf serum could contain 
as much as 400 pg/ml of the endoglycosidase. This calculation 
is based upon the fact that 1 ml of serum contains the release 
products of about 5 x  108 platelets, and that each platelet 
contains approximately 1,000 molecules of the 134,000 dalton 
enzyme (12). Of course, the yield of enzyme is unlikely to be 
100%. Therefore, it is possible that with some serum batches, 
concentrations greater than 0.4% will be necessary to release 
sufficient heparin-like material to inhibit smooth muscle cell 
growth.
Based on the above observations, we would like to propose 
a simple model for the possible role of heparin-like compo­
nents and endoglycosidases in the regulation of cell growth 
within normal and injured vessels. In the normal (uninjured) 
artery, intimal endothelial cells serve as a major source of 
heparin-like substances. These glycosaminoglycans are found 
within the extracellular matrix of the intima as well as the 
media and are ideally positioned to prevent proliferation of 
medial smooth muscle cells. The endoglycosidase has been 
detected in the lysosomal fraction of several types.2 Therefore, 
it is likely that smooth muscle cells and/or endothelial cells 
contain this enzyme. Given that lysosomal components can 
be transported into the external milieu, it is possible that 
endoglycosidases may be present within the vessel wall where 
they could function to release antiproliferative heparin-like 
components from the abluminal surface of the endothelial 
cells or other cells.
If intimal endothelial cells are injured or removed, circulat­
ing platelets would adhere to the exposed vessel wall, undergo 
aggregation and release their cellular contents. Therefore, it 
is likely that components present at the site of injury would 
include platelet-derived growth factor, platelet heparitinase,
2 L. V . Favreau and R . D . Rosenberg, unpublished data.
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and platelet factor 4. The latter protein has a high affinity for 
heparin (28, 29) and penetrates into the media after endothe­
lial cell denudation (30). Our data would suggest that the 
presence of mitogen may not be sufficient to stimulate smooth 
muscle cell migration and proliferation. Indeed, it seems likely 
that the inhibitory effect of heparin-like components must be 
overcome before smooth muscle cells can respond to the above 
stimuli. This supposition is based upon our observations that 
heparin is capable of suppressing smooth muscle growth in 
vitro (10, 11) even in the presence of large amounts of serum 
or platelet extract (up to 20%) as well as under in vivo 
conditions (9). There are at least four possible mechanisms 
for overcoming the inhibitory effect of this mucopolysaccha­
ride: (a) damage or loss of the endothelium removes a major 
source of heparin-like molecules; (6) endoglycosidase from 
platelets adhering to the injured area might cleave heparin­
like substances into inhibitory fragments, but these could be 
washed away since the injury has removed the physical barrier 
to hydraulic flux provided by the endothelium; (c) the local 
concentration of mitogens may be so high that smooth muscle 
cells can proliferate despite the presence of these complex 
carbohydrates; and (d) platelet factor 4 could inactivate hep­
arin-like molecules. Once the suppressing action of heparin is 
negated, the smooth muscle cells can migrate into the ultima 
and proliferate. However, as soon as the damaged area is re- 
endothelialized, smooth muscle cell growth ceases (23, 24). 
This could be due to the presence of heparin-like substances 
released by the endothelial cells behind the regenerating front. 
The observations of Wight et al. (25) that substantial amounts 
of heparan sulfates accumulate behind the regenerating en­
dothelial front support this suggestion.
The cellular and molecular mechanisms of growth regula­
tion in blood vessels are undoubtedly more complicated than 
the simple model presented above. However, alterations in 
the biosynthesis of heparin-like molecules by endothelial cells 
or other cells, changes in the production or release of endo- 
glycosidases by platelets, smooth muscle cells, or endothelial 
cells, and alterations in the response of smooth muscle cells to 
these complex carbohydrates could, in part, be responsible for 
the initiation of the atherosclerotic process.
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Endothelial-Vascular Smooth M uscle C e ll Interactions
R o u s-W h ip p le  A w a rd  Lecture
PAPER
X
M O R R IS  J . K A R N O V S K Y , B S c , M B B C h, D C P  From the Department of Pathology, Harvard Medical School,
Boston, Massachusetts
AM DEEPLY appreciative of the signal honor paid 
iy the American Association of Pathologists in con- 
erring on me the Rous-Whipple Award. In so doing, 
hey honor implicitly my laboratory and my col- 
;agues, with whom I had the good fortune and joy 
if fruitful collaboration.
Since about 1965, our laboratory has been in- 
erested in the pathobiology of blood vessels. Initial- 
/, having developed the use of exogenous perox- 
lases as ultrastructural tracers, and having intro- 
luced 3,3'-diaminobenzidine as a reagent for the 
ltrastructural cytochemical localization of perox- 
iases, we were urged by Lord Florey to undertake 
•ermeability studies on the microvasculature, using 
hese techniques, in order to correlate the structural 
haracteristics of small blood vessels with their per- 
leability properties. We came up with the concept 
hat it is the junctions in the microvasculature that 
re permeable to small hydrophilic molecules and 
epresent the small pore system of Pappenheimer.1 
’his idea has, in fact, proved to be controversial,2 3 
ut the techniques we introduced have been rather 
seful in a variety of applications. We also docu- 
lented that the blood-brain barrier in the cerebral 
licrovasculature resides at the level of the endothe- 
um, the junctions being “tight” and impermeable to 
ydrophilic tracers.4 Similarly, we showed that there 
(’as a blood-thymus barrier at the level of the 
apillary endothelial junctions.5 We have also been 
iterested over the years in the problem of how poly- 
torphonuclear leukocytes stick to the endothelium 
f small blood vessels during the acute inflammatory 
esponse. In brief, we have found that this sticking is 
nhanced by chemotactic agents and that the endo- 
tielium has high affinity receptors for chemotactic 
gents on the surface of the endothelial cells, the oc­
cupancy of which receptors by chemotactic agents 
apparently increases the stickiness of the endothe­
lium for polymorphonuclear leukocytes.6
More recently, we have become interested in pos­
sible endothelium-vascular smooth muscle cell 
regulatory interactions in larger vessels, which we 
think may have important implications in health, 
disease, and therapy.
Among the intriguing aspects of the normal, 
healthy blood vessel is that the intimal endothelial 
cells are nonthrombogenic and form a relatively 
quiescent, continuous monolayer, and the underlying 
medial smooth muscle cells also remain in a quiescent 
growth state. Little is known about the regulation of 
cell growth in the healthy vascular wall. As has be­
come apparent in recent years, when the endotheli­
um is damaged, medial smooth muscle cells migrate 
and proliferate into, and in, the intima, causing 
myointimal thickening. Ross and his colleagues have 
put forth the concept that the deposition of plate­
lets in the area of endothelial damage leads to the 
release of platelet mitogens, which cause the migra­
tion and proliferation of the medial smooth mus­
cle.7 This concept has received substantive support 
from the work of many other laboratories, includ­
ing our own. Ross7 8 and others have shown that 
platelet-derived growth factors are required for the 
smooth muscle cell growth, both in vivo and in vitro.
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More recently, factors released from macrophages 
have been found to stimulate both endothelial and 
vascular smooth muscle cells910; because macro­
phages are also found associated with the athero­
sclerotic lesion, they may also serve as a source of a 
mitogen for smooth muscle cell proliferation. In ad­
dition, it has been reported,11 and we have con­
firmed,12 that endothelial cells in vitro produce a fac­
tor that stimulates the growth of vascular smooth 
muscle cells. The in vivo function, if any, of this fac­
tor is at present unknown. Extracts of the arterial 
wall have been fractionated to produce both stimu­
lators and inhibitors of endothelial cell and smooth 
muscle cell proliferation in vitro.13 These factors are 
at present largely uncharacterized.
Today I will present evidence that exogenous 
heparin is a negative effector of smooth muscle cell 
proliferation following endothelial injury in vivo, 
and also that cultured endothelial cells produce a 
negative effector of smooth muscle cell growth, 
which we believe is a heparin or a heparinlike 
molecule. We will suggest a possible role for heparin 
or similar molecules in the regulation of vascular 
smooth muscle cell growth in vivo, both in the nor­
mal and injured vessel.
In Vivo Studies
We first began some five years ago with a model for 
endothelial injury—the so-called “air-drying” model 
in the common carotid artery system14 of the rat. In 
this rather bizarre system, the contents of the carotid 
artery were evacuated, and a gentle stream of air was 
used to dessicate the endothelium. Then the blood 
flow was restored and the dessicated endothelium 
peeled off the underlying intima, leading to the 
deposition of platelets and, after several days, 
dramatic myointimal proliferation. The advantages 
of this system are that the injury is relatively gentle, 
and as far as we could establish, did not damage the 
underlying smooth muscle, but only the endothe­
lium. Secondly, the myointimal proliferation pro­
duced was sharply defined, and the degree of smooth 
muscle cell proliferation and myointimal thickening 
could be quantitated both by morphometry and by 
autoradiographic methods. Thirdly, the contralateral 
carotid could serve as a control in the same animal. 
Lastly, because there are no branches in the segment 
of this vessel that we utilized, problems of regenera­
tion of endothelium from branches could be ob­
viated, because the endothelium regenerates solely 
from the uninjured distal and proximal segments of 
the vessel, allowing for easy quantitation of the rates
of endothelial regeneration. Myointimal thickening 
was maximal at about 14 days after injury and could 
be most easily quantitated by measurement of in- 
timal-medial ratios. We noticed that in this system, 
smooth muscle cell proliferation seemed to cease 
when the reendothelialization occurred, which is in 
accord with the experience of others.
Because the clotting sequence is activated in 
arterial injury, and because thrombin has been 
recently shown to be a mitogen, at least for some cell 
types,15 we thought it would be important to see 
whether the activation of the clotting sequence was in 
any way related to the smooth muscle cell prolifera­
tion. Therefore, we tested the effect of heparin, 
which prevents thrombin formation by activation of 
antithrombin, on the degree of smooth muscle cell 
proliferation following the “air-drying” injury.16 We 
found that with continuous intravenous infusion of 
heparin—the infusion being given by a catheter 
placed in the left jugular vein with the tip of the 
catheter lying in the superior vena cava —the smooth 
muscle cell proliferation following endothelial injury 
in the carotid artery was almost completely sup­
pressed16 (Figure 1). At the same time, we found that 
there was no effect of the heparin on the number of 
circulating platelets and on the number deposited at 
the site of the lesion, or on their structure. There was 
also no detectable effect on the rate of reendotheliali­
zation of the denuded area.
The next question asked was whether the antipro­
liferative activity of the heparin was related to the an­
ticoagulant activity of heparin. Commercial heparin 
is, as is well known,17 a mixture containing fractions
Figure 1—Histologic sections of right rat carotids at 14 days after 
air-drying injury. A—Control. B—Heparin-treated. The myo­
intimal proliferation (A) is almost completely suppressed by the 
heparin (B). Bar = 20 fi. (From Clowes AW, Karnovsky MJ: Suppres­
sion by heparin of smooth muscle cell proliferation in injured 
arteries. Nature 1977, 265:625-626. Reprinted with permission of 
Macmillan Journals Limited.)
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that bind to antithrombin and are therefore anti­
coagulant in activity, as well as fractions that are 
non-antithrombin-binding, that is, nonanticoagu­
lant. Therefore, the experiments were repeated with 
anticoagulant and nonanticoagulant heparin, sepa­
rated by affinity chromatography with antithrombin 
as the adsorbant.17 It was clear that the nonan­
ticoagulant heparin was just as effective in preventing 
smooth muscle proliferation following endothelial 
injury as was the anticoagulant heparin18 (Figure 2).
In Vitro Studies: Effect of Exogenous Heparin on 
Smooth Muscle Cell Growth
In order to explore the subtleties of the system fur­
ther, we turned to in vitro experiments. The test cells 
(bovine aortic endothelial cells, bovine aortic smooth 
muscle cells, and rat aortic smooth muscle cells) were 
first grown in vitro and then growth-arrested by 
placement in low serum. They were then released 
from Go, with 5-20% serum, and the effects of add­
ing exogenous heparin or other related compounds 
on this stimulation of growth induced by serum after 
release from G0 was measured by counting of cell 
number at various time intervals.
We first tested12 the effect of exogenous heparin on 
smooth muscle cells as compared with endothelium 
in both the exponential and growth-arrested states. It
Figure 2—Similar to Figure 1. A—Control. B—Nonanti­
coagulant heparin-treated. The myointimal proliferation (A) is almost 
completely suppressed (B). Arrow indicates internal elastic lamina. 
Bar = 20 p. (From Guyton, Rosenberg, Clowes, Kamorsky: Inhibi­
tion of rat arterial smooth muscle cell proliferation by heparin: In 
vivo studies with anticoagulant and nonanticoagulant heparin. Circ 
Res 1980, 46:625-634. Reprinted with permission of the American 
Heart Association, Inc.)
Figure 3—Growth curves of rat aortic smooth muscle cells under 
various treatments after serum-induced release from G0. Normal 
medium was supplemented with various concentrations of heparin 
or with confluent bovine aortic endothelial cell conditioned medium 
(BAEC-CM).
was found that whereas growth-arrested smooth 
muscle cells (bovine or rat) were almost completely 
inhibited in their response to serum after growth ar­
rest by heparin (Figure 3), exponentially growing 
smooth muscle cells were much less inhibited. Fur­
thermore, growth-arrested or exponentially grow­
ing bovine aortic endothelial cells showed no inhibi­
tion of growth in the presence of heparin (Figure 3). 
It seemed, therefore, that heparin was highly effective 
in inhibiting the growth of smooth muscle and had 
hardly any effect on endothelial cell proliferation. 
Thus, there was a relative specificity for the vascular 
smooth muscle cell: this was reinforced in that only 
huge doses of heparin suppressed the proliferation of 
several other cell types. Anticoagulant and nonanti­
coagulant heparin were equally effective as inhibitors 
of smooth muscle cell proliferation in vitro. We next 
compared the effects of polyanionic compounds on 
the inhibition of the growth of smooth muscle cells,12 
and it was found that whereas heparin (anticoagulant 
or nonanticoagulant) was highly effective, heparan 
sulfate, dermatan sulfate, chondroitin ABC sulfates, 
and hyaluronic acid, at comparable doses, were hard­
ly effective at all. The effectiveness of the compounds 
paralleled their degree of sulfation.
Size-Effectiveness of Heparin Fragments
The next step was to establish what size molecule 
of heparin was effective in producing this inhibitory
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effect. Therefore, fragments of heparin were made by 
limit digest with nitrous acid and separated by 
chromatography. It was found19 that an inhibitory 
effect on the proliferation of smooth muscle cells re­
quired a fragment that was a hexasaccharide or larger 
in order to obtain a significant inhibition. Maximum 
inhibition was found in the dodecamer to 20-sac­
charide size range. Smaller fragments than hexasac- 
charides were ineffective.
Modified Heparins
We also have begun to look into the chemical 
properties of the heparin molecule that seem to be 
necessary for the antiproliferative effect.19 The aim in 
modifying the heparin was to see what chemical 
groups were responsible, and whether an antipro­
liferative, nonanticoagulant molecule could be ob­
tained. So far, our experiments have indicated that 
O-sulfation is required for the antiproliferative 
effect, and that N-sulfation or some other group 
(neutral or negative) is required to block the positive 
charge of the amine. Thus, for instance, an O- 
sulfated, N-desulfated, N-reacetylated molecule is 
highly effective in its antiproliferative activities and is 
nonanticoagulant. Further work in this area is pro­
ceeding, because a nonanticoagulant, antiprolifer­
ative modified heparin may prove useful clinically.
Heparin Binding
In preliminary experiments, the kinetics of heparin 
binding to rat aortic smooth muscle cells have been 
examined.19 It appears that there are both saturable 
high-affinity and low-affinity sites on the smooth 
muscle cell for heparin, the former having a Kd, of 
about 2 x 10‘9 M, with about 2 x 104 sites per cell, and 
the latter having a Kd2 of about 1 x 10'6 M, with 
about 5-10 X105 sites per cell. The biologic 
significance of heparin binding to these high or low- 
affinity binding sites, in terms of the antiproliferative 
effect, has not as yet been established.
Effects on Cell Metabolism
In regard to the metabolism of the smooth muscle 
cells under the influence of heparin, it has been 
found19 that at low doses—that is, below 100 pg per 
ml of heparin—there is marked and immediate in­
hibition of DNA synthesis down to 20% of normal 
in the smooth muscle cells. A similar inhibition of 
RNA metabolism is obtained but is not as marked. 
However, protein synthesis is not affected early, but 
only late, when it decreases slightly at doses of hep­
arin of 100 pg per ml. Flow microfluorimetry shows 
a rapid effect with decrease entry of the cells into S„ 
and eventually most cells end up in Gi at the end of 
the inhibition experiment.
The pharmacologic effects detailed above are, I 
think, interesting; and it is thought that a nonanti­
coagulant, antiproliferative heparin analog might 
prove to be useful clinically in preventing vascular 
smooth muscle cell proliferation, which might follow 
vascular surgery.
Endothelial Cell Effects on Vascular Smooth Muscle 
Cell Proliferation
As mentioned before, it was our impression from a 
number of our studies involving the air-drying model 
in vivo that smooth muscle cells seem to cease to pro­
liferate when reendothelialization occurs. One pos­
sibility was some form of regulatory influence of en­
dothelial cells on smooth muscle cell proliferation, 
and vice versa. We have therefore examined the pos­
sible secretory effects of the endothelial cells in vitro, 
which might influence smooth muscle cell growth. As 
mentioned before, others11 have shown that en­
dothelial cells secrete a mitogen for smooth muscle 
cells, and in experiments that I will not present today, 
we have confirmed that effect.12 Today, however, I 
want to show our evidence for production by endo­
thelium of a negative effector of smooth muscle cell 
growth that appears to be heparin or a heparinlike 
molecule. It should be mentioned that the conditions 
necessary for the production by endothelial cells of 
the mitogen for vascular smooth muscle cells are 
quite specific, and different from those necessary for 
the production of the negative effector.
We conditioned medium from confluent, primary 
cultures of bovine aortic endothelial cells and studied 
the effect of this conditioned medium on the pro­
liferation of smooth muscle cells released from Go by 
serum. It was found that the conditioned medium 
had a profound inhibitory effect on the proliferation 
of smooth muscle cells12 (Figure 3).
We next examined whether this effect was specific 
for the endothelial cell as the producer cell and was 
specific for the vascular sm ooth muscle cell as the 
target cell. Testing conditioned media from a wide 
variety of cells, including vascular smooth muscle 
cells, we found that only confluent endothelial cell 
cultures produced a conditioned medium inhibitory 
to vascular smooth muscle cell proliferation.12 Ex­
ponentially grown endothelial cells produced the 
mitogen(s) that we have previously mentioned. Fur­
thermore, it was found that only vascular smooth 
muscle cells responded in a highly sensitive way to the
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inhibitory effect of the conditioned medium obtained 
from confluent endothelial cell cultures. It was also 
established that the production of the inhibitory fac­
tor or factors by confluent endothelial cell cultures 
only occurred in primary cultures or within three or 
four passages, being lost after subsequent passage.
Biochemical Properties of the Inhibitory Factor(s)
The biochemical properties of the conditioned 
medium in terms of inhibition of smooth muscle cell 
proliferative activity were then established.”  It was 
found that the activity was not abolished by heating, 
was protease-insensitive, and was also insensitive to 
hyaluronidase and chondroitin sulfate ABC lyase. 
However, a highly purified flavobacterial heparinase, 
which contained no protease activity, and which did 
not degrade chondroitin sulfate, dermatan sulfate, or 
hyaluronic acid, almost completely removed the in­
hibitory activity from the conditioned medium. A 
glycosaminoglycan fraction of the conditioned medi­
um, that is, an ethanol-precipitated trichloracetic 
acid-soluble fraction, had strong inhibitory activity, 
but when this fraction was treated with the flavobac­
terial heparinase, the activity was almost completely 
abolished. It was, therefore, we think, reasonably 
concluded12 that the inhibitory activity produced by 
the endothelial cells was that of a heparin or heparin­
like molecule. Several other groups20"22 have reported 
that endothelial cells in vitro produce heparan sul­
fates, of which heparin may be considered a subclass.
Role of Platelet-Derived Heparinase 
(Endoglycosidase)
It is apparent that the release of the inhibitory ac­
tivity from the endothelial cells required in some way 
the presence of a small amount of serum; for in­
stance, cells placed in platelet-poor plasma did not 
produce a conditioned medium that was inhibitory. 
It was therefore thought that some component of 
serum, possibly a platelet-derived component, was 
necessary for the secretion and/or release of the 
heparin activity by the endothelium.
Recently, Dr. Robert Rosenberg’s laboratory has 
isolated and purified a highly potent and specific 
heparinase (endoglycosidase) from platelets as well as 
from other tissues.23 This enzyme, which is lysosomal 
in location, differs from the bacterial enzyme in that 
it yields, on the average, dodecasaccharides, whereas 
the bacterial enzyme yields, on the average, disac­
charide fractions; the latter would be, as we have 
previously shown, inactive, whereas the former 
would be active in terms of antiproliferative effect.
Now, as mentioned before, serum in the conditioning 
medium was capable of releasing the antiproliferative 
activity from confluent endothelial cell cultures. Con­
ditioning with serum-free medium, or with medium 
plus platelet-poor plasma, were both ineffective. 
However, if to either of these two systems purified 
platelet heparinase was added, a marked inhibitory 
activity was obtained, and if that conditioned 
medium containing the active material was then 
treated with the flavobacterial heparinase, the in­
hibitory activity was almost completely abolished. 
We take these results to indicate that platelet 
heparinaselike activity may well be necessary for the 
release of activity from endothelial cells, and they ex­
plain the previously established serum requirement 
for release of the inhibitory activity. The questions 
arise as to whether endothelial cells and/or vascular 
smooth muscle cells have a similar enzymatic activity 
in the normal, uninjured vessel wall, and whether the 
platelet-derived enzyme plays a role in vascular in­
jury following the release of platelet granules after 
deposition at sites of vascular injury.
Summary
In summary, then, we have shown that exogenous 
heparin inhibits smooth muscle cell proliferation in 
vivo and in vitro, and that other classes of glyco- 
saminoglycans do not so inhibit smooth muscle cell 
growth in vitro. Furthermore, anticoagulant and 
nonanticoagulant heparin seem to be equally effective 
at inhibiting smooth muscle cell growth, both in vivo 
and in vitro. For these effects, however, hexasac- 
charide or larger fragments are required, whereas di- 
or tetrasaccharide fragments are not inhibitory. 
Chemically modified heparins that have lost their an­
ticoagulant activity can, under certain conditions, 
maintain potent antiproliferative activity. It seems 
that confluent primary cultures of endothelial cells 
secrete a heparinlike molecule that inhibits the pro­
liferation of growth-arrested vascular smooth muscle 
cells. A platelet heparinase is capable of releasing this 
inhibitory activity (that is, heparin) from the endo­
thelial cells at very low concentrations.
Speculations
We would speculate, therefore, that heparin, or 
similar compounds, may be involved in the intrinsic 
regulation of vascular smooth muscle cell growth in 
the healthy, uninjured vascular wall. In this regard it 
is interesting that it has been shown that growing 
vessels contain little heparin, whereas in differen­
tiated quiescent vessels, considerable amounts of
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heparin, or heparin-like substances, are present.24-25 
Platelet-derived heparinase-heparin interaction may 
be important in the vascular smooth muscle cell pro­
liferative response following endothelial injury. 
Perhaps heparinase from the adherent platelet is re­
leased and removes heparin bound to the smooth 
muscle cells, thus allowing the platelet mitogens to 
act. We have previously shown that heparin is effec­
tive as an inhibitor of vascular smooth muscle pro­
liferation in vitro in the presence of large amounts 
of serum and/or platelet factors.12 26 The platelet 
heparinase would release bound heparin, possibly, 
from association on and around the vascular smooth 
muscle cell; but, as we have shown, the fractions pro­
duced by the activity of the platelet heparinase are ac­
tive in their inhibitory effect. We would therefore 
postulate that in the injured vessel these released 
fragments are washed away by the increased hy­
draulic flux across the injured area, or inactivated by 
released platelet components much as platelet factor 
IV. With the restoration of the endothelial covering 
by regeneration, the source of heparin could be re­
stored to the system, and heparin would now be avail­
able to inhibit the proliferation of the smooth mus­
cle. Heparan sulfate has been reported27 to increase 
preferentially in the intima covered by regenerating 
endothelium. However, as platelets are not present 
on the normal vessel wall, or on that of the healed 
vessel, one might ask what, then, releases the heparin 
from the endothelium under these circumstances? 
We would postulate either that some of the plate­
let heparinase is circulating in sufficient amounts to 
fulfill this activity or that the endothelial cells or the 
smooth muscle cells produce the heparinase, which 
has similar characteristics and can release active frag­
ments of heparin. Experiments are under way to test 
these hypotheses.
It may be postulated that nonanticoagulant, anti­
proliferative heparin derivatives might prove useful 
as selective antiproliferative agents in certain clinical 
conditions, such as postoperatively in vein grafts, end­
arterectomy, balloon embolectomy, and arteriove­
nous anastamosis, in which injury to the endotheli­
um may possibly lead to myointimal proliferation 
and luminal occlusion.28
It may well be that this vascular model is a model 
for embryonic and differentiation systems. It is in­
triguing to postulate that the control of growth in 
some areas and for some cells might be related to 
changes in the composition of the extracellular 
matrix.
Finally, I must add that one of the pleasures of be­
ing involved in this area of research has been the 
association with several highly creative coin­
vestigators. These include Jay A. Fishman and 
Graeme B. Ryan, who helped develop the air-drying 
model; Alex W. Clowes and John R. Guyton, who 
pursued the in vivo studies with anticoagulant and 
nonanticoagulant heparin; Richard L. Hoover, who 
initiated the in vitro studies, which were continued in 
depth by John J. Castellot, Jr. Our laboratory is 
greatly indebted to Dr. Robert D. Rosenberg, who 
has provided us with biochemical expertise, and with­
out whose help we would not have been able to per­
form many of our experiments.
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